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General introduction
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Body e lectro ly te  balance
Electrolytes are charged particles that are essential for many functions in all organisms. The 
predominant positively charged electrolytes in the body are sodium (Na+), potassium (K+), 
calcium (Ca2+), and magnesium (Mg2+), while negatively charged electrolytes include chloride 
(Cl-), phosphate (PO43-), and bicarbonate (HCO3-). Electrolytes are dissolved in: the plasma 
portion of blood, inside cells (intracellular), and outside cells (extracellular). The 
concentration of these electrolytes varies considerably from one area to the other. However, 
there is a narrow concentration limit of these electrolytes that the body must maintain within 
each of these compartments in order to stay healthy. Two organs determine the plasma 
levels for all electrolytes, namely the intestine and the kidney. For some electrolytes such as 
Ca2+, Mg2+ and PO43- the bone can serve as a buffer. Electrolytes are taken up from the food 
along the intestinal tract. The kidneys are responsible for maintaining the final electrolyte 
concentration via excretion. Therefore, the thesis will primarily focus on the electrolyte 
handling by the kidney.
Figure 1: Morphology of the kidney. At the renal pelvis, the kidney receives blood directly from the 
abdominal aorta via the renal artery. The artery branches into segmental arteries that extend through the 
renal pyramids further into interlobar arteries. Hence, the interlobar arteries are connected to afferent 
arterioles that supply the glomeruli, which are positioned within the outer medulla and cortex. The renal 
tubule receives plasma filtrate from the glomerulus and processes it into pro-urine. Following filtration by the 
glomeruli the tubular fluid is transported by the nephrons and collecting duct system, finally leaving the 
kidney via the ureter. To determine the final concentration in blood, important electrolytes, water, peptides, 
etc are reabsorbed from or secreted to the tubular fluid. Blood departs the kidney via a network of venules 
connected to the interlobar veins, which form the renal vein.
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The renal artery receives blood directly from the abdominal aorta and enters the kidney at 
the renal pelvis. The artery branches into segmental arteries that supply the outer medulla 
and cortical glomeruli. Following filtration by the glomeruli the tubular fluid is transported by 
the nephrons and collecting duct system, finally exiting the kidney via the ureter. The kidney 
determines the final excretion of electrolytes and water, via reabsorption to and secretion 
from the blood compartment through individual segments of the nephrons [1]. Subsequently, 
the urine leaves the kidney via a network of venules that connect to the renal vein (Figure 1).
Figure 2: Morphology of the 
nephron. Following the 
glomerulus, each tubule is 
differentiated into several 
specialized segments: the PT, 
which descends towards the outer 
medulla. The intermediate tubule 
is located within the inner medulla 
and consists of the TDL that turns 
within the inner medulla to become 
the thin ascending loop of Henle. 
The distal tubule includes several 
segments, including the TAL that 
ascends to the cortex and 
becomes the DCT. Following, the 
CNT and CDs are positioned in the 
renal cortex where several 
nephrons join. Each of these 
segments is specialized in the 
reabsorption and/ or secretion of 
one or more minerals via specific 
expression of specialized transport 
machinery.
Each nephron consists of several specialized segments (F igure 2): i) the proximal tubule 
(PT), which descends in the outer medulla; ii) the intermediate tubule, which is located within 
the inner medulla and consists of the thin descending loop of Henle (TDL), which after a 
hairpin turn becomes the thin ascending loop of Henle; iii)  the distal tubule, which includes 
the thick ascending loop of Henle (TAL) and the distal convoluted tubule (DCT); iv) the 
connecting tubule (CNT) and collecting ducts (CD) form the last part of the nephron (Figure 
2) [2]. Each of these segments is specialized in reabsorption and/or secretion of one or more
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minerals via specific transport machinery. In the studies described in this thesis, the 
molecular transport processes in the DCT were investigated in detail.
The d ista l convo luted  tubu le
The DCT localizes to the renal cortex and consists of two subsegments named DCT1 and 
DCT2. The high density and large size of mitochondria characterizes DCT1 cells [3]. The 
large mitochondria are located along the basolateral membrane, while numerous small 
mitochondria and other organelles such as the nucleus, ER and Golgi apparatus localize to 
the luminal side [3, 4]. The generation of substantial amounts of ATP by these mitochondria 
may be required to drive Na+/K+-ATPase activity, which of all nephron segments is the 
highest in DTC [5]. Presumably, the high Na+/K- ATPase activity is necessary to support 
substantial active transcellular transport mechanisms in this segment.
Figure 3: Timeline of seminal discoveries related to the transport processes of DCT.
In 1958, hydrochlorothiazide and related compounds, were developed in search for potent 
inhibitors of the enzyme carbonic anhydrase (Figure 3) [6]. Nowadays thiazides are among 
the most often used therapeutics for their diuretic and antihypertensive properties. More than 
40 years ago, the DCT1 region of the kidney was identified as the thiazide-sensitive region 
[7], but, at that time the molecular identity of the thiazide-sensitive mechanism was unknown.
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Stokes et al. identified a typical NaCl absorption mechanism in the gall bladder of Winter 
flounder that could be inhibited by thiazide diuretics (Figure 3) [8 ]. Many years later, by using 
an expression cloning strategy the thiazide-sensitive Na+-Cl- cotransporter (NCC) was 
identified and shown to localize to the teleost urinary bladder and the epithelium of 
mammalian DCT (Figure 2 and 3) [9]. Similar to chronic thiazide treatment, inactivating 
mutations in NCC cause renal NaCl wasting and activation of the renin-angiotensin- 
aldosterone system [10-12]. This likely leads to hypokalemic alkalosis as a result of 
increased Na+ load and compensatory reabsorption in the CNT/CD region via the epithelial 
Na+ channel (ENaC), in exchange for K+ and H+ [13, 14]. Other phenotypic features include 
secondary hypocalciuria and hypomagnesemia [10-12]. The mechanisms for Ca2+ 
reabsorption were shown to reside in the PT, TAL and the DCT region of the nephron 
(Figure 2). Recently, micropuncture experiments in mice showed increased reabsorption of 
Na+ and Ca2+ in the PT during chronic thiazide treatment, whereas Ca2+ reabsorption in the 
TAL and DCT appeared unaffected [15].
The hypomagnesemia presumably results from decreased abundance of the epithelial Mg2+ 
channel transient receptor potential melastatin 6  (TRPM6 ) in the DCT, however, the 
responsible mechanism remains poorly understood. Interestingly, severe hypotrophy of the 
DCT has been observed in rats treated with thiazide diuretics and NCC deficient mice [16, 
17]. Additionally, administration of low-doses of thiazides did not induce degeneration of 
DCT1, although downregulation of TRPM6  was still observed [15].
Altogether, these observations suggest a prominent function of the DCT1 in overall Na+ and 
Mg2+ handling. This has been confirmed by the identification of disease genes in families with 
inherited forms of Na+ and Mg2+ wasting [18-23]. Hence, several players of the DCT1 Na+ 
and Mg2+ transport machinery have been identified. In short, Na+ and Cl- are transported 
across the luminal membrane via NCC [17]. Following, Na+ is extruded across the 
basolateral membrane through the Na+/K+-ATPase while Cl- exit occurs via the chloride 
channel, subunit b (ClC-Kb). TRPM6  mediates influx of Mg2+ across the luminal membrane of 
DCT1 cells [20]. At this point the mechanism for Mg2+ extrusion across the basolateral 
membrane is unknown (Figure 4). The following paragraphs will discuss these Na+- and 
Mg2+-associated phenotypes and corresponding genotypes.
Sodium  reabsorption in the  DCT
Under physiological conditions, renal tubules are capable of reabsorbing 99% of filtered Na+. 
High percentages of Na+ are reabsorpted by the PT (70%) and TAL (20%), while only 5-10%
14
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of transport occurs in the DCT1. As mentioned above, NCC and ClC-Kb are shown to be 
involved in transport of Na+ in the DCT1 segment. Impairment of these proteins both lead to 
the clinical picture of Gitelman syndrome (GS), which will be discussed in the coming 
paragraph.
Figure 4: Electrolyte handling in the DCT. TRPM6 is located at the luminal membrane of the DCT where it 
facilitates transport of Mg2+ from the pro-urine into the cell. The epidermal growth factor (EGF) was discovered as 
a magnesiotropic hormone directly regulating active Mg2+ reabsorption via TRPM6. The Na+/K+-ATPase, situated 
in the basolateral membrane, provides Na+ gradient that is used by NCC to facilitate cotransport of Na+ and Cl- 
from the pro-urine into the cytoplasm. The efflux of Cl- to the interstitium occurs through ClC-Kb. The y-subunit of 
the Na+/K+-ATPase may regulate the function of the a  and/or p subunits, however, the exact function is unknown.
Gitelman syndrome
GS is an autosomal recessive disorder characterized by hypokalemic metabolic alkalosis in 
conjunction with significant hypomagnesemia and hypocalciuria (OMIM 263800; Table 1) 
[24]. GS is one of the most frequently occurring renal tubular disorders with a prevalence of 
1:40.000 in the Caucasian population (heterozygotes 1:100) [25]. The GS phenotype can be 
observed from the age of 6  years, but in most instances the diagnosis is made during 
adulthood. Most GS patients suffer from periods of muscle weakness and tetany, particularly 
when extra Mg2+ is lost as a result of vomiting or diarrhoea. Some patients with GS 
experience fatigue, which interferes with their daily activities. In general, growth is normal in 
GS patients, although it can be delayed in patients with severe hypokalemia and
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hypomagnesemia [26]. Many adult patients suffer from chondrocalcinosis, which is supposed 
to result from chronic hypomagnesemia [27]. Most patients with GS remain untreated. 
However, in view of the assumption that chondrocalcinosis is due to Mg2+ deficiency there is 
a clear argument for lifelong supplementation of Mg2+. Normalization of plasma Mg2+ is 
difficult to achieve since high doses can cause diarrhoea. Hypokalemia can be treated with 
drugs that antagonize aldosterone activity or drug such as amiloride that block ENaC in the 
CD.
Table 1: Clinical and biochemical characteristics of hypomagnesemia-causing genes.
Gene Protein Phenotype:
Blood:
M g2'  Ca2‘ K* Na* pH
Urine:
MgJ- Ca*' K* Na*
Other:
Ref#.
SLC12A3 NCC 1 ~  1 ~  t t ii nd nd Increased bone mineral density 22, 24
TRPM6 TRPM6 H I  ° t t Mental retardation; epilepsy 20. 23.41
EGF EGF I  *+ nd nd Mental retardation 51. 52
FXYD2 yNa'/K* ATPase H  —  - * ~  — tt nd nd None 19. 59
Clinical and biochemical characteristics of genes associated with inherited forms of hypomagnesemia resulting in 
impaired Mg2+ reabsorption in the DCT. The biochemical characteristics of plasma and urine are indicated for 
each affected gene. 4, low; T, high; o ,  normal; nd, not defined; #Low plasma Mg2+ levels and normal urinary Mg2+ 
excretion indicates a renal Mg2+ reabsorption defect.
The underlying causes for the GS phenotype are homo- or compound heterozygous 
mutations or deletions in the solute carrier family 12, member 3 (SLC12A3) gene that 
encodes NCC (OMIM 600968) [22]. As a result of the high prevalence, many loss-of-function 
mutations have been discovered in patients with GS. Most are missense mutations 
substituting a conserved amino acid residue, whereas nonsense-, frame shift-, and splice- 
site mutations and gene rearrangements are less frequently observed. NCC is expressed at 
the luminal membrane of DCT, where it facilitates cotransport of Na+ and Cl- from the pro­
urine into the cell (Figure 4).
Functional expression studies of mutant NCC transporters in Xenopus laevis oocytes 
revealed different disease-causing mutants, which are classified according to the previously 
published CFTR nomenclature [28]. Class I mutants lead to complete absence of the 
transporter due to improper processing or unstable mRNA. Examples of class I NCC mutants 
have not been detected yet. Most NCC mutants are class II mutants, which exhibited no 
significant thiazide-sensitive Na+ transport. These improperly glycosylated mutant 
transporters are fully translated, but are retained in the endoplasmic reticulum (ER) as a 
result of misfolding. Immunolocalization studies of Xenopus laevis oocytes expressing 
mutant transporters show diffuse immunopositive staining just below the plasma membrane. 
Another group of NCC mutants represent a subclass of class II, which exhibits a significantly
16
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lower thiazide-sensitive Na+ transport compared to the wild-type transporter. Accordingly, 
these glycosylated mutants were detected both at and below the plasma membrane [29]. 
Finally, the third group of NCC mutants are characterized by a lack of intrinsic activity despite 
normal glycosylation and plasma membrane expression [30], which are characteristics of 
class III and IV mutants. In case of Class III mutants the transporter activation and regulation 
is impaired, while class IV mutants display reduced ion conductance. Additional experiments 
are required to find out whether these are Class III or IV mutants.
Following transport via NCC, Na+ is extruded across the basolateral membrane through the 
Na+/K+-ATPase, while Cl- exit occurs ClC-Kb. A minority of patients with GS have a mutation 
in the CLCNKB gene. Interestingly, mutations in the CLCNKB gene, coding for ClC-Kb, can 
cause a phenotypic spectrum ranging from antenatal Bartter syndrome (BS) to a more GS- 
like phenotype with hypomagnesemia and hypocalciuria (Table 1). BS is a renal autosomal 
recessive disorder, defined by hypokalemic metabolic alkalosis, which is usually more severe 
than the GS phenotype [31]. Immunohistochemistry (IHC) revealed ClC-Kb expression in the 
basolateral membrane of both the TAL and the DCT (Figure 2) [32]. The patient phenotype 
as well as the expression pattern suggests that ClC-Kb facilitates basolateral Cl- transport in 
both the TAL and the DCT (Figure 2 and F igure 4) [33].
Magnesium reabsorption in the  DCT
Following passive reabsorption by the PT and TAL, 5-10% of the filtered Mg2+ is reabsorbed 
by DCT1 in an active transcellular manner [34, 35] (Figure 2). Importantly, the DCT1 
segment determines the final plasma Mg2+ concentration, as the more distal parts of the 
nephron (DCT2, CNT and CD) are largely impermeable to Mg2+. These observations propose 
a prominent role for Mg2+ reabsorption by the DCT.
Mg2+ is a versatile electrolyte shown to be involved in many cellular processes. It functions as 
a co-factor in the energy metabolism, nucleotide and protein synthesis and as a regulator of 
Na+, K+ and Ca2+ channels. In order to maintain these cellular functions, plasma Mg2+ levels 
should be maintained within a narrow range (0.7-1.1 mmol/L). Hypomagnesemia is a 
common finding in hospitalized patients [36-40] and often an acquired disorder resulting from 
insufficient oral intake or accelerated urinary or intestinal loss. Patients with inherited forms 
of hypomagnesemia are rare. Symptoms of hypomagnesemia include muscle cramps, 
tremors, tetany, a short QT interval on the electrocardiogram (ECG) and in some instances 
cardiac arrhythmia. Persistent hypomagnesemia can eventually cause death. Patients 
suffering from severe hypomagnesemia are often supplemented with Mg2+. A high dose of
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oral Mg2+, however, can have serious adverse effects such as abdominal cramping and 
diarrhoea. The most important genetic causes as well as the acquired forms of 
hypomagnesemia will be discussed in the following paragraphs.
P athophysio logy of m onogenetic d isorders in hypom agnesem ia
Familial hypomagnesemia with Secondary Hypocalcemia (HSH)
Walder et al. reported three consanguineous kindred’s suffering from hypomagnesemia and 
secondary hypocalcemia (HSH; OMIM 602014; Table 1). The phenotype manifested 2-8 
weeks after birth and consisted of neurologic symptoms such as tetany, muscle spasms, and 
seizures [23]. These patients displayed low plasma Mg2+ levels (0.1-0.4 mmol/L) that are 
caused by defective intestinal and renal (re-) absorption of Mg2+ (Table 1) [41]. The low 
plasma Ca2+ levels are secondary, most likely due to parathyroid (PTH) failure caused by 
chronic and severe hypomagnesemia. Hypomagnesemia blocks the secretion of PTH, 
resulting in decreased reabsorption of Ca2+ by the kidney [42]. Untreated, the disease may 
be fatal or result in severe neurological damage [43]. Immediate intravenous administration 
of Mg2+ and lifelong treatment with a high dose of oral Mg2+ relieves clinical symptoms and 
normalizes Ca2+ homeostasis.
A whole genome scanning approach showed linkage to chromosome 9p22 [41]. In the 
following years, two groups independently identified new HSH families that were used to 
narrow down the critical genomic region by use of haplotype analysis. Subsequent screening 
for candidate genes in the mapped region resulted in the identification of mutations in the 
TRPM6 (OMIM 607009) gene (Table 1) [20, 23], encoding the TRPM6  protein. The majority 
of mutations, identified in HSH patients, result in premature stop codons, exon deletions or 
frameshifts, thus resulting in complete loss-of-function of the protein [44]. A sporadic S141L 
missense mutation was demonstrated to cause impaired trafficking of TRPM6  towards the 
plasma membrane [45].
TRPM6  belongs to the family of TRP channel proteins, which constitute a diverse family of at 
least 25 proteins, which are involved in many tissues and display large functional 
heterogeneity (i.e. thermal-, tactile-, taste-, osmolality-, fluid flow sensing and transepithelial 
transport) [46]. By use of immunohistochemistry, the TRPM6  protein was shown to localize to 
the luminal membrane of DCT cells and the brush-border membrane of the intestine [47]. 
The closest relative of TRPM6  is TRPM7, which is ubiquitously expressed. A striking feature 
of both channels is the a-kinase domain, which is located at the intracellular carboxy (C)- 
terminus. Functional analysis identified TRPM6  as a Mg2+ and Ca2+-permeable channel,
18
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although the affinity for the latter ion is five times lower [47]. The a-kinase domain is 
proposed to function as a sensor of intracellular Mg2+ concentration [48, 49]. As a 
consequence, the Mg2+ influx via TRPM6  is regulated, preventing intracellular Mg2+ overload. 
Future studies should elucidate the exact function of this unique channel kinase. The 
knowledge concerning the regulation of Mg2+ balance via TRPM6  is limited. Dietary Mg2+ 
restriction in mice has been shown to up-regulate renal TRPM6  mRNA and protein levels, 
while TRPM7 mRNA and protein levels were unaltered [50]. Another factor shown to regulate 
TRPM6  content in the kidney is 17p-estradiol. TRPM6  expression levels are significantly 
decreased in ovariectomized rats. Importantly, 17p-estradiol supplementation in these rats 
normalized TRPM6  expression levels [50].
Isolated Recessive renal Hypomagnesemia (IRH)
Recently, epidermal growth factor (EGF) was identified as a novel magnesiotropic hormone 
[51]. Geven et al. reported two sisters from consanguineous parents with autosomal 
recessive isolated renal hypomagnesemia (IRH) (HOMG4; OMIM 611718; Table 1) [52]. The 
patients who suffered from epileptic seizures and psychomotor retardation during childhood 
are nowadays adults with moderate mental retardation. Both sisters displayed low plasma 
Mg2+ values (~0.4 mmol/L), while the urinary excretion of Mg2+ was within normal range 
indicating a diminished tubular Mg2+ reabsorption. Interestingly, no disturbances in urinary 
Ca2+ excretion were observed in these patients [52]. By use of a whole genome linkage 
analysis and a subsequent candidate gene approach, EGF (OMIM 131530) was identified as 
the affected gene in these patients [51].
The EGF gene codes for pro-EGF, a small peptide hormone expressed in several organs, 
including the gastrointestinal tract, the respiratory tract and the kidney. In rat kidney, pro-EGF 
localizes primarily to the DCT [51, 53] (Figure 2). Pro-EGF is a type-1 membrane protein that 
is sorted and subsequently inserted into the luminal and basolateral membrane of the 
epithelial cells [54]. It consists of a small intracellular C-terminal tail, one transmembrane 
domain and a large extracellular amino (N)-terminal segment. Upon membrane insertion, 
pro-EGF is processed by proteases into a functional EGF peptide hormone, which activates 
the EGF receptor (EGFR) on the basolateral membrane (Figure 4). As a result, EGF will 
stimulate the trafficking of TRPM6  channels to the luminal membrane, which consequently 
increases the reabsorption of Mg2+ via TRPM6  (F igure 4) [55]. The function of EGF at the 
luminal membrane is unknown, which is particularly interesting as EGFRs are absent at this 
site of the DCT cells [56]. The mutation, observed in the family with IRH, disrupts the 
basolateral-sorting motif in pro-EGF. For that reason, pro-EGF can likely not travel to the
19
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basolateral membrane leading to impaired stimulation of the EGFR and subsequent reduced 
Mg2+ transport by TRPM6  (Figure 4).
Isolated Dominant Hypomagnesemia with associated hypocalciuria (IDH)
Another gene proposed to have a role in Mg2+ homeostasis is FXYD2 (OMIM 601814). 
FXYD2 encodes the y-subunit of Na+/K+-ATPase and is mutated in patients with autosomal 
dominant renal hypomagnesemia associated with hypocalciuria (IDH; OMIM 154020; Table 
1) [19]. The plasma Mg2+ concentration in these patients can be as low as 0.40 mmol/L, 
which sometimes result in generalized convulsions [19, 57]. At adult age, most IDH patients 
develop chondrocalcinosis. The FXYD2 gene encodes two splice variants, namely ya and 7b, 
which locate to different segments of the nephron. Both variants are expressed along the 
nephron and colocalize in the PT and TAL. Splice variant ya is specifically expressed in the 
MD and CD, while 7b localizes to the basolateral membrane of the DCT and CNT region 
(Figure 2) [58]. The y-subunit is proposed to have an important role in the modulation of 
Na+/K+-ATPase activity to maintain the resting membrane potential [59]. Immunolocalization 
studies of y-subunit-expressing cells showed normal membrane localization of wild-type y- 
subunit, while mutant y-subunit membrane trafficking was impaired [60].
Interestingly, two individuals with a heterozygous 11q23-ter deletion, including the FXYD2 
gene, were shown to have normal plasma Mg2+ levels, indicating that the loss of one FXYD2 
gene copy is not sufficient to cause the Mg2+ deficient phenotype [19]. These findings 
strongly suggest that the FXYD2 gene mutation, identified in the IDH family, is caused by a 
dominant negative effect rather than by FXYD2 haploinsufficiency. The recent finding that 
FXYD2 knockout (KO) mice display normal plasma Mg2+ levels and unaltered excretion of 
Mg2+ is consistent with this hypothesis [61]. The exact molecular mechanism by which the y- 
subunit regulates Mg2+ handling in the DCT remains elusive. Possibly, the y-subunit 
facilitates the basolateral extrusion of Mg2+ in renal epithelial DCT cells. Alternatively, the y- 
subunit may be involved in regulation of other transport mechanisms that localize to the 
basolateral membrane such as the Na+/K+-ATPase (Figure 4) or the unidentified basolateral 
extrusion mechanism for Mg2+.
A cquired hypom agnesem ia
Acquired renal Mg2+ wasting is commonly caused by drug therapy (i.e. diuretics [12], 
cisplatinum [62], immunosuppressive agents such as cyclosporin [63]), alcohol and osmotic
20
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diuresis (i.e. diabetes mellitus [64]). Hypomagnesemia has previously been described as a 
frequent and sometimes severe side-effect of cetuximab therapy. Cetuximab is a monoclonal 
antibody against the EGFR which is used in the treatment of colorectal cancer [65]. 
Interestingly, Mg2+ salts are often given in case of severe asthma attacks [6 6 ] and to treat 
pre-eclampsia in pregnant women [67]. The molecular mechanism by which Mg2+ improves 
the pathological conditions is at present unknown.
O utline  o f th is  thesis
The affected genes in inherited forms of renal electrolyte handling (GS, FSH, IRH and IDH) 
encode proteins with important functions in the DCT. For example, loss of function of NCC or 
ClC-Kb causes GS, while TRPM6 , pro-EGF and y-subunit of Na+/K+-ATPase are affected in 
inherited renal hypomagnesemia (IDH, IRH and FSH, respectively). In recent years, the 
functional role of these proteins in electrolyte handling of DCT has been investigated. NCC 
facilitates the movement of Na+ and Cl- across the luminal membrane, following efflux of Cl- 
to the interstitium by ClC-Kb. Moreover, the TRPM6  channel was shown to transport Mg2+ 
from the tubular lumen into DCT cells and to be regulated by the novel hormone pro-EGF. 
Nevertheless, detailed molecular insight in these processes is still lacking. This thesis aims 
to study the molecular mechanisms of electrolyte handling by the DCT in detail and to 
identify new players in this process. Chapter 2 describes the mutation analysis of the 
SLC12A3 gene, encoding NCC, in a cohort of 263 patients with GS phenotype. Novel 
missense mutations were selected to investigate the effect of the genotype on NCC 
transporter function. We investigated the Na+ uptake in Xenopus laevis oocytes, expressing 
wild-type and mutant NCC. Moreover, plasma membrane localization of GFP-tagged wild­
type and mutant NCC was studied by use of confocal microscopy. Chapter 3 reports the 
identification of the affected gene (KCNA1) by a positional cloning approach in a large family 
with isolated autosomal dominant hypomagnesemia. Immunohistochemistry was performed 
to investigate the renal localization of the identified channel. Functional analysis was carried 
out by the use of the whole-cell patch clamp technique and the plasma membrane 
localization of the channel was studied via cell surface biotinylation experiments. In Chapter
4, the effect of the identified mutation (Chapter 3) on channel function was studied using the 
patch clamp technique. The functional consequence was explored by substituting this 
residue with other hydrophobic, polar or charged amino acids. In Chapter 5, the molecular 
mechanism by which the anti-tumor drug cisplatinum causes hypomagnesemia was 
investigated in mice. A possible role for cisplatinum in DCT tubular toxicity and the regulation
21
of Mg2+ handling was addressed. Finally, the results of this thesis are summarized and 
discussed in Chapter 6 .
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A bstract
Gitelman syndrome (GS) is an autosomal recessive disorder characterized by hypokalemic 
metabolic alkalosis in conjunction with significant hypomagnesemia and hypocalciuria. 
Periods of muscle weakness and tetany are commonly observed in GS patients. The 
underlying cause for the GS phenotype is genetic aberrations in the solute carrier family 12, 
member 3 (SLC12A3) gene that encodes the thiazide-sensitive NaCl cotransporter (NCC). 
NCC localizes to the luminal membrane of the distal convoluted tubule (DCT), where it 
facilitates cotransport of Na+ and Cl- from the pro-urine into the cell. Here, we analyzed DNA 
samples of 263 GS patients by direct sequencing of all 26 exons of the SLC12A3 gene. In 
total 114 different mutations were identified, 50 of which have not been reported in literature 
before. These novel variants include 7 deletions, 30 missense-, 9 splice site- and 4 nonsense 
mutations. We selected 7 missense mutations (Glu121Asp, Thr392Ile, Asn442Ser, 
Ser475Cys, Tyr489His, Pro751Leu, Gln1030Arg) to investigate their effect on NCC activity 
and plasma membrane localization by using the Xenopus laevis oocyte expression system. 
The Thr392Ile mutant was retained in the endoplasmic reticulum (ER) (class 2 mutation), 
while the Asn442Ser and Gln1030Arg NCC mutants showed decreased plasma membrane 
localization and consequently function, likely due to impaired trafficking (class 3 mutation). 
Even though the NaCl uptake was hampered for NCC mutants Glu121Asp, Pro751Leu, 
Ser475Cys and Tyr489His, the transporters reached the plasma membrane (class 4 
mutation), suggesting an effect on NCC regulation or ion affinity. The present study identifies 
and characterizes new mutations in NCC, thereby providing insight into the mechanisms that 
regulate NCC.
In troduction
GS (OMIM 263800) is an autosomal recessive renal tubular salt wasting disorder, primarily 
characterized by hypokalemic metabolic alkalosis in combination with significant 
hypomagnesemia and low urinary calcium [1]. GS is the most frequently occurring renal 
tubular disorder with a prevalence of 1:40,000 in the Caucasian population (heterozygotes 
1:100) [2]. The GS phenotype can be observed from the age of 6 years, but in most 
instances the diagnosis is made during adulthood [3]. Transient periods of muscle weakness 
and tetany [1, 4] sometimes accompanied by abdominal pain, vomiting and fever are often 
seen in GS patients. Remarkably, some patients are completely asymptomatic except for the 
appearance of chondrocalcinosis at adult age [5, 6].
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GS results from loss-of-function mutations in the SLC12A3 gene, which consists of 26 exons 
and is located on the long arm of chromosome 16 (16q13). The SLC12A3 gene encodes the 
1030 amino acid NCC protein (NM_000339.2; OMIM 600968) [7]. The two-dimensional 
structure of NCC is predicted to contain 12 transmembrane segments (S) with large 
intracellular amino (N)- and carboxy (C)-terminal regions and a large hydrophilic extracellular 
loop between S7 and S8 [8]. NCC localizes to the luminal membrane of the DCT segment of 
the nephron [9], where it facilitates the cotransport of Na+ and Cl- from the pro-urine to the 
intracellular compartment. NCC is the target for thiazide-type diuretics, which are currently 
recommended as the first-line pharmacological treatment of hypertension [10]. Chronic 
thiazide administration, on the other hand, induces similar electrolyte disturbances as seen in 
GS [11].
At present, ~150 distinct loss-of-function mutations have been discovered in patients with GS 
(http://archive.uwcm.ac.uk/uwcm/mg). Most are missense mutations substituting a conserved 
amino acid residue, whereas nonsense, frameshift, and splice site mutations and gene 
rearrangements are less frequently observed. These mutations presumably impair the 
function of the encoded NCC protein as a result of structural changes and/or altered cellular 
localization. So far, functional analysis has been performed for only a limited number of 
mutations [12-15]. Studies to investigate Na+ transport by NCC and cell surface localization 
using Xenopus laevis oocytes as a model system, confirmed disease-causing NCC mutants. 
These mutants are categorized according to standard nomenclature as established for renal 
Na+ transporters NCC and Na+-K+-Cl- cotransporter 2 (NKCC2) mutations [16]. Class 1 
mutants lead to complete absence of the NCC protein due to improper processing of mRNA. 
Small out-of-frame deletions, larger deletions involving (part of) the gene, splice site 
mutations, and nonsense mutations, belong to this group [10, 16-18]. Class 2 NCC mutants 
exhibited no significant thiazide-sensitive Na+ transport. These improperly glycosylated 
mutant transporters are fully translated, but are retained in the ER [12, 13]. Class 3 mutants 
are correctly folded NCC proteins, which, presumably as a result of disrupted insertion in the 
plasma membrane, are only partially functional [12, 15]. Class 4 NCC mutants show a 
significantly lower thiazide-sensitive Na+ transport compared to wild-type transporters. These 
correctly glycosylated mutants localize to the plasma membrane [14], but the transporter 
activation, regulation or ion affinities are affected. Finally, class 5 mutations include 
membrane proteins that display accelerated removal or degradation from the plasma 
membrane.
Here we report the identification of 50 novel SLC12A3 sequence variants in a cohort of 263 
patients referred to our DNA diagnostics laboratory with clinical suspicion of GS. We selected 
7 missense mutations (6 novel mutations and one previously described) to characterize their
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functional and molecular properties by performing a quantitative analysis comparing wild­
type to mutant NCC plasma membrane expression as well as by evaluating their NCC 
transport activity. The present study expands the spectrum of SLC12A3 mutations and 
evaluates their effect on NCC function to ultimately elucidate the molecular mechanisms 
underlying GS.
Material and m ethods
Patients- Patients were referred to the DNA diagnostic service of the department of Human 
Genetics of our hospital. The GS diagnosis was made by the referring clinician, and all 
patients sent in between 2000 and 2009 are incorporated in this study.
Mutation analysis- DNA was extracted from peripheral blood lymphocytes using standard 
procedures. All individual exons of the SLC12A3 gene were PCR amplified (primers and 
PCR conditions available upon request), and direct sequencing was performed on an ABI 
3730 automated DNA sequencer (Applied Biosystems). The segregation of mutations has 
been studied if family members were available.
Multiplex Ligand-dependent Probe Amplification- For the multiplex Ligand-dependent probe 
amplification (MLPA) analysis, the SALSA MLPA kit P136 (MRC-Holland, Amsterdam, The 
Netherlands) was used. This kit contains 25 MLPA probes covering all exons, except exon 6 
of the SLC12A3 gene. Furthermore, a home-designed kit was used containing synthetic 
probes including all coding exons (also exon 6). The analysis and data processing was 
performed as described by Koolen et al. [28].
DNA constructs- To allow hNCC detection at the plasma membrane of Xenopus laevis 
oocytes, eGFP was introduced at the N-terminus of hNCC. The eGFP-hNCC pT7Ts 
construct was obtained by replacement of the N-terminal flag-tag of the previously described 
flag-hNCC pT7Ts construct [12] by the eGFP from the eGFP-hNCC pCB7 construct using 
Nco1 and Nae1 restriction enzymes (New England Biolabs). All selected mutations were 
introduced into eGFP-hNCC pT7Ts by use of the Quikchange® Site-Directed Mutagenesis Kit 
(Stratagene), according to the manufactures instructions. The primers are depicted in 
Supplem entary tab le  2.
In vitro NCC cRNA translation- To prepare cRNA, all clones were linearized using Nsil (New
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England Biolabs), and cRNA was in vitro transcribed using a T7 RNA polymerase 
mMESSAGE machine kit (Ambion), according to manufacturer directions. Additionally, all 
samples were resolved on a 1% w/v formaldehyde agarose gel to evaluate the cRNA quality, 
while the concentration was determined by absorbance reading at 260 nm using the 
NANODROP 2000c (Thermo scientific). cRNA aliquots were stored at -80°C.
Xenopus laevis oocyte preparation- The animal ethics board of the Radboud University 
Nijmegen approved the animal studies. Micro-injection, isolation, and 22Na+ tracer uptakes in 
Xenopus laevis oocytes were performed as described previously [29], with minor 
modifications. In brief, oocytes were harvested by postmortem surgery (abdominal 
laparotomy) after decapitation of adult female Xenopus laevis and incubated in frog Ringer 
ND96 (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl, and 5 mM Hepes/Tris, pH 7.4) in 
the presence of collagenase B (2 mg/ml) for 1 h. The oocytes were washed four times in 
ND96, defolliculated, and incubated overnight at 18 °C in ND96 supplemented with 2.5 mM 
sodium pyruvate and 5 mg/100 ml of gentamicin. Next day, mature oocytes were micro­
injected with 50 nl of water only or containing cRNA (10 ng of cRNA/oocyte). The oocytes 
were incubated at 18 °C for 3 days in ND96 with 2.5 mM sodium pyruvate and 5 mg/100 ml 
gentamicin that was changed every 24 h. The night before the uptake experiments were 
performed, the oocytes were incubated in Cl--free ND96 (96 mM Na+-isethionate, 2 mM K+- 
gluconate, 1.8 mM Ca2+-gluconate, 1 mM Mg2+-gluconate, 5 mM Hepes, pH 7.4, 2.5 mM 
sodium pyruvate, and 5 mg/100 ml gentamicin).
Xenopus laevis oocyte total membrane isolation- For the isolation of the total membrane 
fraction, oocytes were homogenized in 20 |o.l Hba buffer, 20 mM TRIS, pH 7.4, 5 mM 
NaH2PO4, 1 mM EDTA, 80 mM Sucrose, 1 mM PMSF, 1 |j.g/ml leupeptin and 10 |j.g/ml 
pepstatin) per oocyte and centrifugated twice for 10 minutes at 100g at 4oC. Following, 
membranes were isolated by 20 minutes centrifugation at 14,000g. The pellet was 
resuspended 2 |j.l leammli/DTT per oocyte.
Western blotting- eGFP-NCC expression was analyzed by immunoblot analysis for the total 
plasma membrane fraction. Protein samples were incubated for 10 minutes at room 
temperature in leammli-buffer, subjected to electrophoresis on a 10% w/v SDS- 
polyacrylamide gel and immunoblotted onto PVDF membranes (Millipore Corporation) 
according to standard procedures. Membranes were blocked for 1 hour in 5% w/v nonfat- 
dried milk in TBS-T (TBS with 0.1% v/v Tween-20). Overnight, blots were incubated with a
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rabbit polyclonal BFP antibody (1:5000 in 1% w/v milk TBS-T) [30], following 2 hours 
incubation with a PO-conjugated anti-rabbit antibody (1:10000 in 1% w/v milk TBS-T) 
(Sigma, no. A 491). The blots were incubated with SuperSignal West Pico (Thermo scientific) 
before visualization by chemiluminescence in the chemidoc XRS imager (Biorad).
22Na+ transport assays- Human eGFP-NCC cotransporter function was determined by 
assessing tracer 22Na+ uptake (PerkinElmer Life Sciences) in groups of 25 oocytes following 
a standard protocol of 30 minutes of incubation in a Cl--free ND96 medium containing 1 mM 
ouabain, 0.1 mM amiloride, and 0.1 mM bumetanide, following 1 hour of uptake in K+-free, 
NaCl medium (40 mM NaCl, 56 mM sodium-gluconate, 4 mM CaCl2, 1 mM MgCl2, and 5 
mM Hepes/Tris, pH 7.4) containing 1 mM ouabain, 0.1 mM amiloride, 0.1 mM bumetanide 
and 2 ^Ci of 22Na+/ml [31]. As a control, one group of water-injected oocytes has been 
included to determine the basal unspecific tracer 22Na+ uptake in all experiments.
Immunofluorescence microscopy- Human eGFP-NCC cotransporter Xenopus laevis oocyte 
membrane localization was assessed in groups of ~10 oocytes by use of confocal 
microscopy (modified after Pacheco-Alvarez et al. [32]). The images were obtained with an 
Olympus FV1000 Confocal Laser Scanning Microscope, emitting at 488 nm with a 30-mW 
argon laser. The plasma membrane fluorescence was quantified for all images by measuring 
pixel intensity using ImageJ software.
Statistical analysis- In all experiments, the data are expressed as mean ± SEM. Overall 
statistical significance was determined by one-way ANOVA, followed by a Bonferroni post­
hoc test. P < 0.05 was considered significant.
Results
Screening for SLC12A3 mutations
We performed sequence analysis of the entire coding region and flanking splice sites of the 
SLC12A3 gene, revealing 303 mutations in 263 patients with a clinical diagnosis of GS 
(Supplem entary tab le  1). Mutations were identified on both SLC12A3 alleles in 139 
patients. 38 patients carry homozygous SLC12A3 mutations whereas 101 are compound 
heterozygotes. If available, segregation of SLC12A3 mutations was confirmed in family 
members of these probands (data not shown). 25 patients displayed a single mutation in the 
SLC12A3 gene and in 99 patients no mutation was detected (Supplem entary tab le  1 ).
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Table 1: Novel SLC12A3 sequence variants in patients with clinical suspicion of GS
Mutation
type
Nucleotide
change
Exon Predicted effect on 
coding sequence
Missense c.184G>C 1 p.Asp62His
C.2470T 1 p.Arg83Trp
c.248G>A 1 p.Arg83Gln
c.363G>C 2 p.Glu121Asp
C.4030T 2 p.Arg135Cys
c.450T>G 3 p.lle150Met
c.470T>C 3 p.Leu157Pro
c.473G>T 3 p.Arg158Leu
C.4970T 3 p.Ala166Val
c.575T>C 4 p.lle192Thr
c.581C>T 4 p.Thr194lle
c.704C>G 5 p.Thr235Arg
c.775G>A 6 p.Asp259Asn
c.815T>C 6 p.Leu272Pro
c.1325A>G 10 p.Asn442Ser
c.1424C>G 11 p.Ser475Cys
c.1465T>C 12 p.Tyr489His
c.1519C>T 12 p.Arg507Cys
c.1601A>G 13 p.Asn534Ser
c.1636A>G 13 p.Ser546Gly
c.1679C>G 14 p.Pro560Arg
c.1939G>A 16 p.Val647Met
c.2204C>G 18 p.Pro735Arg
c.2252C>T 18 p.Pro751Leu
C.2497T>A 21 p.Ser833Thr
c.2548G>C 21 p.Gly850Arg
c.2572C>T 22 p.Leu858Phe
c.2642T>C 22 p.Met881Thr
C.28270T 24 p.Arg943Trp
c.3089A>G 26 p.Gln1030Arg
Nonsense c.1024G>T 8 p.Gly342X
c.2164C>T 17 p.Gln722X
c.2821G>T 24 p.Glu941X
c.2869A>T 24 p.Lys957X
Splice site c.505+5G>A Intron 3 Splice defect
c.602-16G>A Intron 3 Splice defect
C .1096-1 G>A Intron 8 Splice defect
C .1335+1 G>A Intron 10 Splice defect
c.1335+1 G>C Intron 10 Splice defect
c.1669+5G>T Intron 13 Splice defect
c.2037+4A>G Intron 16 Splice defect
c.2368+5G>A Intron 19 Splice defect
c.2548+1G>T Intron 21 Splice defect
Deletion C .-6 6  23del 
(? -6) 852+?del 
C.506-? 852+?del 
C.602-? 852+?del 
C.2179-? 2285+?del 
C.2748-? 2951+?del 
C.2952-? 3077+?del
Partial deletion exon 1 
Deletion exons 1-6 
Deletion exons 4-6 
Deletion exons 5 and 6 
Deletion exon 18 
Deletion exons 24 and 25 
Deletion exon 26
GenBank accession number NM_000339.2 is used as a reference sequence in which the A of ATG is number 1. 
Intron sequences can be found in NT_010498.15.
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A large fraction of the identified mutations (80%) has been described previously [7, 12, 14, 
18-21]. The most frequently encountered mutations in our cohort were c.815T>C 
(p.Leu272Pro; 22/526 alleles), c.2221G>A (p.Gly741Arg; 35/526 alleles) and c.2883+1G>T 
(27/526 alleles) (Supplem entary tab le  1). In total, 43 novel mutations were detected, 
including 30 missense-, 4 nonsense- and 9 splice site mutations (Table 1). An in-silico-based 
method was used to assess the effect of a mutation on splicing (splice prediction tool of the 
Alamut software (http://www.interactivebiosoftware.com/alamut/doc/1.5/index.html)), which 
was also applied as an intermediate to investigate the effect of the different missense 
mutations on the protein. Only variants that are classified as UV3 or UV4, according to the 
guidelines of the CMGS and VKGL (British and Dutch molecular genetic societies), are 
included as mutations in this paper (see
http://www.cmgs.org/BPGs/pdfs%20current%20bpgs/UV%20GUIDELINES%20ratified.pdf).
O Glu121Asp e Thr392lle Q Asn442Ser
Human 117« L V E G E A G T S •125 388- A s a It G S C 438- Y G L 1 N Y  YQT-444
Chimpanzee 117 L V E G E A G T S •125 388- A S A T G S C 090 438* Y G L  1 NYYQT- 4 4 «
Rabbit 116 L V E D E A G A G •124 386- A S A T G S C -394 436* Y G L  1 NYYQT- 4 4 4
Rat 115 L V E D E T G A N - 1 2 3 388- A S A T G S C *395 438- Y G L  I N Y Y Q T - 4 4 4
Mouse 114 L V E D E T G T N - 1 2 2 385* A S A T G S C *393 435- Y G L  1 NYYQT- 4 4 3
Cow 117 L V E D E A G  I N •125 388* A S A T G S C -398 438- Y G L  1 NYYQT- 4 4 6
Horse 117 L V E D E A G T G - 1 2 6 388 - A S A T G S C -396 438- Y G L  1 NYYQS- 446
Zebrafish 90 - - E D E O - E P •1W 370* 1 S A T G S C *378 4 2 0 - Y G L S N Y Y Q S  '428
Winter flounder 114 D S S E E E E E E - 1 2 2 385- 1 s  a |t G A C *393 437- HG 1 M N Y Y Q S - 4 4 5
Figure 1: Multiple alignment analysis shows conservation among species of the identified NCC mutant amino 
acids (light blue bar). Blue and black letters represent conserved and non-conserved amino acids, respectively.
Screening for SLC12A3 deletions
To investigate the occurrence of deletions or duplications, multiplex ligation-dependent probe 
amplification (MLPA) analysis was performed for cases with only a single heterozygous 
mutation, and for cases with a homozygous mutation in which segregation in the family could 
not be confirmed. In these patients we identified 6 heterozygous deletions, which affect at 
least part of the SLC12A3 coding region. Moreover, patient 94, in whom exons 5 and 6 could 
not be amplified by sequence analysis, a homozygous deletion of both exons was 
discovered. All deletions detected in this study are predicted to result in a frame shift and
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premature translational termination (Table 1; supp lem entary tab le  1). Altogether, the GS 
diagnosis was confirmed in 164/263 patients (62%), and 303/526 alleles (58%) have been 
identified.
Figure 2: Schematic topological representation of NCC, which consists of large intracellular N -and C-terminal 
domains, which are located within the cell, 12 transmembrane segments (S) and a large hydrophilic extracellular 
loop between S7 and S8 comprising two glycosylation sites. Every dot represents one amino acid and the 
localization of the newly identified NCC mutations is denoted by a white dot (number 1-7).
Wild-type and mutant NCC transport activity
At present, SLC12A3 missense mutations have been shown to affect 158 of the in total 1030
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NCC amino acids. Nevertheless, the functional consequence of most mutations has not been 
investigated. 7 identified NCC missense mutations, including 6 previously unidentified 
(Glu121Asp, Asn442Ser, Ser475Cys, Tyr489His, Pro751Leu, Gln1030Arg) and one known 
variant (Thr392Ile) were selected to study their effect on NCC function. Thr392Ile was 
picked, as it appeared de novo together with the Asn442Ser variant in one patient. These 
NCC mutants affect amino acids, which are highly conserved among species (F igure 1). The 
localization of each examined mutant in the proposed topology of NCC is shown in F igure 2. 
The Glu121Asp mutation is located within the N-terminus, the Thr392Ile and Asn442Ser 
mutations are positioned in the large extracellular loop, the Ser475Cys and Tyr489His are 
located in the fourth intracellular loop and the Pro751Leu and Gln1030Arg mutations reside 
in the C-terminus. The functionality of each mutant NCC transporter was investigated using 
the Xenopus laevis oocyte heterologous expression system. To compare 22Na+ uptake 
between wild-type and each mutant NCC, all groups of oocytes were injected with 10 ng 
cRNA/oocyte. At the same day of the NCC-mediated 22Na+ uptake experiments, in parallel, 
micro-injected Xenopus laevis oocytes were selected to determine total membrane NCC 
protein expression using Western blotting analysis.
As shown in F igure 3A, total NCC expression was identical in all tested mutants. 22Na+ 
uptake by wild-type and mutant NCC-expressing oocytes was performed in the absence and 
presence of the thiazide diuretic, metalozone. In comparison to wild-type (100%), the 
thiazide-sensitive 22Na+ uptake was significantly diminished for all mutants (Glu121Asp, 46 ± 
5%; Thr392Ile, 37 ± 4%; Asn442Ser, 74 ± 10%; Ser475Cys, 61 ± 8%; Tyr489His, 67 ± 7%; 
Pro751Leu, 72 ± 5%; Gln1030Arg, 68 ± 7%) (% relative to wild-type, n=53 to 69 oocytes) 
(Figure 3B). In the presence of thiazides, wild-type and mutant NCC expressing oocytes 
showed equal levels of 22Na+ uptake as H2O-injected oocytes, demonstrating specific tracer 
uptakes for wild-type and mutant-mediated NCC uptake. Interestingly, the transport activity of 
the Thr392Ile mutant appeared totally abolished (similar levels of uptake for the Thr392Ile 
mutant in the absence and presence of thiazides or H2O-injected oocytes) (Figure 3B). 
Decreased transport activity, as observed for each NCC mutant, can result from impaired 
processing, disrupted membrane internalization or reduced function at the cell membrane. To 
assess which of these processes are involved for each specific NCC mutant the cell surface 
localization was examined.
Surface expression of wild-type and mutant NCC
Xenopus laevis oocytes were injected with H2O, wild-type or mutant enhanced Green 
Fluorescent Protein (eGFP)-NCC to study cell surface expression using confocal microscopy
[22].
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A
Figure 3: Expression and functional consequence of exogenous wild-type and mutant NCC in Xenopus laevis 
oocytes. A. Western blotting analysis of the total membrane fraction of oocytes injected with H2O, wild-type or 
mutant NCC cRNA. B. 22Na+ uptake was measured in oocytes injected with H2O, wild-type or mutant NCC cRNA 
(open bars). For all groups, transport assays were also performed in the presence of NCC blocker metolazone 
(black bars). Uptake values were shown as percentage in which wild-type was set as 100%. Wt: wild-type; 121: 
Glu121 Asp; 392: Thr392Ile; 442: Asn442Ser; 475: Ser475Cys; 489: Tyr489His; 751: Pro751Leu; 1030: 
Gln1030Arg; NCC glyc: glycosylated NCC; kDa: kilodalton. Data is presented as means ± SEM. * P<0.05, 
indicates significant difference in relation to Wt NCC- injected oocytes.
F igure 4A depicts representative images of Xenopus laevis oocytes injected with H2O, wild­
type or mutant eGFP-NCC as stated, while F igure 4B presents the combined densitometric 
quantification of 3 independent experiments (~10 oocytes/ experiment), in which the total 
fluorescence of wild-type eGFP-NCC was quantified and set at 100%. The total fluorescence 
of oocytes expressing wild-type eGFP-NCC proteins was significantly different from H2O- 
injected oocytes (100 ± 9%, n=44 versus 6 ± 1%, n=62, respectively). In addition, the 
surface localization of NCC was significantly impaired for some of the mutants, namely 
Thr392Ile (38 ± 5%), Asn442Ser (44 ± 5%) and Gln1030Arg (68 ± 7%) (n=26 to 53; Figure 
4). The plasma membrane localization of the NCC mutants Glu121Asp (104 ± 13%), 
Ser475Cys (108 ± 15%), Tyr489His (97 ± 10%) and Pro751Leu (110 ± 16%) was not 
affected (n=22 to 44; F igure 4), which points towards an intrinsic defect in NCC function as 
the reason for the observed decreased transport activity.
B
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Figure 4: Surface expression of wild-type or mutant NCC protein in Xenopus laevis oocytes, assessed by 
measuring fluorescence using laser-scanning confocal microscopy. A. representative confocal images of 
Xenopus laevis oocytes expressing wild-type or mutant eGFP-NCC. B. All wild-type (open bar) and mutant (black 
bars) images were quantified by measuring pixel intensity, while wild-type was set to 100%. Wt: Wild-type; 121: 
Glu121 Asp; 392: Thr392Ile; 442: Asn442Ser; 475: Ser475Cys; 489: Tyr489His; 751: Pro751Leu; 1030: 
Gln1030Arg. Data is presented as means ± SEM. * P<0.05, indicates significant difference in relation to Wt NCC- 
injected oocytes.
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D iscussion
GS is an autosomal recessive salt wasting disorder characterized by hypokalemic metabolic 
alkalosis and secondary hypomagnesemia and hypocalciuria (OMIM 263800). The 
underlying cause for GS is loss-of-function mutations and deletions in the SLC12A3 gene 
[19, 20, 23]. In the present study the DNA of 263 patients with a clinical suspicion of GS was 
collected. The complete SLC12A3 coding and flanking regions were screened for mutations 
in these patients. In patients with a single heterozygous mutation, and in patients with a 
homozygous mutation we subsequently analyzed all exons for the occurrence of deletions 
using MLPA.
Altogether, the GS phenotype was explained for 38 homozygous (15%) and 101 compound 
heterozygous (38%) patients. However, in 25 patients (10%) a mutation in only one of the 
alleles was identified, while 99 patients presented no mutation (38%) (Supplem entary table
1). The pattern of inheritance for GS is autosomal recessive, which is confirmed by the fact 
that heterozygous relatives are clinically and metabolically asymptomatic. For that reason, it 
is likely that there was a failure to detect a mutation on the other allele in case of the 
heterozygous patients. Several possibilities may explain why 38% of our cohort was negative 
for mutations in SLC12A3: (i) patients may be misdiagnosed for GS; (ii) the genetic 
alterations are located in gene regions that were not analyzed, such as promoter sequence, 
3' or 5’ UTR or intronic sequences; (iii) mutations in a second gene may also cause GS. For 
instance, mutations in the CLCNKB gene, encoding ClC-Kb, can cause a phenotypic 
spectrum from antenatal Bartter syndrome (BS) to a more GS-like phenotype with 
hypomagnesemia and hypocalcemia. BS is a renal autosomal recessive disorder, defined by 
hypokalemic metabolic alkalosis, which is similar to the GS phenotype.
The SLC12A3 gene encodes the thiazide-sensitive NCC protein, which localizes to the 
luminal membrane of the DCT in the kidney. In these epithelial cells, NCC mediates the 
reabsorption of Na+ and Cl- from the pro-urine to the intracellular compartment. As previously 
shown for Na+ transporters such as NKCC2 and NCC, there are at least five potential 
mechanisms (class 1-5) by which mutations can reduce or abolish the activity of the 
transporter [16].
Class 1 mutants exhibit decreased protein stability leading to a complete absence of the 
transporter due to improperly processed or unstable mRNA. This often results from promoter 
alterations, splice site mutations, premature stop codons or deletions. In the present study 
we identified 9 splice site mutations, 4 nonsense mutations and 7 deletions (Supplem entary 
tab le  1 and Table 1), which may result in abnormal splicing of the mRNA transcript, insertion 
of a premature termination codon or frame shift in the transcript, leading to a truncated
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mutant mRNA transcript, and therefore low levels of NCC protein expression [24]. The effect 
of the c.(?_-6)_852+? and c.-66_23del deletions are unclear, since the start codon is within 
the deletion. For the c.-66_23del deletion it can be expected that either no protein is 
produced or that the translation initiation site has been moved downstream to Met53. The 
deletion of exons 1-6 (c.(?_-6)_852+?) probably disrupts protein production. The 4 intragenic 
deletions (exons 4-6, 5-6, 18 and 24) and the 9 identified splice site mutations are predicted 
to lead to a frameshift and premature stopcodon. Due to this premature termination (which 
also holds true for the four newly identified nonsense mutations), nonsense-mediated decay 
of the RNA is predicted and therefore probably no protein will be produced on these mutant 
alleles. The terminal deletion of exon 26 does not lead to nonsense-mediated decay, but 
probably will mimic missense mutations in the C-terminal part of the protein.
Table 2: Summary of the different classes of NCC mutant in the present GS patients
Uptake (%) Membrane localization (%)
Mutant
class
H20 17 ± 3 6 ± 1 -
(n = 81)
■'3'II£=
Wild-type 100 ±8 100 ±9 -
(n = 65) i  = 62)
Glu121Asp 46 ±5 104 ± 13 4
(n = 62) (n = 33)
Thr392lle 37 ±4 38 ±5 2
(n = 53) (n = 26)
Asn442Ser 74 ± 10 44 ±5 3
(n = 64) (n = 31)
Ser475Cys 61 ±8 108 ± 15 4
(n = 75) (n = 26)
Tyr489His 67 ± 7 97 ±10 4
(n = 58) (n = 26)
Pro751 Leu 72 ±5 110± 16 4
n = 59) n = 22)
Gln1030Arg 68 ±7 69 ±7 3
(n = 69) (n = 53)
The NCC mutant class (1-5) 
was determined by 
measuring Na+ uptake 
capacity (Figure 3) and cell 
surface localization (Figure 
4) in Xenopus laevis 
oocytes, expressing wild­
type or one of the 7 
selected NCC mutants 
(Table 1). Class 1) 
decreased protein stability; 
class 2) impaired protein 
processing; class 3) 
disrupted insertion of an 
otherwise functional protein 
into plasma membrane; 
class 4) impair functional 
properties of the 
cotransporter at the cell 
membrane; class 5) 
accelerated protein removal 
or degradation.
Additionally, we discovered 30 novel SLC12A3 missense mutations, which lead to amino 
acid substitutions with an unknown effect on NCC function. 6 of these novel missense 
mutations and one previously described missense mutation [25] were selected and 
introduced into NCC to study their effect on protein stability, cellular localization and uptake 
activity by use of the Xenopus laevis oocyte as an established heterologous expression
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system (F igure 1). Mutations in class 2 do not affect protein translation, but impair protein 
processing. As a result of misfolding, the NCC protein is retained in the ER and consequently 
targeted for degradation. Several studies have shown examples of class 2 NCC mutants [12­
14].
In our study, we identified one mutant with class 2 NCC mutant characteristics. The 
Thr392Ile mutation displayed severely reduced Na+ uptake, which was identical to 
background. Furthermore, the amount of Thr392Ile NCC mutant on the plasma membrane 
was severely decreased (Figure 3B and Table 2). Previously, Hoover et al. showed that 
proper N-linked glycosylation of both residues (N404 and N424) in NCC is required for 
sufficient processing [22]. The Thr392Ile mutation is situated in close proximity of these sites 
and may therefore hamper glycosylation. Interestingly, the upper band, which represents 
glycosylated NCC, seems to be absent for the Thr392Ile mutation on the Western blot 
(Figure 2B). So, impaired glycosylation of the Thr392Ile mutant, likely obstructs processing 
to the plasma membrane and consequently diminishes the NCC transport activity.
Class 3 mutants disrupt insertion of an otherwise functional protein into the plasma 
membrane. These mutations are characterized by a reduced Na+ uptake and cytoplasm/ ER 
and plasma membrane localization. Most previously identified NCC mutants belong to class 
3 [12-14] and examples in our study are Asn442Ser and Gln1030Arg (Table 2). Presumably, 
these mutations produce NCC proteins of which the plasma membrane trafficking or 
internalization is affected. Interestingly, the Gln1030Arg mutation changes the last amino 
acid of NCC. Possibly, the Gln1030 amino acid is part of a protein-protein interaction motif, 
which is essential for trafficking.
Most of the mutations in our study belong to class 4. The Glu121Asp, Ser475Cys, Tyr489His 
and Pro751Leu mutations did reach the plasma membrane, however, their Na+ uptake rate 
was significantly reduced in comparison to wild-type NCC (Table 2). Notably, mutants 
Glu121Asp and Pro751Leu are situated within the N- and C-terminus of the protein (Figure 
1B), suggesting a role in activation or regulation. The Ser475Cys and Tyr489His mutants are 
positioned in or nearby the large extracellular loop, which may indicate a role for these amino 
acids in ion affinity. The Glu121Asp, Pro751Leu, the Ser475Cys and Tyr489His NCC 
mutants are interesting candidates to be tested for NCC transport regulation and kinetics. 
None of the studied mutants meet the criteria of a class 5 mutation in which protein removal 
or degradation is accelerated.
Interestingly, substances that assist protein folding (chemical chaperones) have been 
successfully used to restore the trafficking and function of mutant proteins in case of the 
vasopressin type 2 receptor and cystic fibrosis transmembrane conductance regulator [26, 
27]. It would be interesting to investigate chaperone-induced trafficking of mutant NCC
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proteins (Table 2), to ultimately use these chaperones as potential therapeutic agents. 
Altogether, this data contributes to the further understanding of the function and regulation of 
NCC. Future studies are needed to evaluate phenotype-genotype correlations to ultimately 
be able to predict, prevent or treat GS.
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Supplem entary figu res
Supplementary table 1: SLC12A3 sequence variants in patients with clinical suspicion of GS.
Fam 
. no.
Allele 1 Allele 2
1 c.815T>C p.Leu272Pro - -
2 c. 1175C>T p.Thr392Ile c.2965G>A p.Gly989Arg
3 c.1925G>A p.Arg642His c.1925G>A p.Arg642His
4 c.2576T>C p.Leu859Pro c.2883+1 G>T splice defect
5 c.514T>C p.Trp172Arg c.514T>C p.Trp172Arg
6 c.581 C>T p.Thr194Ile c.2899A>G p.Arg967Gly
7 c.1465T>C p.Tyr489His c.1567G>A p.Ala523Thr
8 c.1121G>A p.Gly374Glu c.1335+1 G>A splice defect
10 c.2883+1G>T splice defect c.2883+1G>T splice defect
11 c.248G>A p.Arg83Gln c.433C>T p.Arg145Cys
13b c.2089_2095del p. Thr697fs c.2089_2095del p. Thr697fs
16 c.3053G>A p.Arg1018Gln c.3053G>A p.Arg1018Gln
17 c.2883+1G>T splice defect - -
18 c.2883+1G>T splice defect c.2179-? 2285+?delc p.Ala727X
20b,d c.704C>G p.Thr235Arg c.1145C>T p.Thr382Met
c.2221 G>A p.Gly741Arg c.1145C>T p.Thr382Met
21 c.2965G>A p.Gly989Arg c.2965G>A p.Gly989Arg
22b c. 1924C>T p. Arg642Cys c.2368+5G>A splice defect
23e c.2883+1G>T splice defect - -
24b c. 1315G>A p.Gly439Ser c.2965G>A p.Gly989Arg
25 c.741 +1 G>A splice defect c.2687G>A p.Arg896Gln
26b c.2581 C>T p.Arg861Cys c.2981 G>A p.Cys994Tyr
28 c. 1925G>A p.Arg642His c.2221 G>A p.Gly741Arg
29 c. 1925G>A p.Arg642His c.2221 G>A p.Gly741Arg
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31a c.2981 G>A p.Cys994Tyr
34 c.775G>A p.Asp259Asn
35 c. 1606T>C p.Phe536Leu
36 c.-66 23del p.0? f
37 c.1195C>T p.Arg399Cys
38g c.1196 1202dup p.Ser402X
39a c.2089 2095del p. Thr697fs
40 c.938C>T p.Ala313Val
41 c.2221 G>A p.Gly741Arg
42 c. 1387G>A p.Gly463Arg
43 c.363G>C p.Glu121Asp
44 c.1196 1202dup p.Ser402X
46b c.1636A>G p.Ser546Gly
49 c.1180+1G>T splice defect
50 c.1024G>T p.Gly342X
51 c. 1664C>T p.Ser555Leu
52b c.2221 G>A p.Gly741Arg
53 c.457G>A p.Val153Met
54 c.2929C>T p.Arg977X
56 c.514T>C p.Trp172Arg
57 c.2883+1G>T splice defect
58a c.815T>C p.Leu272Pro
59 c.2687G>A p.Arg896Gln
60bj c.2687G>A p.Arg896Gln
64 c.2660+1G>C splice defect
68 c. 1924C>G p.Arg642Gly
69a c.2186G>T p.Gly729Val
70 c.1325A>G p.Asn442Ser
75 c.247C>T p.Arg83Trp
76b c.626G>A p.Arg209Gln
77 c.2883+1G>T splice defect
78 c. 1928C>T p.Pro643Leu
79b c.2037+4A>G splice defect
81 c.1335+1G >C splice defect
82 c. 1387G>A p.Gly463Arg
84 c.2221 G>A p.Gly741Arg
85 c.2965G>A p.Gly989Arg
86 c.237 238dup p.Arg80fs
87k c. 1387G>A p.Gly463Arg
88 c.1196 1202dup p.Ser402X
89 c.506-1G>A splice defect
90 c. 1315G>A p.Gly439Ser
91a c.911 C>T p.Thr304Met
93 c.1424C>G p.Ser475Cys
94 c.602-? 852+?del p.Gly502fs
95 c.2221 G>A p.Gly741Arg
97g c. 179C>T p.Thr60Met
98 c.488C>T p.Thr163Met
99a c.2531 G>A p.Trp844X
100 c.1669+5G>T splice defect
101 c.473G>T p.Arg158Leu
102b c.247C>T p.Arg83Trp
103b c.2186G>T p.Gly729Val
1 05 c.2883+1 G>T splice defect
107 c.470T>C p.Leu157Pro
111 c.2221 G>A p.Gly741Arg
112 c.2883+1G>T splice defect
c.2981 G>A p.Cys994Tyr
c.2221 G>A p.Gly741Arg
c.1180+1G>T splice defect
c.1195C>T p.Arg399Cys
c.2965G>A p.Gly989Arg
c.2089 2095del p. Thr697fs
c.2221 G>A p.Gly741Arg
(?_-6)_852+?delh p.0?f
c.602-16G>A splice defect
c.1196 1202dup p.Ser402X
c.1925G>A p.Arg642His
c.1180+1G>T splice defect
c.2221 G>A p.Gly741Arg
c.2965G>A p.Gly989Arg
c.1925G>A p.Arg642His
p.Lys918_Thr985d
c.2748-? 2951+?del el
c.1664C>T p.Ser555Leu
c.1196 1202dup p.Ser402X
c.815T>C p.Leu272Pro
(?_-6)_852+?delh p.0?f
c.2221 G>A p.Gly741Arg
c.2891 G>A p.Arg964Gln
c.2642T>C p.Met881Thr
c.2869A>T p.Lys957X
c.2204C>G p.Pro735Arg
c.2186G>T p.Gly729Val
c.2186G>T p.Gly729Val
c.2883+1 G>T Splice defect
c.1387G>A p.Gly463Arg
c.2891 G>A p.Arg964Gln
c.3089A>G p.Gln1030Arg
c.237 238dup p.Arg80fs
c.2581 C>T p.Arg861Cys
c.506-1G>A splice defect
c.2883+1 G>T splice defect
c.1925G>A p.Arg642His
c.602-?_852+?dell p.Gly502fs
c.2581 C>T p.Arg861Cys
c.2221 G>A p.Gly741Arg
c.488C>T p.Thr163Met
c.2952-?_3077+?delm p.Ile984fs
c.1180+1G>T splice defect
c.514T>C p.Trp172Arg
c.3052C>T p.Arg1018X
c.2965G>A p.Gly989Arg
c.2221 G>A p.Gly741Arg
c.2981 G>A p.Cys994Tyr
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114 c.815T>C p.Leu272Pro c.2883+1 G>T splice defect
115 c.2252C>T p.Pro751 Leu - -
118 c.450T>G p.Ile150Met c.2883+1 G>T splice defect
120 c.2221 G>A p.Gly741Arg c.2883+1 G>T splice defect
121 c.1519C>T p.Arg507Cys c.506-? 852+?n p.Val169fs
122b c.2542G>A p.Asp848Asn c.2965G>A p.Gly989Arg
1 23 c.910A>C p.Thr304Pro c.2883+1 G>T splice defect
128 c. 1928C>T p.Pro643Leu c.1928C>T p.Pro643Leu
129 c.2572C>T p.Leu858Phe c.2572C>T p.Leu858Phe
134 c.961 C>T p.Arg321Trp c.1844C>T p.Ser615Leu
138 c.2221 G>A p.Gly741Arg c.248G>A p.Arg83Gln
1 40 c.1964G>A p.Arg655His c.3053G>A p.Arg1018Gln
147o c.1175C>T p.Thr392Ile c.1325A>G p.Asn442Ser
148 c.1096-1G>A splice defect c.1096-1G>A splice defect
149 c.237 238dup p.Arg80fs - -
152 c.2089 2095del p.Thr697fs c.2089_2095del p.Thr697fs
153 c.815T>C p.Leu272Pro - -
1 54 c.2576T>C p.Leu859Pro c.3053G>A p.Arg1018Gln
1 55 c. 1000C>T p.Arg334Trp c.2221 G>A p.Gly741Arg
159b c.184G>C p.Asp62His c.237_238dup p.Arg80fs
163 c.533C>T p.Ser178Leu c.2827C>T p.Arg943Trp
165 c.505+5G>A splice defect c.2221 G>A p.Gly741Arg
166 c.2221 G>A p.Gly741Arg c.3052C>T p.Arg1018X
168 c.965-1 976delins12 p.Asp323fs c.2532G>A p.Trp844X
1 69 c.1664C>T p.Ser555Leu c.2883+1 G>T splice defect
170a c.2221 G>A p.Gly741Arg - -
171 c.2883+1G>T splice defect c.2221 G>A p.Gly741Arg
173 c.2883+1G>T splice defect c.2221 G>A p.Gly741Arg
175 c.2877 2878del p.Arg959fs c.2929C>T p.Arg977X
176 c.2221 G>A p.Gly741Arg c.2981 G>A p.Cys994Tyr
177 c.2965G>A p.Gly989Arg c.1195C>T p.Arg399Cys
181 c.1956del p.Asn653fs c.626G>A p.Arg209Gln
182 c.2221 G>A p.Gly741Arg - -
1 84 c.2883+1 G>T splice defect c.1601 A>G p.Asn534Ser
185 c.247C>T p.Arg83Trp c.2221 G>A p.Gly741Arg
186 c.2883+1G>T splice defect c.2883+1G>T splice defect
187 c.815T>C p.Leu272Pro c.1844C>T p.Ser615Leu
189 c.910A>C p.Thr304Pro c.910A>C p.Thr304Pro
190 c.497C>T p.Ala166Val c.2981 G>A p.Cys994Tyr
192 c.2164C>T p.Gln722X - -
193 c. 1924C>T p.Arg642Cys c.2965G>A p.Gly989Arg
196 c.1196 1202dup p.Ser402X - -
197 c.815T>C p.Leu272Pro c.815T>C p.Leu272Pro
1 98 c.2221 G>A p.Gly741Arg c.363G>C p.Glu121Asp
1 99 c.2576T>C p.Leu859Pro c.2221 G>A p.Gly741Arg
200 c.2883+1G>T splice defect c.2883+1G>T splice defect
202 c.506-1 G>A splice defect c.505+5G>A splice defect
203 c.2830C>Tp p.Arg944Trp - -
204 c.815T>C p.Leu272Pro c.2883+1 G>T splice defect
205 c.815T>C p.Leu272Pro c.1664C>T p.Ser555Leu
206b c.2548G>C p.Gly850Arg c.2548G>C p.Gly850Arg
207 c.2089_2095del p.Thr697fs c.947G>T p.Gly316Val
209 c.2221 G>A p.Gly741Arg c.2821G>T p.Glu941X
212 c.247C>T p.Arg83Trp c.247C>T p.Arg83Trp
213 c. 1928C>T p.Pro643Leu c.1928C>T p.Pro643Leu
216 c.815T>C p.Leu272Pro c.2929C>T p.Arg977X
217 c.2204C>G p.Pro735Arg c.602-16G>A splice defect
219a c.2981 G>A p.Cys994Tyr c.2981 G>A p.Cys994Tyr
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220 c.2221 G>A p.Gly741Arg c.817dup p.Ala273fs
221 c. 1315G>A p.Gly439Ser c.1315G>A p.Gly439Ser
222 c.2884-6G>A splice defect - -
223 c.1390G>A p.Ala464Thr c.2548+1G>T splice defect
c.[575T>C;1698 1700 p.[Ile192Thr;Asn c.[575T>C;1698 1700 p.[Ile192Thr;Asn
225q del] 566del] del] 566del]
226 c.815T>C p.Leu272Pro c.1335+1 G>T splice defect
227 c.1939G>A p.Val647Met c.1939G>A p.Val647Met
228 c.815T>C p.Leu272Pro c.815T>C p.Leu272Pro
229 c.815T>C p.Leu272Pro c.815T>C p.Leu272Pro
230 c.815T>C p.Leu272Pro c.815T>C p.Leu272Pro
235 c.2221 G>A p.Gly741Arg c.2981 G>A p.Cys994Tyr
236a c.2497T>A p.Ser833Thr
p.Gln433_Cys436
- -
238 c.1298 1308delinsTG delinsLeu c.815T>C p.Leu272Pro
239 c.1568-4G>A splice defect - -
245 c.1679C>G p.Pro560Arg c.1679C>G p.Pro560Arg
248 c.2221 G>A p.Gly741Arg c.2221 G>A p.Gly741Arg
252 c.2611 C>T p.Arg871Cys
p.Lys706_Ile713d
c.247C>T p.Arg83Trp
253 c.2115 2139dup up c.2883+1 G>T splice defect
255 c.815T>C p.Leu272Pro c.2883+1 G>T splice defect
256 c.403C>T p.Arg135Cys - -
257 c.3053G>A p.Arg1018Cys c.3053G>A p.Arg1018Cys
258 c.2221 G>A p.Gly741Arg c.2883+1 G>A splice defect
261 c.815T>C p.Leu272Pro c.1274G>A p.Trp425X
262 c.2221 G>A p.Gly741Arg c.2221 G>A p.Gly741Arg
263 c.815T>C p.Leu272Pro c.1664C>T p.Ser555Leu
GenBank accession number NM_000339.2 is used as a reference sequence in which the A of ATG is number 1. 
Intron sequences can be found in NT_010498.15. Mutations that have not been described before are indicated in 
bold.
a MLPA analysis could not be performed because of insufficient DNA, or did not give reliable results
because of poor DNA quality. For all other samples with a homozygous mutation, or a single 
heterozygous mutation, MLPA analysis has been performed 
b Mutations are located on opposing alleles.
c Deletion of exon 18
d In this family the father has two mutations (p.Thr235Arg and p.Thr382Met). Both children inherit the
p.Thr235Arg from their father and the p.Gly741Arg mutation from their mother (who is a healthy carrier 
of the disease)
e Mother and both children carry the mutation. The mother only suffers from low Mg levels, whereas the
children both have typical GS features. A second mutation on the paternal allele has not been detected. 
f Probably no protein is produced, because the start codon is deleted.
g Two affected children both have the same mutations. DNA of the parents was not available for analysis.
Thus, it is not proven that both mutations are on opposite alleles. 
h Deletion of exons 1 to 6. The 5' end of the MLPA probe is located on position -6 (i.e. 6 bases preceding
the start codon)
I Deletion of exons 24 and 25 (in frame)
j In this family pseudo-dominant inheritance is seen. The index patient has two mutations, whereas both
his affected children inherit only one mutation. The mutation on the second allele could not be identified. 
k Mutation p.Arg852Cys is inherited from the father. The other mutation, p.Glu463Arg is de novo in the
patient, but could theoretically be located on the same allele. 
l Deletion of exons 5 and 6
m Deletion of exon 26. The 3'end of the MLPA probe is located on position 3077. 
n Deletion of exons 4 to 6
o Both mutations occurred de novo
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This variant could be a polymorphism because no second mutation has been identified and the variant is 
in dbSNP (rs56125220... )
Both mutations are present homozygously. Deletions have been excluded by MLPA. Based on the 
conservation and the location of the amino acids involved, we assume that the p.Ile192Thr mutation is 
causing the phenotype in the patient.
Insertion of ACCGAAAATTTT.
p
Supplementary table 2: Primer sequences used to Introduce mutations In NCC.
Am ino acid 
(Mutation)
Primer sequence (5 -3 ')
G lu121Asp F GATGGGCTGGTGGAGGGCGAcGCAGGCACCAGCAGCGAG
R CTCGCTGCTGGTGCCTGCgTCGCCCTCCACCAGCCCATC
Thr392lle F CCTGGCCATCTCAGCCAtCATTGGCTCCTGCGTGG
R CCACGCAGGAGCCAATGaTGGCTGAGATGGCCAGG
Asn442Ser F CCACTACGGCCTCATCAgCTATTACCAGACCATGAG
R CTCATGGTCTGGTAATAGcTGATGAGGCCGTAGTGG
Ser475Cys F CTGGCCTGCCTTGTCTgTGCTGCCAAAGTCTTCC
R GGAAGACTTTGGCAGCAcAGACAAGGCAGGCCAG
Tyr489His F CTTTGCGAGGACCAGCTGcACCCACTGATCGGCTTC
R GAAGCCGATCAGTGGGTgCAGCTGGTCCTCGCAAAG
Pro751Leu F CTGGCAGTCGGCTCACCtGGCCACAGTGGAAGAC
R GTCTTCCACTGTGGCCaGGTGAGCCGACTGCCAG
Gln1030Arg F CTCACCTTTTACTGCCgGTAACTCCAGGCTTTGAC
R GTCAAAGCCTGGAGTTACcGGCAGTAAAAGGTGAG
Primers used to introduce the selected GS mutations in the NCC constructs using mutagenesis PCR. F: Forward; 
R: Reverse.
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A bstract
Primary hypomagnesemia forms a heterogeneous group of disorders characterized by renal 
or intestinal magnesium (Mg2+) wasting, resulting in tetany, cardiac arrhythmias, and 
seizures. The kidney plays an essential role in maintaining serum Mg2+ levels with a 
prominent function for the Mg2+-transporting channel TRPM6 in the distal convoluted tubule 
(DCT). In DCT, Mg2+ reabsorption is an active transport process primarily driven by the 
negative potential across the luminal membrane. Here, by use of a positional cloning 
approach in a family with isolated autosomal dominant hypomagnesemia we identified a 
N255D mutation in KCNA1, a gene encoding the voltage-gated potassium (K+) channel 
Kv1.1. Patch clamp analysis showed that the mutation results in a non-functional channel 
with a dominant negative effect on wild-type Kv1.1 channel functioning. Cell surface 
biotinylation experiments demonstrated that wild-type Kv1.1, Kv1.1 N255D and combinations 
hereof were able to reach the plasma membrane in similar amounts. Furthermore, Kv1.1 is 
expressed in the kidney, where it co-localizes with the Mg2+-permeable channel TRPM6 
along the luminal membrane of DCT. Thus, Kv1.1 is a renal K+ channel that establishes a 
favourable luminal membrane potential in DCT cells to control the TRPM6-mediated Mg2+ 
reabsorption.
In troduction
Occurrence of hypomagnesemia (serum Mg2+ levels below 0.70 mmol/L) in the general 
population has been estimated around 2%, while hospitalized patients are more prone to 
develop hypomagnesemia (12%) [1]. Recent studies of intensive care patients have even 
estimated frequencies as high as 60% [2]. The blood Mg2+ concentration depends on the 
renal Mg2+ excretion in response to altered uptake by the intestine. Hence, the kidney is 
essential for the maintenance of the Mg2+ balance [3]. The majority of filtered Mg2+ is 
reabsorbed along the proximal tubule and the thick ascending limb of Henle’s loop via a 
passive paracellular pathway [4]. However, fine-tuning of Mg2+ excretion occurs in the distal 
convoluted tubule (DCT) in an active transcellular fashion initiated by the Mg2+-permeable 
Transient Receptor Potential Melastatin subtype 6 channel (TRPM6) [5, 6]. Since the extra- 
and intracellular Mg2+ concentration are both in the millimolar range, it has been 
hypothesized that the membrane potential across the luminal membrane acts as the primary 
driving force for Mg2+ entry via TRPM6 [6, 7]. Previously, genetic studies in families with 
hereditary renal Mg2+ wasting syndromes revealed several new genes involved in Mg2+
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homeostasis, including tight junction proteins claudin 16 and 19 [8, 9], the thiazide-sensitive 
sodium chloride cotransporter (NCC) [10], the y-subunit of the Na+,K+-ATPase (FXYD2) [11], 
TRPM6 [12, 13] and the recently discovered magnesiotropic hormone epidermal growth 
factor (EGF) [14]. Despite these discoveries, our knowledge of renal Mg2+ handling remains 
far from complete.
Materials and m ethods
Subjects- We identified a large family (46 family members, 21 affected) with autosomal 
dominant hypomagnesemia (F igure 1A). Phenotype in the proband (IV-3) starting from 
infancy; recurrent muscle cramps, tetanic episodes, tremor and muscle weakness, especially 
in distal limbs. There were no seizures, recurrent urinary tract infections, polyuria, polydipsia 
and renal stones. At 4 years, a significant hypomagnesemia (0.37 mmol/L; normal 0.70-0.95 
mmol/L) was determined. Serum K+ (3.9 mmol/L; normal 3.5-5.0 mmol/L), Ca2+ (2.35 mmol/L; 
normal 2.15-2.50 mmol/L), sodium, phosphate, uric acid, bicarbonate, urea, creatinine, 
glucose, bilirubin, aminotransferases, alkaline phosphate, lactate dehydrogenase were all 
normal. Urinary creatinine clearance, urinary Mg2+ excretion (2.8 mmol/24h; normal 2.1-6.2 
mmol/24h) and Ca2+ excretion were also normal. The patient received a daily dose of 
magnesium chloride, which improved muscular weakness, but slight muscle cramps 
persisted particularly after physical activity. One of her younger brothers (IV-1, F igure 1A) 
died in infancy by a severe attack of cramps and tetany. At that time the serum Mg2+ level 
was as low as 0.28 mmol/L. In addition to these two patients 18 other family members had 
shown similar clinical manifestations and biochemical features. The proband was tested for 
signs of cerebellar dysfunction, and admitted to have experienced several periods of 
uncertainty in walking, where she was not able to walk straight. Objective clinical signs of 
cerebellar dysfunction, including nystagmus, multistep or overshoot saccades, dysmetria in 
the finger-nose test, and decomposition of movement of the legs on heel-to-shin test, were 
absent. However, on a cerebral MRI of the proband we found evidence of slight atrophia of 
the cerebral vermis (data not shown). Furthermore, electromyographs of some affected 
members showed myokymic discharge in line with the previously observed mixed phenotype. 
We collected blood samples of the family members (both affected and non-affected; Figure 
1A) for linkage analysis. Subsequently, DNA was extracted according to standard protocols. 
Control genomic DNA samples (n=100) were kindly provided by Dr. H. van Bokhoven 
(Department of Human Genetics, Radboud University Nijmegen Medical Centre, The
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Netherlands). The study was approved by the Clinical Hospital, Parana Federal University 
(Curitiba, Parana, Brazil) and written informed consent was obtained from the subjects.
Genetic linkage analysis- A genome-wide linkage approach was performed for 12 family 
members selected based on simulations in SLINK using the Affymetrix GeneChip® mapping 
10K 2.0 Array harboring 10,204 SNPs. Sample preparation and hybridization was performed 
according to the manufacturer’s protocol (Affymetrix, Inc., Santa Clara, CA, USA) [29]. 
Briefly, 250 ng of genomic DNA was digested using 10 units XbaI (Westburg, Leiden, The 
Netherlands) followed by ligation using T4 DNA ligase (Westburg) of universal adaptors to 
the digested products. Primers complementary to the adaptors were used for amplification of 
the digested products. After purification of the products using MinElute™ plates (Qiagen, 
Venlo, The Netherlands) a fragmentation was performed on 20 |jg purified PCR product. 
Fragmented products were end-labeled and hybridized to the Affymetrix 10K GeneChip® 
overnight. Hybridized arrays were washed and stained using the Fluidics Station 400 
(Affymetrix). The GeneChip® Scanner 3000 was used to scan the hybridized arrays. 
Automatic SNP calls were generated using GeneChip DNA analysis software (GDAS; 
Affymetrix). SNP calls are AA or BB for homozygous SNPs, AB for heterozygous SNPs. 
When the software was unable to make a call (AA, BB or AB), the SNP was scored as No 
Call. LOD scores were calculated using Merlin software 
(www.sph.umich.edu/csg/abecasis/Merlin/index.html). Eight microsatellite markers 
(D12S1626, D12S1725, D12S99, D12S374, D12S1623, D12S336, D12S77 and D12S89) 
were selected to fine-map the newly identified hypomagnesemia loci on the short arm of 
chromosome 12 (http://genome.ucsc.edu/cgi-bin/hgGateway). Marker analysis using 
fluorescently labeled primers was performed according to the protocol for the LMS-MD10 
version 2.5 (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). Reactions for 
each marker were performed separately, with products being pooled into size and label 
specific sets before typing. Markers were typed on an ABI 3730 DNA analyzer (Applied 
Biosystems) using GeneMapper 4.0 software (Applied Biosystems). Allele binning was 
performed with the Excel 2000 (Microsoft, Redmond, USA) macro Linkage-designer 
developed by van Camp and coworkers [30], and we checked Mendelian inheritance of 
alleles with PedCheck 1.0 software (http://watson.hgen.pitt.edu) [31]. Multipoint LOD score 
and haplotype analysis was performed with GeneHunter, version 2.1 release 5, in the 
easyLINKAGE software package[32] and Haplopainter software 
(haplopainter.sourceforge.net/html/index.html).
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Mutation analysis- From the critical region, we selected the KCNA1 gene for mutation 
analysis using the UCSC genome browser database (http://genome.ucsc.edu/). DNA 
amplification reactions were performed in a thermal cycler with heated lid (MJ Research, 
PTC-200). The KCNA1 exon sequence and flanking regions were amplified from genomic 
DNA of individual III-1 (Figure 1A) using multiple overlapping primer sets based on GenBank 
accession code BC101733 (Table 1). PCR products of correct sizes were selected by DNA 
agarose gel electrophoresis, following excision and subsequent purification with GenElute™ 
Gel Extraction Kit (Sigma-Aldrich) according to manufacturer’s protocol. The fragments were 
sequenced on both strands by use of the ABI PRISM Big Dye Terminator Cycle Sequencing 
V2.0 Ready Reaction kit and the ABI PRISM 3730 DNA analyzer (Applied Biosystems).
Table 1: Overview of primers sets
P rim e r se q u en ce  
Forward (5'-3’) Reverse (5'-3’)
KCNA1 set 1 GAGGGGGATTCCAAACTGAG AACTTCTCCATGGCCTCCTC
KCNA1 set 2 GTACTTCTTCGACCGCAACC CCCAGCGTGATGAAATAAGG
KCNA1 set 3 CCCTTCTTCATCGTGGAAAC AGCAACTGAGCCTGCTCTTC
KCNA1 set 4 GACAATTGGAGGCAAGATCG CCCAAAATCCTCAATGCAAC
These primer sets, overlapping the human KCNA1 coding region, were used for mutation analysis based on 
GenBank accession code BC101733.
Immunohistochemistry- Immunohistochemistry was performed as previously described [33]. 
In short, either co-immunohistochemical staining or staining of serial sections for Kv1.1 with 
TRPM6, calbindin-D28K and AQP2, was performed on 7-^m sections of fixated frozen mouse 
kidney samples. The mouse kidney cryosections were incubated for 16 hr at 4oC with the 
primary antibodies: rabbit anti-Kv1.1 (1:300) (Alamone #APC-009), guinea pig anti-TRPM6 
(1:1000) [6], guinea pig anti-AQP2 (1:1000) (kindly provided by dr. P.M.T. Deen), and mouse 
anti-calbindin-D28K (1:750) [34]. For detection of calbindin-D28K and AQP2, sections were 
incubated with Alexa-conjugated secondary antibodies. The tyramide signal amplification kit 
(NEN Life Science Products, Zaventem, Belgium) was used after incubation with biotin- 
coated goat anti-rabbit and goat anti-guinea pig secondary antibodies to visualize Kv1.1 and 
TRPM6, respectively. Images were taken with a confocal laser scanning imaging system 
(Olympus Fluoroview, FV1000).
DNA constructs- The KCNA1 wild-type and N255D mutant sequences were obtained by 
amplification of genomic DNA from a non-affected and affected family member respectively, 
using primers 5’-GCCGAATTCGGCCACCATGACGGTGATGTC-3’ and 5’-
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GCCGTCGACATGCAACAACGCATTGACAG-3’. Both PCR products were cloned into 
pCMV-SPORT6 vectors (Invitrogen, Breda, The Netherlands) using restriction enzymes 
EcoRI and SalI following verification by sequence analysis. Subsequently, both the KCNA1 
wild-type and N255D sequences were subcloned via the Gateway® pDONR™221 entry 
vector into a pCIneo IRES-GFP destination clone creating human KCNA1 pCIneo IRES GFP 
(wild-type Kv1.1) and human KCNA1 N255D pCIneo IRES GFP (Kv1.1 N255D). The pCIneo 
IRES GFP construct was used as a control (mock) in the experiments. The wild-type TRPM6 
pCIneo IRES GFP construct has been described previously (6).
Electrophysiology- HEK293 cells were cultured and transfected as described previously [35]. 
Whole-cell recordings were performed as described in a previous study [14]. Recorded Kv1.1 
currents were evoked as described previously, using the same standard pipette and bath 
solutions [36]. The membrane potential of transfected HEK293 cells was measured using the 
current clamp mode, with continuous recording from a holding current of 0 pA. The pipette 
solution contained (mM): 140 KCl, 1 Na2-ATP, 10 HEPES/KOH (pH 7.3). The bath solution 
contained (mM): 138 NaCl, 5.4 KCl, 1.2 MgCl2, 1 CaCl2, 10 glucose, and 10 HEPES/KOH 
(pH 7.3). To measure TRPM6-mediated currents, a linear voltage ramp from -100 to +100 
mV (within 450 ms) was applied every 2 s from a holding potential of 0 mV. The standard 
pipette solution contained 150 mM NaCl, 10 mM EDTA, and 10 mM HEPES/KOH (pH 7.2). 
The extracellular solutions contained 150 mM NaCl, 10 mM HEPES/KOH (pH 7.4). The 
analysis and display of patch clamp data were performed using Igor Pro software 
(WaveMetrics, Lake Oswego, USA). Current densities were obtained by normalizing the 
current amplitude to the cell membrane capacitance.
Cell surface biotinylation- HEK293 cells were transiently transfected using Lipofectamin 2000 
(Invitrogen-Life Technologies) with 1 |jg DNA of wild-type Kv1.1, 1 |jg Kv1.1 N255D, 1 |jg 
mock, or co-transfected with 0.5 |jg wild-type Kv1.1 and 0.5 |jg Kv1.1 N255D. Cell surface 
labelling with biotin was performed as described previously [37]. At 48 hours after 
transfection, the biotinylation assay was performed. Cells were homogenized in 1 ml lysis 
buffer as described previously [37], using the sulfo-NHS-LC-LC-biotin (Pierce, Etten-Leur, 
The Netherlands). 1% of the total protein amount was collected as an input sample. 
Subsequently, biotinylated proteins (plasma membrane fraction) were precipitated using 
neutravidin-agarose beads (Pierce). Kv1.1 expression was analyzed by immunoblot analysis 
for the input and the plasma membrane fraction using the monoclonal Kv1.1 antibody 
(1:1000).
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Chemicals and statistical analysis- The guinea pig antibody against AQP2 was kindly 
provided by Dr. P.M. Deen (Radboud University Nijmegen Medical Centre). Mouse anti- 
calbindin-D28K was purchased from Sigma. Rabbit polyclonal and mouse monoclonal 
antibodies specific for Kv1.1 were purchased from Alamone Labs (Jerusalem, Israel) and 
Neuromab (Davis, CA, USA), for immunohistochemistry and Western Blotting, respectively. 
Dendrotoxin-K (DTX-K) was purchased from Sigma. Data are shown as mean ± SEM. 
Statistical significance was determined using ANOVA Tukey’s test. Differences in means with 
P < 0.05 were regarded as statistically significant. Statistical analysis was performed using 
Prism (GraphPad, San Diego, USA) software.
Results
A heterozygous KCNA1 A763G mutation is causative for hypomagnesemia 
Here, we identified a large Brazilian family (46 family members of which 21 affected) with 
autosomal dominant hypomagnesemia (Figure 1A). Affected individuals showed low serum 
Mg2+ levels (< 0.40 mmol/L, normal range 0.70-0.95 mmol/L), while their urinary Mg2+ 
excretion was normal, suggesting impaired tubular Mg2+ reabsorption. The phenotype of the 
proband (IV-3, F igure 1A) starting from infancy consists of recurrent muscle cramps, tetanic 
episodes, tremor and muscle weakness, especially in distal limbs. A single nucleotide 
polymorphism (SNP)-based linkage analysis identified a 14.3 cM locus on the short arm of 
chromosome 12 (Figure 1B) which was subsequently narrowed down by fine mapping with 
microsatellite markers to an 11.6 cM region containing 31 genes between the markers 
D12S1626 and D12S1623 (maximum multipoint LOD score 3.0) (Figure 1B and 
Supplem entary Figure 1). Other genes previously associated with hypomagnesemia are 
located outside this critical region and therefore excluded as a candidate gene in our family. 
From the identified locus we sequenced KCNA1 and identified a heterozygous mutation 
A763G (Figure 1C) in the affected individual III-1 (F igure 1A) that co-segregates with the 
disorder and was absent in 100 control chromosomes (data not shown).
KCNA1 encodes the Shaker-related voltage-gated K+ channel Kv1.1 in which the identified 
mutation causes substitution of the highly conserved asparagine at position 255 for an 
aspartic acid (N255D) (F igure 1D). The predicted amino acid topology of Kv channels shows 
six transmembrane spanning a-helical segments (S1-6), with the S4 segment acting as the 
voltage-sensor and a hydrophobic pore region between S5 and S6 (Figure 1E) [19]. The 
newly identified N255D mutation is positioned in the third transmembrane segment (S3) 
close to the voltage sensor (Figure 1E).
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Figure 1: Heterozygous KCNA1 A763G mutation causes isolated hypomagnesemia. A: Pedigree with 5 
generations (I-V) of a Brazilian family with autosomal dominant hypomagnesemia. Affected family members are 
depicted in black, male and female members are shown as squares and circles, respectively. A diagonal line 
indicates that the individual is deceased. The red number indicates individuals included in the STS mapping. B: A 
10K SNP array-based haplotyping approach was performed that showed linkage to a 14,3 cM region between 
SNP rs717596 and rs252028 on the short arm of chromosome 12. This region was confirmed and narrowed down 
with STS markers to a 11,6 cM region between markers D12S1626 and D12S1623 containing 31 genes, including 
the KCNA1 gene. C: Mutation analysis of KCNA1 revealed a heterozygous A763G missense mutation in affected 
individual III-1. KCNA1 encodes the voltage-gated potassium channel Kv1.1 where the observed mutation results 
in a N255D amino acid substitution (underlined). D: Multiple alignment analysis shows conservation of the N255 
amino acid (red bar) among species and Kv1 family members. Mutated amino acids in other families with the 
Kv1.1 genotype are depicted as dark blue dots [15-18]. Blue and black colored letters represent conserved and 
non-conserved amino acids, respectively. E: Schematic representation of the Kv1.1 channel that consists of a 
voltage sensor in transmembrane segment S4 and a pore forming region (S5 and S6). Localization of the newly 
identified N255D mutation is denoted by the red dot, while other nearby mutations are indicated by dark blue dots.
Localization of Kv1.1 in the DCT of the kidney
So far, all proteins implied in familial hypomagnesemia, showed expression in kidney 
underlining the pivotal role of this organ in body Mg2+ homeostasis. To study the (sub)cellular 
localization of Kv1.1 in kidney, we used a rabbit polyclonal antibody raised against the Kv1.1 
channel. Immunopositive staining was observed along the luminal membrane of distinct 
tubules present in the superficial cortex of the mouse kidney (Figure 2). Using serial kidney 
sections, we demonstrated that Kv1.1 co-localizes with the epithelial Mg2+ channel TRPM6 in 
DCT (Figure 2A). To confirm this localization we co-stained kidney sections for Kv1.1 and 
calbindin-D28K, showing a partial overlap in Kv1.1 and calbindin-D28K expression (F igure 2B).
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A B C
Figure 2: Immunohistochemical analysis of Kv1.1 in kidney. A. Staining for Kv1.1 (green) and TRPM6 (red) of 
mouse serial kidney sections (right panels, overview of a cortical region; left panels, magnified images of 
immunopositive tubules). The asterisks indicate the same distal tubules on serial sections intensively stained for 
Kv1.1 and TRPM6. B. Mouse kidney sections were co-stained for Kv1.1 (green) and calbindin-D28K (red) (lower 
panels, immunopositive tubules; upper panel, merged DIC (differential interference contrast) image). C. Co- 
staining of Kv1.1 (green) and aquaporin-2 (red) in mouse kidney sections (lower panels, immunopositive tubules; 
upper panel, merged DIC image). Abbreviations used: G, glomerulus; DCT, distal convoluted tubule; CNT, 
connecting tubule; 28K, calbindin-D28i<; AQP2, aquaporin-2. Bar denotes the indicated magnification.
This pattern can be explained by earlier observations that calbindin-D28K, besides in DCT, is 
also expressed in connecting tubule (CNT) [20], confirming that Kv1.1 is localized primarily in 
DCT. Indeed, co-staining between Kv1.1 and aquaporin-2 (AQP2), a marker for CNT and the 
collecting duct, was not observed (F igure 2C). These findings support the restricted 
localization of Kv1.1 in the Mg2+-transporting DCT segment of the kidney.
Kv1.1 N255D results in non-functional channels with dominant negative effect on wild-type 
channel function
To determine the effect of the Kv1.1 N255D mutation on channel activity, Human Embryonic 
Kidney 293 (HEK293) cells were transiently transfected with mock, wild-type Kv1.1 and/or 
Kv1.1 N255D. Using the whole-cell patch clamp technique, outward K+ currents were 
measured by dialyzing the cells with a pipette solution containing 140 mM K+. Cells 
expressing wild-type Kv1.1 channels produced typical delayed rectifying currents, while 
Kv1.1 N255D-expressing HEK293 cells showed small currents similar to mock-expressing 
cells (Figure 3A and F igure 3B). Considering the autosomal dominant inheritance in our 
family, a potential dominant negative effect was investigated by co-transfection of equal 
amounts of plasmid DNA encoding wild-type Kv1.1, Kv1.1 N255D or mock in HEK293 cells. 
The K+ current amplitude in HEK293 cells co-expressing wild-type Kv1.1 and Kv1.1 N255D
64
- Chapter 3 -
was significantly reduced compared to cells expressing wild-type Kv1.1 alone or co­
expressing wild-type Kv1.1 and mock (P < 0.05) (Figure 3C). Next, the influence of Kv1.1 
N255D expression on the amount of Kv1.1 channels at the plasma membrane was examined 
by cell surface biotinylation experiments. As shown in F igure 3D, co-expression of wild-type 
Kv1.1 and Kv1.1 N255D in HEK293 cells did not affect the plasma membrane localization of 
Kv1.1 channels. Of note, Kv1.1 was equally expressed in all conditions as analyzed in the 
total cell lysates (Figure 3D, bottom panel). Kv1.1 channels are composed of four subunits 
and this result suggests that similar amounts of both homotetrameric channels wild-type 
Kv1.1 and Kv1.1 N255D, and heterotetrameric channels composed of wild-type Kv1.1 with 
Kv1.1 N255D are located at the plasma membrane.
Figure 3: Electrophysiological analysis of mock, wild-type Kv1.1 (Kv1.1 WT) or Kv1.1 N255D transfected HEK293 
cells. A. Representative original traces of outward K+ currents of mock (•), Kv1.1 WT (□), Kv1.1 N255D (A), or 
Kv1.1 WT and mock (O) elicited by voltage steps from -100 to +50 mV in 10 mV increments, applied from a 
holding potential of -80 mV, every 10 s. B. The I-V relationships of mock (•, n=5), Kv1.1 WT (□, n=11), Kv1.1 
N255D (A, n=10), Kv1.1 WT and mock (O, n=9); C. Histogram presenting averaged current densities at +50 mV 
of mock (n=5), Kv1.1 WT (n=11), Kv1.1 WT and mock (n=9), Kv1.1 WT and Kv1.1 N255D (n=9), and Kv1.1 
N255D (n=10). Asterisk indicates significance (P < 0.05) compared to mock while hash indicates significance (P < 
0.05) compared to Kv1.1 WT. D. Cell surface biotinylation of mock, Kv1.1 WT, Kv1.1 WT and mock, Kv1.1 WT 
and Kv1.1 N255D, and Kv1.1 N255D transfected HEK293 cells. Kv1.1 expression was analyzed by 
immunoblotting for plasma membrane fraction (PM) and input from the total cell lysates (IP). Representative 
immunoblot of four independent experiments is shown. E. Histogram presenting averaged current densities at +80 
mV after 200 s of TRPM6 and mock (n=26), TRPM6 and Kv1.1 WT (n=26), and TRPM6 and Kv1.1 N255D (n=25). 
F. Membrane potential of mock, Kv1.1 WT and Kv1.1 N255D upon acute application of Dendrotoxin K (DTX-K, 10 
nM), measured in current clamp mode of whole-cell patch clamp configuration. Representative recordings of eight 
independent experiments are shown. The error bars denote SEM.
65
Defective Kv1.1 causes hypomagnesemia
Kv1.1 regulates TRPM6 Mg2+ influx by setting the membrane potential 
Since Kv1.1 and TRPM6 are present in the same nephron segment, we investigated by 
which mechanism Kv1.1 controls Mg2+ influx through TRPM6. We studied the potential direct 
effect of Kv1.1 on TRPM6 activity by patch clamp analysis. To this end, TRPM6 (1.0 |j.g) was 
co-transfected with mock (0.1 |j.g), wild-type Kv1.1 (0.1 |j.g) or Kv1.1 N255D (0.1 |j.g) in 
HEK293 cells. The TRPM6-mediated Na+ currents between the three experimental 
conditions were virtually identical (Figure 3E). Subsequently, the current clamp mode of the 
patch clamp technique was used to measure the membrane potential of HEK293 cells 
expressing wild-type Kv1.1 or Kv1.1 N255D. A significant hyperpolarization (P < 0.05) was 
observed in wild-type Kv1.1-expressing HEK293 cells (-39±3 mV, n=9) compared to mock or 
Kv1.1 N255D-expressing cells (-3±1 mV, n=7, and -8±2 mV, n=7, respectively). Dendrotoxin 
K (DTX-K, 10 nM), a specific Kv1.1 channel blocker, significantly depolarized the membrane 
potential in wild-type Kv1.1-expressing cells (from -39±3 mV to -14±2 mV, n=8, P < 0.05) 
(Figure 3F). The membrane potential of mock or Kv1.1 N255D-expressing cells was not 
affected by DTX-K application (Figure 3F). Furthermore, co-transfection of wild-type Kv1.1 
and Kv1.1 N255D resulted in an intermediate hyperpolarization compared to the cells 
expressing only wild-type Kv1.1 (-23±1 mV vs. -39±3 mV, respectively, n=15, P < 0.05). 
These results suggest that the Kv1.1 N255D channel diminishes the negative membrane 
potential compared to the normal situation.
D iscussion
In this study, we identified a large Brazilian family with autosomal dominant 
hypomagnesemia. Affected individuals showed low serum Mg2+ levels, while serum K+ and 
Ca2+ levels, and urinary Ca2+ excretion were not affected, which is distinct from previously 
described forms of inherited hypomagnesemia. For example, families bearing a mutation in 
claudin 16 and 19 (Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis; 
OMIM 248250) are hypercalciuric, while mutations in FXYD2 (Isolated Dominant 
Hypomagnesemia (IDH); OMIM 154020) and TRPM6 (Hypomagnesemia with Secondary 
Hypocalcemia; OMIM 602014) result in hypocalciuria and hypocalcemia, respectively. 
Furthermore, patients with Gitelman Syndrome (GS; OMIM 263800), caused by mutations in 
NCC, suffer from hypomagnesemia, hypocalciuria and hypokalemia. The phenotype in the 
proband starting from infancy consists of recurrent muscle cramps, tetanic episodes, tremor 
and muscle weakness, especially in distal limbs. Serum electrolyte levels were measured 
during severe attacks of cramps and tetany in two affected family members (proband V-3; V-
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2), with serum Mg2+ levels of 0.37 and 0.25 mmol/L, respectively, while Ca2+ and K+ 
concentrations were normal. As a result, all affected family members received a daily dose of 
magnesium chloride. Importantly, the proband was recently hospitalized because of a 
sudden episode of facial myokymia, tremor, severe muscle spasms, muscular pain, cramps, 
muscular weakness and tetanic contraction episodes, all of which improved shortly after 
intravenous magnesium treatment. This observation further confirmed that the observed 
symptoms are a consequence of the low serum Mg2+ levels.
By use of a positional cloning approach we revealed a heterozygous mutation in KCNA1, 
encoding the voltage-gate potassium channel Kv1.1, by which the asparagine at amino acid 
position 255 was converted into an aspartic acid (N255D). Remarkably, the Kv1.1 N255D 
genotype causes hypomagnesemia, whereas mutations in KCNA1 thus far have been shown 
to result in episodic ataxia type 1 (EA1). F igure 1D and F igure 1E shows the previously 
identified mutations in close proximity to the N255D mutation [15-18, 21, 22]. EA1 is a 
dominant human neurological disorder presumably caused by defective Kv1.1 in the 
cerebellum. Furthermore, abnormal Kv1.1 activity originating in the distal motor axons results 
in muscle hyperactivity, indicative for myokymia [23, 24]. In addition to the classical 
description of this disorder, phenotypic variants include EA1 with partial epilepsy [16, 21], 
EA1 without myokymia [22], and isolated neuromyotonia [16]. We also analyzed the affected 
members of our Brazilian family for episodic ataxia. On a cerebral MRI of the proband we 
obtained evidence of a slight atrophia of the cerebral vermis (data not shown). Furthermore, 
electromyographs of some affected members showed myokymic discharge in line with the 
previously observed mixed phenotype (data not shown). Now, we present hypomagnesemia 
as a new phenotypic characteristic associated with a mutation in KCNA1. Thus, it would be 
highly interesting to perform in the near future a large-scale phenotypical characterisation of 
patients with identified mutations in the KCNA1 gene including neurological description, 
serum Mg2+ levels and functional analysis of the corresponding Kv1.1 mutations. Previously, 
genetic studies in familial hypomagnesemia revealed several new proteins with a 
predominant expression in kidney underlining its involvement in Mg2+ homeostasis. Our 
immunohistochemical data clearly demonstrated localization of Kv1.1 along the luminal 
membrane of TRPM6-expressing DCT cells consistent with a potential link between Kv1.1- 
mediated K+ secretion and Mg2+ influx by TRPM6. Therefore, we assessed the role of Kv1.1 
in controlling Mg2+ influx through TRPM6. Electrophysiological analysis of wild-type Kv1.1 
and Kv1.1 N255D revealed that the mutation results in a non-functional Kv1.1 channel. Kv1.1 
channels consist of four subunits arranged symmetrically around an aqueous pore, forming a 
so-called tetrameric structure [25, 26]. It has been shown that Kv1.1 channel subunits can 
assemble with other Kv channel subunits to form heterotetramers [27]. Importantly,
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hypomagnesemia in the Brazilian family is inherited in an autosomal dominant manner and 
patients with the N255D mutation are heterozygous. Expression of both alleles likely results 
in the formation of heterotetrameric channels composed of wild-type and mutated channel 
subunits leading to a dominant negative effect by the Kv1.1 N255D subunit, as shown in this 
study. The mutation replaces a neutral amino acid (asparagine) by one with an acidic side- 
chain (aspartic acid), which may destabilize the secondary or tertiary channel structure and 
thereby channel formation or trafficking. However, we demonstrated that wild-type Kv1.1 
channels, Kv1.1 N255D channels, and the combination hereof are expressed in equal 
amounts at the plasma membrane. Considering the striking localization of Kv1.1 in the 
TRPM6-expressing distal convoluted tubules, we investigated a potential direct functional 
effect of Kv1.1 on TRPM6 activity. However, wild-type Kv1.1 nor Kv1.1 N255D altered the 
TRPM6-mediated Na+ currents and it is, therefore, unlikely that Kv1.1 directly regulates the 
activity of the Mg2+-permeable channel TRPM6. Mg2+ is actively reabsorbed in the DCT. 
Here, Mg2+ influx through TRPM6 is driven by a favorable membrane voltage [6, 7]. This 
membrane potential is maintained by a so far unidentified apical K+ efflux pathway, while the 
K+ gradient is provided by the basolaterally localized Na+,K+-ATPase. Previously, a mutation 
in the Na+,K+-ATPase y-subunit was shown to be the underlying cause for autosomal 
dominant renal Mg2+ wasting and secondary hypocalciuria [11]. Interestingly, K+ efflux 
through K+-permeable channels primarily determines the resting membrane potential. Kv 
channels are widely expressed in excitable and non-excitable cells, where they play an 
essential role in the establishment of the electrical properties of the cell, instrumental for 
many processes [28]. By use of the current clamp mode of the patch clamp technique we 
demonstrated that Kv1.1 significantly hyperpolarizes the plasma membrane compared to 
mock or Kv1.1 N255D-expressing cells. This effect was reversible by DTX-K, a specific 
Kv1.1 channel blocker, confirming the involvement of Kv1.1 in setting the negative 
membrane potential. We now hypothesize that the voltage-gated Kv1.1 channel is 
responsible for the establishment of the negative membrane potential across the luminal 
membrane of the DCT cell. The N255D mutation leads to depolarization of the luminal 
membrane, notably diminishing the driving force for Mg2+ uptake from the pro-urine (Figure 
4). In conclusion, a new direct coupling between K+ secretion and active Mg2+ reabsorption is 
disclosed by this study, which is highlighted by our discovery of the N255D mutation in the 
KCNA1 gene in autosomal dominant hypomagnesemia. The encoded K+ channel Kv1.1 co- 
localizes with the Mg2+ influx channel TRPM6 along the luminal membrane of DCT, the main 
site of active renal Mg2+ reabsorption. Kv1.1 channels harboring the N255D mutation show 
close to background currents impairing their ability to set a favorable membrane potential
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facilitating TRPM6-mediated Mg2+ influx. These findings will open a new window for other 
studies on the interrelationship of renal K+ and Mg2+ disturbances.
Figure 4: Schematic model of the Mg2+- 
reabsorbing DCT cell in the kidney. 
Mg2+ uptake from the pro-urine via the 
epithelial Mg2+ channel TRPM6 is 
primarily driven by the negative 
potential across the luminal membrane. 
This luminal membrane potential is 
maintained by an apical K+ efflux via 
Kv1.1 energized by the action of the 
Na+,K+-ATPase. At the basolateral 
membrane, Mg2+ extrusion to the blood 
side occurs via an unknown 
mechanism. The identified N255D 
mutation results in a non-functional 
Kv1.1 channel and thereby decreases 
the driving force for Mg2+ influx, thus 
resulting in renal Mg2+ wasting.
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Supplementary figure 1: Haplotype analysis of the autosomal dominant hypomagnesemia locus on the short 
arm of chromosome 12 in the Brazilian family. Affected family members are shown in black; circles and squares 
refer to female and male individuals, respectively. A diagonal line indicates that the individual is deceased. 
Microsatellite markers are depicted on the left. The haplotypes are illustrated by different colors. The brown 
haplotype co-segregates with the disease. Critical recombinations are pinpointed by arrow heads (►) in 
individuals III-7 (telomeric) and IV-16 (centromeric). KCNA1 is located within the critical region between markers 
D12S1725 and D12S99 (black bar).
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A bstract
Mutations in the voltage-gated K+ channel Kv1.1 have been linked with a mixed phenotype of 
episodic ataxia (EA) and/or myokymia. Recently, we presented autosomal dominant 
hypomagnesemia as a new phenotypic characteristic associated with a mutation in Kv1 .1 
(N255D). A conserved asparagine at position 255 in the third transmembrane segment was 
converted into an aspartic acid, resulting in a non-functional channel. In this study, we 
explored the functional consequence of this conserved residue by substitution with other 
hydrophobic, polar or charged amino acids (N255E, N255Q, N255A, N255V, N255T, 
N255H). Upon overexpression in human embryonic kidney (HEK293) cells, cell surface 
biotinylation revealed plasma membrane expression of all mutant channels. Next, we used 
the whole-cell patch clamp technique to demonstrate that the N255E and N255Q mutants 
were non-functional. Substitution of N255 with other amino acids (N255A, N255V, N255T, 
and N255H) did not prevent ion conduction and these mutant channels activated at more 
negative potentials compared to wild-type channels, -41.5±1.6, -45.5±2.0, -50.5±1.9, and - 
33.8±1.3 mV to -29.4±1.1 mV, respectively. The time constant of activation was significantly 
faster for the two most hydrophobic mutations, N255A (6.2±0.2 ms) and N255V (5.2±0.3 ms), 
and the hydrophilic mutant N255T (9.8±0.4 ms) in comparison to wild-type (13.0±0.9 ms). 
Furthermore, the voltage-dependence of inactivation was shifted ~13 mV to more negative 
potentials in all mutant channels except for N255H. Taken together, our data showed that an 
asparagine at position 255 in Kv1.1 is required for normal voltage-dependence and kinetics 
of channel gating.
In troduction
Voltage-gated K+ channels (Kv) are a diverse family of membrane proteins, with the Shaker- 
related group (Kv1) representing a major sub-family [1-3]. Its members play an important role 
in excitable cells by setting the resting membrane potential, shaping the action potentials, 
and by controlling the neuronal excitability [4]. Kv channels comprise of four subunits that 
encircle a central ion conduction pathway [5, 6]. Each subunit consists of six 
transmembrane-spanning a-helices (S1-S6) with both the amino (N) and the carboxyl (C) 
terminal on the intracellular side. The S1-S4 segments form the voltage sensing domain, 
whereas S5 and S6 along with the intervening re-entrant P-loop form the pore domain [7, 8]. 
Kv channels are known to switch between the closed and open conformation upon cell
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depolarization [8, 9]. Several molecular mechanisms on voltage-sensing motion have been 
described, i.e. the canonical or helical screw model, the transporter model, the paddle model, 
and the twisted S4 model [8]. It is generally accepted that the array of positive charges on 
the S4 helix form the principal structural elements responsible for voltage sensing [8].
Kv1.1 was the first mammalian subunit of the Kv family to be cloned and is abundantly 
expressed in excitable and non-excitable cells [10, 11]. Studies with Kv1.1 knock-out (KO) 
mice showed that deletion of Kv1.1 results in a seizure disorder similar to epilepsy [12]. 
Mutations in Kv1.1 in humans are the cause of periodic episodic ataxia type 1 (EA1) and/or 
myokymia [13-18]. Electrophysiological analyses of these mutant Kv1.1 channels showed 
either a significant reduction in current amplitude or altered kinetic properties compared to 
wild-type Kv1.1 channels [14, 19, 20].
Recently, a novel mutation, in the third transmembrane segment of Kv1.1 was identified in a 
family with isolated autosomal dominant hypomagnesemia. Surprisingly, hypomagnesemia 
had thus far not been reported in patients with mutations in Kv1.1. Furthermore, this study 
demonstrated Kv1.1 expression in the apical membranes of the renal distal convoluted 
tubule (DCT) segment, where active Mg2+ reabsorption takes place. The mutation resulted in 
the single amino-acid substitution of an asparagine at position 255 for an aspartic acid 
(N255D) [21]. The mutant channel was non-functional with a dominant negative effect on 
wild-type channel activity. Aim of the present study is to characterize the N255D mutation in 
Kv1.1. To examine the importance of this position in channel function, we systematically 
substituted six amino acids with different chemical and physical properties. The mutant Kv1.1 
channels were electrophysiology and biochemically analyzed.
Material and m ethods
DNA constructs- Full-length wild-type KCNA1 and N255D mutant were constructed in the 
pCIneo-IRES-GFP expression vector as previously described [21]. Other KCNA1 mutants 
(N255A, N255E, N255Q, N255H, N255T, N255V) were created using the QuickChange site- 
directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer’s 
protocol. All constructs were verified by sequence analysis.
Electrophysiology- HEK293 cells were grown in DMEM (Bio Whittaker Europe, Vervier, 
Belgium) containing 10% (v/v) fetal calf serum, 2 mM l-glutamine and 10 pg/ml Ciproxin at 37 
°C in a humidity-controlled incubator with 5% (v/v) CO2. Cells were transiently transfected 
with the respective constructs using Lipofectamine 2000 (Invitrogen-Life Technologies,
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Breda, The Netherlands), as described previously [34], and electrophysiological recordings 
were performed 48 hours after transfection. Transfected cells were identified by their green 
fluorescence when illuminated at 488 nm. Non-transfected (GFP-negative) cells from the 
same batch were used as controls. Patch clamp experiments were performed in the tight 
seal whole cell configuration at room temperature (20-25°C). An EPC-10 patch clamp 
amplifier computer was used and controlled by PatchMaster Classic 1.20 software (HEKA 
Elektronik). Currents were digitized at 20 kHz and digitally filtered at 2.9 kHz. Patch pipettes 
were pulled from thin-walled borosilicate capillaries (1.5 mm OD, 1.17 mm ID); pipette 
resistance was typically between 2 and 4 MQ. The liquid junction potential was not corrected. 
The pipette solution contained (mM): 140 KCl, 1 MgCl2, 0.1 CaCl2, 2 EGTA, 10 HEPES/KOH 
(pH 7.3), and 1 Na2-ATP. The bath solution contained (mM): 138 NaCl, 5.4 KCl, 1.2 MgCl2, 1 
CaCl2, 10 EGTA, 10 HEPES/NaOH (pH 7.3), and 10 glucose. Recordings of Kv1.1 were 
obtained by voltage steps, applied every 10 sec, consisting of 150 ms steps from -100 mV to 
+50 mV (10 mV increments). The holding potential was -80 mV. Equimolar pipette and bath 
solutions of K+ (140 mM) were used to determine the voltage dependence of activation. For 
steady-state inactivation, cells were held at -80 mV, and then subjected to steps from -90 mV 
to +30 mV (10 mV increments) for 10 s, followed by a depolarizing step to +30 mV. Linear 
leak and capacitance currents were corrected with a P/5 leak subtraction procedure [35]. The 
analysis of patch clamp data was performed using Igor Pro software (WaveMetrics, Lake 
Oswego, USA). Current densities were obtained by normalizing the current amplitude to the 
cell membrane capacitance.
Cell surface biotinylation- Cell surface labelling with biotin was performed as described 
previously [36]. HEK293 cells were transiently transfected with 1 |jg wild type or mutants 
Kv1.1 constructs using Lipofectamin 2000 (Invitrogen-Life Technologies), in 6-well plates (1,5 
million cells per plate). At 48 hours after transfection, the biotinylation assay was performed 
using the sulfo-NHS-LC-LC-biotin (Pierce, Etten-Leur, The Netherlands). Cells from each 6 
well were homogenized in 1 ml lysis buffer as described previously [37]. Next, 5% of the total 
protein amount was collected as an input sample. Subsequently, biotinylated proteins 
(plasma membrane fraction) were precipitated using neutravidin-agarose beads (Pierce). 
Kv1.1 expression was analyzed by immunoblot analysis for the input and the plasma 
membrane fraction using the monoclonal Kv1.1 antibody (Neuromab, Davis, CA, USA).
Sequence analysis and structure modelling- The structural model of Kv1.1 was built based 
on the 3D structure of a chimeric Kv1.2-Kv2.1 channel [22] (PDB-file 2R9R). In order to 
obtain optimal modeling results, we used a re-refined version of this template from the
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PDB_REDO data bank [38]. The sequences of the template and Kv1.1 share 75% sequence 
identity. The WHAT IF server (http://swift.cmbi.ru.nl) was used for model building, Yasara 
[39] was used for loop building, energy minimization and subsequent mutation analysis. The 
tetrameric model was obtained by superposing four models on the biological subunit of PDB 
file 2R9R, followed by an energy minimization in Yasara. Visit 
http://www.cmbi.ru.nl/~hvensela/Kv1.1/ for more details.
Statistical analysis- Data are shown as mean ± SEM values. Statistical significance was 
determined using ANOVA followed by Tukey’s test. Differences in means with P < 0.05 were 
regarded as statistically significant. Statistical analysis was performed using Prism 
(GraphPad, San Diego, USA) software.
Results
Structure analysis of Kv1.1 N255
A few years ago, the crystal structure of the mammalian Kv channel, Kv1.2, has been solved. 
This crystallized structure has been used to construct a paddle-chimera channel where the 
Kv2.1 voltage sensor paddle (S3b and S4 helices) has been transferred to Kv1.2 [5, 22]. 
Based on this latter chimaeric Kv1.2-Kv2.1 structure, homology modeling of Kv1.1 was 
performed (Figure 1B; http://www.cmbi.ru.nl/~hvensela/Kv1.1/). The sequence identity 
between Kv1.2-Kv2.1 and Kv1.1 was 75%, which is enough to build a good homology model
[23]. Kv1.1 subunits consist of six transmembrane a-helices with both the N- and the C- 
terminal tails of the protein at the intracellular side (Figure 1C). Recently, a missense 
mutation in Kv1.1 was found in patients with isolated autosomal dominant hypomagnesemia, 
converting the highly conserved aspargine at position 255 (F igure 1A) into an aspartic acid 
[21].This mutation is positioned in the third transmembrane segment (S3) close to the 
intracellular compartment (Figure 1B and F igure 1C). Electrophysiological analysis of the 
Kv1.1 N255D channel expressed in HEK293 cells demonstrated a significantly reduced 
current amplitude compared to the wild-type Kv1.1 expressing cells (72.0±3.2 pA/pF vs. 
398±83 pA/pF) [21]. Importantly, both channels were expressed at the plasma membrane in 
equal amounts [21]. To examine the importance of N255 in Kv1.1 channel function, we 
substituted the asparagine by six different amino acids with distinct chemical and physical 
properties (N255E, N255Q, N255A, N255T, N255V, and N255H). We used the homology 
model to study the effect of these mutations on the structure of the channel (Figure 1D; 
http://www.cmbi.ru.nl/~hvensela/Kv1.1/).
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transmembrane segment 3
248
mouse Kv1.1 N I M N F D I V A I P Y F
rat Kv1.1 D F F N I M N F D I V A I P Y F
dog Kv1.1 D F F K N I M N F D I V A I P Y F
chicken Kv1.1 E F F K N I M N F D I V A I P Y F
drosophila Kv1.1 N C R D V N V D I A I P Y F
human Kv1.1 D F F K 'N I M N D I V A I P Y F
human Kv1.2 G F T I M N J D I V A I P Y F
human Kv2.1 K K G P L A D L L A L P F
intracellular
N (WT)
.  S r i  flgik. fS r l. fgri
Figure 1: Structural analysis of mutations in Kv1.1 at position 255. A. Multiple alignment analysis shows 
conservation of the N255 amino acid (black bar) among species, and human family members Kv1.2 and Kv2.1. 
Light gray and dark grey colored letters represent conserved and non-conserved amino acids, respectively. B. 
The predicted 3D-structure model of the tetrameric Kv1.1 channel. C. Schematic representation of the Kv1.1 
channel, which consists of six transmembrane segments (S1-S6) with S1-S4 functioning as a voltage sensing 
domain and a pore-forming region between S5 and S6. Localization of the N255 position is denoted by the light 
gray dot. D. Enlarged view of the predicted 3D-structure model showing the side chains of the polar residues 
surrounding N255 and the mutated amino acids at this position.
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Figure 2: Expression of wild-type and mutant Kv1.1 channels. A. Cell surface biotinylation of mock, Kv1.1, Kv1.1 
N255D, Kv1.1 N255E, Kv1.1, N255Q, Kv1.1 N255A, Kv1.1 N255V, Kv1.1 N255T, and Kv1.1 N255H expressing 
HEK293 cells. Kv1.1 expression was analyzed by immunoblotting for plasma membrane fraction and input from 
the total cell lysates. Representative immunoblot of four independent experiments is shown. B. The I-V 
relationships of the outward K+ currents in HEK293 cells expressing mock (o), wild-type Kv1.1 (■), Kv1.1 N255D 
(O), Kv1.1 N255E (A), Kv1.1 N255Q (□) (right panel). The I-V relationships of the outward K+ currents in HEK293 
cells expressing Kv1.1 N255A (A), Kv1.1 N255V (•), Kv1.1 N255T (♦ ) , and Kv1.1 N255H (▼) (left panel). Mean 
± SEM values are shown. C. Histogram presenting averaged current densities at +50 mV of mock (n=4), wild-type 
Kv1.1 (WT, n=11), Kv1.1 N255D (D, n=6), Kv1.1 N255E (E, n=4), Kv1.1 N255Q (Q, n=4), Kv1.1 N255A (A, n=10), 
Kv1.1 N255V (V, n=7), Kv1.1 N255T (T, n=9), and Kv1.1 N255H (H, n=9) expressing HEK293 cells. Asterisk 
indicates significance (P < 0.05) in comparison to Kv1.1 wild-type expressing cells. Mean ± SEM values are 
shown.
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The asparagine was converted into a glutamic acid or histidine to investigate the involvement 
of charge in channel function. Further, glutamine was used as a control to test the possible 
steric hindrance of the extra CH2-group in glutamic acid. Next, we introduced alanine and 
valine as non-polar amino acids that are not able to participate in hydrogen bonding. 
Threonine was used as a control for residue size as alanine is a smaller amino acid.
150 m s
I________________ I
+50 mV
-80 mV
-100 mV
-80 mV
25 ms
B
V«<mV) Vt„,(mV)
V,«(mV) (mV)
Figure 3: Channel activation of wild-type and mutant Kv1.1 channels. A. Representative tail currents of wild-type 
Kv1.1 at -80 mV, recorded in response to a set of 150 ms voltage steps from -100 to +50 mV in 10 mV increments 
every 10 s. B. The activation curve of the wild-type Kv1.1 (n=5) and Kv1.1 N255A currents (n=4), wild-type Kv1.1 
(n=5) and Kv1.1 N255T currents (n=5), wild-type Kv1.1 (n=5) and Kv1.1 N255V currents (n=5), and wild-type 
Kv1.1 (n=5) and Kv1.1 N255H currents (n=4), respectively. Normalized tail currents are plotted as a function of 
the pre-pulse potential. The lines reflect the best fits to the averaged current-voltage data points, according to the 
Boltzmann equation: I = Imax / (1 + exp (( V-W2 ) / k)), where I is the current measured at each test potential, V; 
Imax is the maximal current; Vv2 is the voltage of half-maximal activation; and k is the slope factor.
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Surface expression of the Kv1.1 mutants
The effect of the substituted amino acids on the amount of Kv1.1 channels at the plasma 
membrane was examined by cell surface biotinylation experiments. As shown in F igure 2A, 
the substitution of N255 by other amino acids did not affect the expression of Kv1.1 channels 
at the plasma membrane.
Electrophysiological characterization of Kv1.1 mutants
Whole-cell patch clamp recordings from HEK293 cells transiently expressing the wild-type 
Kv1.1 gave typical delayed rectifying currents, in response to a depolarization step from -100 
mV to +50 mV (Figure 2B). We observed in the Kv1.1 mutants a clear difference in current 
amplitude corresponding to the amino acid substituted. The Kv1.1 N255E and N255Q 
mutants showed small current amplitudes, similar to mock and the described Kv1.1 N255D 
mutation [21]. The voltage dependence of activation was determined by recording tail 
currents after pre-pulse voltage steps. The amplitude of the tail currents was normalized to 
the maximum current and plotted as a function of the conditioning potential. Data points were 
fitted with a Boltzmann equation to determine the potential of half-maximal activation (V1/2) 
and the slope factor of voltage dependence (k). This revealed that V1/2 for all mutant 
channels was shifted to more negative potentials compared to wild-type, with extreme shifts 
of 15 to 20 mV for Kv1.1 N255V and N255T (Figure 3B and Table 1). Further, Kv1.1 N255A, 
N255T, and N255H displayed slightly increased current amplitudes compared to wild-type 
Kv1.1. The other substituted amino acid (N255V) did not affect the current amplitude of 
Kv1.1 (Figure 2B and F igure 2C). In order to characterize the activation from the functional 
mutant and wild-type Kv1.1 channels, tail currents were elicited by 150 ms depolarizing 
pulses from -100 mV to +50 mV in 10 mV increments every 10 s, from a holding potential of - 
80 mV (F igure 3A). The slope factor was not significantly changed for the Kv1.1 mutants 
compared to wild-type Kv1.1 (Table 1). Mono-exponential functions were used for fitting K+ 
current rise to quantify the time dependence of activation (Figure 4A). Means of the 
calculated activation time constants were plotted against the test potentials (Figure 4B), 
demonstrating that the mutant channels activated ~2-3 times faster, except for Kv1.1 N225H 
that was not different from wild-type Kv1.1 (14.6±0.7 ms vs. 13.0±0.9 ms) (F igure 4B and 
Table 1). The inactivation of the total outward currents was determined using a standard 
double-pulse protocol (Figure 5A). With the holding potential of -8 0  mV, 10 s conditioning 
potentials were given from -9 0  to +30 mV in 10 mV increments, every 10 s. Then, the 
membrane was depolarized to +30 mV for 300 ms (Figure 5A). The rate of inactivation was 
quantified by measuring the peak current (Ipeak) and the current at the end of the conditioning 
pulse (Ifinal). The ratio, Ifinal/Ipeak, showed that inactivation kinetics were not altered in the
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mutant channels compared to wild-type channels (F igure 5B). Voltage-dependence of 
inactivation was investigated by plotting the relative amplitudes of the elicited outward 
currents at +30 mV as function of the potentials.
B
Figure 4: Time dependence of activation from wild-type and mutant Kv1.1 channels. A. Representative current 
traces of wild-type Kv1.1 elicited in response to a set of 150-ms voltage steps from -100 to +40 mV in 10 mV 
increments every 10 s. These activating traces were fitted with a mono-exponential function. B. The time 
constants of activation for wild-type Kv1.1, Kv1.1 N255A, Kv1.1 N255T, Kv1.1 N255V, and Kv1.1 N255H 
channels were plotted as a function of pre-pulse potentials and fitted with the equation: t  = t V1/2 exp ( V-V1/2 ) / k, 
where TV1/2 is the time constant at the half-maximal activation voltage (V1/2) of the channels, and k is the slope 
factor for the voltage-dependence of the time constants.
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Figure 5: The steady state inactivation of wild-type and mutant Kv1.1 channels. A. The representative wild-type 
Kv1.1 currents recorded with the double-pulse protocol. Outward currents were evoked on membrane 
depolarizations to +30 mV after (10 s) conditioning pre-pulses to potentials between -90 and +30 mV from a 
holding potential of -80 mV. B. Histogram of current amplitudes at the end of the conditioning voltage step (final) at 
+30 mV relative to the peak current amplitude at the beginning of the step (Ipeak). C. The steady-state inactivation 
curve of the wild-type Kv1.1 (n=5) and Kv1.1 N255A currents (n=5), wild-type Kv1.1 (n=5) and Kv1.1 N255T 
currents (n=5), wild-type Kv1.1 (n=5) and Kv1.1 N255V currents (n=5), and wild-type Kv1.1 (n=5) and Kv1.1 
N255H currents (n=2), respectively. The peak amplitudes of currents at +30 mV evoked from each conditioning 
potential were measured in individual cells and normalized to the amplitude of the current evoked after the 
conditioning pulse at -80 mV. Normalized currents are plotted as a function of the conditioning potential. The lines 
represent the best Boltzman fits to the data points I = Imax / (1 + exp (( V-V1/2 ) / k )), where I is the current 
measured at each test potential, V; Imax is the maximal current; V1/2 is the voltage of half-maximal inactivation; and 
k is the slope factor.
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The derived steady-state inactivation curve was fitted to the Boltzmann function, 
demonstrating the voltage-dependence of inactivation (Figure SC). The N255A, N255T, 
N255V, N255H mutant channels showed 50% inactivation at -46.7±1.8, -46.9±1.8, - 
46.8±1.5, and -39.6±1.7 mV, respectively, compared to -33.5±1.0 mV for wild-type Kv1.1 
(Figure SC and Table 1).
Table 1: Electrophysiological characteristics of kv1.1 wild-type and mutant channels.
WT A T V H
Voltage-dependence
Vli2(mV)
k (mV)
(n=5) 
-29,4±1,1 
12.1±1.0
(n=4)
-41.511.6* 
13.7+1.4
<n=5)
-50.511.93
11211.7
(n=5)
-45.5120’
13.9±1.8
<n=4)
-33.8H.3
12.3±1.2
Activation
T V1/2
(n=8)
13.010.9
(n=5)
6.2±0.2a
<n=4)
9.610^
(n=5)
5.2l0.3a
<n=5) 
14 6 ±0.7
Inactivation
 ^final ^  p^eak
Steady-state
inactivation
(n=4)
0.44±0.07
(n=5)
-33.5±1,0
(n=5) 
0.49 ±0.01
(n=5)
-46.711.8*
(n=4)
0.5010.04
{n=5)
-46.911.8s
(n=6) 
0.41 ±0.04
(n=5)
-46.811.5*
(n=3)
0.4010.08
(n=2)
-39.611.7
The voltage-dependent parameters of activation and inactivation (V1/2 and k) were obtained from the Boltzmann 
equation as described in Fig. 3 and Fig. 5, respectively. Activation time constants at V1/2 (xvi/2) were derived from 
Figure 4. Inactivation was measured at 30 mV and is presented as the ratio Ifinai/Ipeak- Data are presented as 
mean±SEM, with the number of investigated cells in parenthesis. aP < 0.01 (compared to WT) bP < 0.05 
(compared to WT).
D iscussion
Voltage-gated potassium (Kv) channels are gated in response to changes in transmembrane 
voltage [24]. Kvl.1 is abundantly expressed in excitable and non-excitable cells [3, 10, 11]. 
Recently, a mutation in Kv1.1 (N255D) was found in a large Brazilian family with isolated 
autosomal dominant hypomagnesemia [21]. In the present study, we investigated the nature 
of the Kv1.1 N255D mutation and demonstrated that the asparagine at position 255 is 
essential for normal voltage-dependence and kinetics of channel gating. First, homology 
modeling of Kv1.1 was performed, based on 75% sequence identity with the crystallized
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Kv1.2-Kv2.1 chimaera. Subsequently, the N255 was substituted into different amino acids 
(N255E, N255Q, N255A, N255V, N255T, N255H), which did not affect the expression of the 
channels at the plasma membrane. Second, the N255E and N255Q mutant channels 
displayed current amplitude close to the control situation (mock) and N255D, and were 
considered as non-functional. Third, the other mutants (N255A, N255V, N255T) showed a 
negative shift in V1/2 compared to wild-type Kv1.1 and had a faster time constant of activation 
except for N255H. Fourth, the half-maximal inactivation voltage was shifted to more negative 
potentials for all mutants, with N255H as the exception.
Affected family members from the Brazilian family with inherited hypomagnesemia showed 
low plasma Mg2+ levels (0.40 mmol/L; normal range, 0.70-0.95 mmol/L) and suffered from 
muscle cramps, tetanic episodes, tremor, and muscle weakness. Remarkably, mutations in 
Kv1.1 thus far were known to result in a mixed phenotype of episodic ataxia (EA1) and 
myokymia [13-16, 18, 21], a neurological phenotype in which hypomagnesemia has not been 
reported. Kv1.1 was shown to localize to the apical membrane of DCT cells and postulated to 
be involved in the generation of a favorable apical membrane voltage as a driving force for 
Mg2+ entry [21]. It is puzzling that distinct mutations in nearby amino acid residues in Kv1.1 
can result in phenotypes with dysfunction in two different organs (brain and kidney). A 
possible reason is that the composition of Kv1.1 channels in brain and kidney is different, 
due to tissue-specific expression of auxiliary p-subunits or co-assembly with other Kv1 
subunits that define the functional characteristics of these channels [25-27]. As a result, 
mutations at close locations within the protein may have tissue-specific effects, giving rise to 
diverse phenotypic characteristics.
Electrophysiological analyses of the EA1/myokymia-related mutant Kv1.1 channels showed 
either a significant reduction in current amplitude or altered kinetic properties compared to 
wild-type Kv1.1 channels [14, 19, 20]. The mutation identified in the Brazilian family caused 
substitution of the asparagine at amino acid position 255 into an aspartic acid (N255D). The 
asparagine at position 255 is highly conserved among species and Kv1 family members, 
which suggests its importance in channel function. Indeed, we demonstrated that the change 
of the neutral asparagine into a negatively charged aspartic acid results in a non-functional 
channel [21]. In the present study, we investigated the amino acid substitution at position 255 
in relation to channel function more extensively.
The tertiary structure of Kv1.1 was modeled by the WHAT-IF server, based on 75% 
sequence identity with the crystallized Kv1.2-Kv2.1 chimearic channel [5, 22]. The 
asparagine residue (N255) is located in the third transmembrane segment (S3) close to the 
S4 voltage-sensor element. S4 contains a long array of positive charges that are shown to 
sense differences in voltage and start the transition from the closed to open conformation by
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forming stabilizing hydrogen bonds with the external and internal negative clusters in the 
voltage-sensing domain [28, 29]. In general, mutations can affect channel activity via loss-of- 
function at the plasma membrane, protein instability or lack of plasma membrane targeting. 
Importantly, cell surface biotinylation studies showed that all mutants were expressed at the 
plasma membrane. Thus, the change in amino acid at position 255 had no effect on channel 
trafficking. However, the amino acid substitution has a clear effect on channel activity, as we 
demonstrated that N255E and N255Q channel were non-functional. This indicates that next 
to the addition of a negative charge at position 255 also an additional CH2-group in the side- 
chain influences channel function, likely via affecting conformational rearrangements. 
Subsequently, the voltage-dependence and kinetics of channel gating of the wild-type 
functional mutant channels were examined. All mutations stabilized the open state of Kv1.1, 
measured as negative shifts in the voltage dependence of channel activation. There was no 
obvious correlation between charge and the magnitude of the shift in V1/2 and k  as the effect 
was not significantly changed for N255H.
Depending on the polarity of the side chain, amino acids vary in their hydrophilic or 
hydrophobic character [30]. These properties are important determinants of the protein 
structure and the physical properties of the side chains influence the amino acid residues' 
interactions with other structures, both within a single protein and between proteins. 
Therefore, the hydrophilic asparagine could be important for structural rearrangements within 
the channel in response to voltage changes, which can be affected by conversion into 
hydrophobic amino acids as alanine and valine. Interestingly, the change in activation 
kinetics was most evident with these two residues as N255A and N255V activated 2 to 3-fold 
faster than wild-type channels. Furthermore, these mutants significantly shifted the voltage- 
dependence of activation. However, the magnitude of shift in V1/2 was highest for N255T, 
which suggests that channel gating is independent of hydrogen bonding with the residue at 
position 255.
Inactivation, besides activation, is another important property with respect to channel 
function. Interestingly, the voltage-dependence of inactivation was significantly affected in all 
mutant Kv1.1 channels compared to wild-type Kv1.1 except for N255H. Substitution of the 
asparagine with other amino acids shifted the half-point for inactivation to more negative 
potentials. The acceleration of the inactivation process is also of interest, as it is explained by 
a constriction mechanism of the outer mouth of the channel vestibule [31, 32]. It has been 
demonstrated that negatively charged clusters in the S2 and S3 segments, together with the 
positive charges in S4, are involved in the opening and closing of Kv1 channels [22]. In line 
with this, an earlier study showed that mutation of conserved negatively charged residues in 
the S2 and S3 segments selectively modulate channel gating. Mutation of the aspartic acid
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at position 258 in Kv1.1 abolished channel activity [33]. Therefore, we suggest that an 
additional negative charge nearby this cluster in S3 could keep the channel in the inactivated 
state, which may explain the non-functionality of the mutation found in patients with 
hypomagnesemia (N255D). However, there were no significant changes in inactivation 
kinetics between wild-type and mutant channels. Taken together, we have previously 
described hypomagnesemia as a new phenotypic variability associated with a mutation in 
Kv1.1 (N255D) [21] In this study, we provided more information about the structural 
arrangement of N255 and its involvement in channel activity. We have demonstrated that 
N255 is essential for normal channel function, since substitution by other amino acids 
significantly altered channel activity, voltage-dependence and kinetics of Kv1.1 channels.
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A bstract
Cisplatin (cisDDP) and related compounds are important anticancer drugs, which are widely 
used in the treatment of solid tumors. Unfortunately, the use of cisDDP is limited due to its 
toxicity to normal tissues, particularly the kidneys. Most cisDDP-treated patients suffer from a 
mixed phenotype, which includes Mg2+, Ca2+ and Na+ wasting, hypokalemic alkalosis, 
reduced glomerular filtration rate (GFR) and polyuria. The molecular mechanism that causes 
these electrolyte disturbances is unclear. In this regard, mice were intraperitoneally injected 
with one (acute group) or two (chronic group) dosages of 7.5 mg/kg body weight cisDDP or 
vehicle (control group). Acute CisDDP treatment significantly reduced serum Mg2+ levels 
(1.24±0.03 mmol/L and 1.41 ±0.05 mmol/L, treated versus control, respectively, P<0.05), 
serum K+ levels (4.9±0.2 mmol/L and 7.4±0.2 mmol/L, treated versus control, respectively, 
P<0.05) and the excretion of Ca2+ (3.1±0.4 Ca2+/creatinine ratio and 4.8±0.3 Ca2+/creatinine 
ratio, treated versus control, respectively, P<0.05). Chronic CisDDP treatment lowered serum 
Mg2+ (1.27±0.05 mmol/L and 1.46±0.03 mmol/L, treated versus control, respectively, P<0.05) 
and serum K+ (5.4±0.3 mmol/L and 7.4±0.2 mmol/L, treated versus control, respectively, 
P<0.05) levels. Surprisingly, in contrast with acute treatment, the excretion of Ca2+ (5.9±1.1 
Ca2+/creatinine ratio and 3.8±0.2 Ca2+/creatinine ratio, treated versus control, respectively, 
P<0.05) was increased in the chronically-treated mice group. Next, the expression level of 
Na+ transport proteins, including the Na+-H+ exchanger 3 (NHE3), the Na+-K+-Cl- 
cotransporter (NKCC2), the Na+-Cl- cotransporter (NCC) and the epithelial Na+ channel 
(ENaC), as well as the epithelial Mg2+ channel, transient receptor potential melastatin 6 
(TRPM6), were measured to identify the affected tubular segment. The NCC (45±5% and 
51 ±7% versus 100±4%, acute and chronic versus control, respectively, P<0.05) and the 
TRPM6 (32±6% and 45±4% versus 100±3%, acute and chronic versus control, respectively, 
P<0.05) mRNA levels were significantly reduced in both groups. Since NCC and TRPM6 
localize specifically to the distal convoluted tubule (DCT), we propose that impaired transport 
in the DCT can explain the electrolyte imbalances observed following cisDDP treatment.
In troduction
Cis-Diamminedichloroplatinum(II) (Cisplatin; cisDDP) is a commonly used cytotoxic agent 
with a broad range of actions against solid tumors, including ovarian, endometrial, cervical, 
urothelial, testicular, head/neck and lung cancer [1]. CisDDP causes cytotoxic lesions in 
rapidly dividing cells, such as tumor cells, due to the formation of cross-links with RNA, DNA
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and protein [2]. Despite its effect as an anti-cancer agent, clinical use is limited as ~20% of 
the patients who receive high-dose cisDDP develop severe renal dysfunction, often leading 
to acute renal failure (ARF) [3-5]. DNA-damaging agents usually have a less toxic effect on 
non-proliferating cells, yet, selective tubular epithelial cell damage has been demonstrated. 
Treatment with cisDDP or related compounds cause inflammation, oxidative stress injury, 
necrosis and/or apoptosis [4] of particularly the renal proximal tubule (PT) [6, 7] and/or DCT 
[8-10] in humans and a variety of animal models.
The observed nephrotoxicity likely results from elevated cisDDP accumulation in the kidneys, 
which is 5-times higher in comparison with other tissues. Although platinum compounds are 
bound to proteins in the plasma, most cisDDP is unbound [5] and can be freely filtered by the 
glomerulus. Next to filtration, renal cells secrete cisDDP from the blood to the tubular lumen 
[11]. The extent to which either pathway is responsible for the induction of cisDDP-induced 
renal cell death is unclear. CisDDP is rapidly removed from the body as ~65% of the cisDDP 
is excreted via the urine within the first 4 hours following treatment [12].
CisDDP enters the cell by passive diffusion and active uptake via transport mechanisms. 
Recent studies identified the organic cation transporter 2 (OCT2) [13] and the copper 
transporter 1 (CTR1) [14] as cisDDP-transporting proteins. Interestingly, both OCT2 and 
CTR1 are expressed in the kidney as well as in malignant tissues [15-17] and are, for that 
reason, candidates to facilitate the entry of cisDDP into renal cells. The renal phenotype 
associated with high concentrations of cisDDP is multifold. The majority of cisDDP-treated 
patients suffer from hypomagnesemia [18, 19], often associated with a reduced GFR, 
polyuria and electrolyte disturbances such as Na+, Ca2+ and Mg2+ wasting and/or 
hypokalemic alkalosis [20-23]. At this point the molecular mechanism responsible for these 
particular electrolyte disturbances is unknown.
The aim of the present study is, therefore, to identify the molecular mechanism responsible 
for the electrolyte disturbances following cisDDP treatment. The effect of acute (cisDDP 
injection: day 0; sacrificed: day 4) and chronic (additional dose: day 7; sacrificed: day 11) 
treatment on serum concentration and urinary excretion of Na+, K+, Ca2+ and Mg2+ was 
evaluated in mice. Additionally, the mRNA expression level of the renal Na+ and Mg2+ 
transporting proteins was measured.
Material and m ethods
Animal studies- 10 week old female C57Bl6/J mice were purchased from Harlan/CPB (Zeist, 
The Netherlands) and roomed in a temperature- and light-controlled room with ad libitum
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access to standard pellet chow (SSNIFF spezialdiaten GmbH, Soest, Germany) and 
deionized drinking water. Mice were randomly assigned to a control, an acute cisDDP and a 
chronic cisDDP treatment group (n=10 per group). CisDDP was administered using an 
intraperitoneal (ip) injection of 7.5 mg/kg body weight, while control animals received an ip 
injection of vehicle only. The animals were treated for three days, after which they were 
housed in metabolic cages enabling the collection of 24-h urine. Following, mice in the acute 
cisDDP group were sacrificed to collect blood and tissue. One week after the first injection, 
the control and chronic cisDDP group received a second ip injection of vehicle and 7.5 mg/kg 
body weight cisDDP, respectively. Animals in both groups were again treated for three days, 
after which they were housed in metabolic cages to collect 24-hour urine. Next, mice in both 
groups were sacrificed for the collection of blood and tissue. Kidneys were sampled and 
frozen immediately in liquid nitrogen. Blood samples were taken and blood was led to clot at 
room temperature, incubated overnight at 4 °C and spun down for 5 ’ at 13,250 x g. Next the 
serum was collected and used for analytical procedures. All experiments were performed in 
agreement with the animal ethics board of the Radboud University Nijmegen.
Analytical procedures- Serum and urinary Mg2+ concentrations were determined using a 
colorimetric assay kit according to the manufacturer’s protocol (Roche Diagnostics, 
Woerden, the Netherlands) [24]. Serum and urinary Ca2+ was measured as described 
previously [25]. A flame spectrophotometer (FCM 6343; Eppendorf) was used to measure 
serum and urinary Na+ and K+ concentrations, while urine and serum concentrations of Na+ 
and K+ were determined using an automated analyzer (AU 5000 chemistry analyzer, 
Olympus, Tokyo, Japan).
Table 1: Quantitative real-time PCR primers
mRNA Primer sequence 
Forward (5-3’) Reverse (5’-3')
TRPM6 CTTCGGCCACTGGCATTCTG GATGGCAAGGTAGGAGATGG
NCC AAAGCCATGCGAGTTATCAGC CTTCACAATGAAAACCTGCCC
PV CGCTGAGGACATCAAGAAGG CCGGGTTCTTTTTCTTCAGG
ENaC CATGCCTGGAGTCAACAATG CCATAAAAGCAGGCTCATCC
NKCC2 GGCTTGATCTTTGCTTTTGC CCATCATTGAATCGCTCTCC
NHE3 TGCCTTGGTGGTACTTCTGG TCGCTCCTCTTCACCTTCAG
OCT2 ATCTACCCAATAGCGGCATC GACCATCTGCAACACAATGG
CTR1 ACCACCTCAGCCTCACACTC TCTCGGGCTATCTTGAGTCC
Primers used to perform SYBR Green real-time PCR. TRPM6: transient receptor potential member 6; NCC: Na+- 
Cl- cotransporter; PV: parvalbumin; ENaC: epithelial Na+ channel; NKCC2: Na+-K+-Cl- cotransporter; NHE3: Na+- 
H+ exchanger 3; OCT2: organic cation transporter; CTR1: copper transporter 1.
99
CisDDP-induced injury of the DCT
Total kidney RNA isolation and cDNA synthesis- Total RNA was isolated from kidney using 
TriZol Total RNA Isolation Reagent according to standard procedures (Gibco BRL, Breda, 
The Netherlands). The obtained RNA was subjected to DNase treatment (Promega, 
Madison, WI) to prevent genomic DNA contamination, which may lead to overestimation of 
the copy number of an mRNA. All samples were resolved in 1 (w/v) % formaldehyde agarose 
gel to evaluate the RNA quality, while the RNA concentration was determined by measuring 
the ratio of the UV absorbance at 260 nm and 280 nm using the NANODROP 2000c 
(Thermo scientific). Thereafter, 1.5 |jg of RNA was reverse transcribed by Molony-Murine 
Leukemia Virus-Reverse Transcriptase (Invitrogen) into cDNA as described previously [24].
Semi-quantitative PCR analysis- SYBR Green PCR- Primer3 software 
(http://frodo.wi.mit.edu/primer3/) was used to design real-time PCR primers according to the 
following criteria: 1) amplicon size: 75-200 bp; 2) percentage of GC residues: between 50­
60%; 3) melting temperature: between 50-65oC. All primer sequences used in this study are 
shown in Table 1. Prior to Real-time PCR reactions the efficiency (95-105%) and dynamic 
range (R2>0.98) was evaluated for each primer set. Real-time PCR reactions were 
performed on a Biorad CFX96™ Real-Time PCR and Biorad C1000™ Thermal Cycler system. 
Reactions were performed in duplo using 6.25 |j.l 2-times concentrated SYBR®-Green Master 
Mix (Applied Biosystems), 12.5 ng of template cDNA and 400 nM of each primer in a final 
volume of 12.5 |o.l. All amplicons were the correct sizes after gel electrophoresis and the 
dissociation curves showed one distinct melting peak, ensuring the absence of a non-specific 
byproduct or primer dimers.
Statistical analysis- Data are expressed as mean ± SEM. Overall statistical significance was 
determined by one-way ANOVA, followed by a Bonferroni post-hoc test. The Student’s t-test 
was used to verify statistical comparisons between two groups. P<0.05 was considered 
statistically significant.
Results 
Serum and urine  e lectro ly te  levels o f cisDDP-treated m ice
10-week-old C57Bl/6 mice were ip injected with 7.5 mg/kg body weight cisDDP (n=20) or
0.9% (w/v) NaCl solution as a vehicle (n=10). After 3 days, the animals were placed into 
metabolic cages for the collection of 24-hour urine. Next, 10 mice from the cisDDP-treated 
group were sacrificed for the collection of blood and tissue (acute group). Serum and urinary
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electrolyte levels and body weight are displayed in Table 2. Compared to control mice, body 
weight (Table 2), serum Mg2+ (Figure 1A) and K+ (Figure 1C) levels were significantly 
reduced in the acute cisDDP group (n=10), while no differences were observed in serum Na+ 
(Figure 1D) and Ca2+ levels (Figure 1B). The excretion of Ca2+, Mg2+, Na+ and K+ was 
corrected by urinary concentration of creatinine to rule out volume concentration or dilution of 
the urine. In comparison with the control group, the renal excretion of Ca2+ was significantly 
lower in the acute cisDDP group (Figure 2C). The excretion of Mg2+, K+ and Na+ was 
unchanged (Figure 2A, F igure 2E and F igure 2G, respectively). After one week, the 
remaining mice in the cisDDP-treated group received a second injection with 7.5 mg/kg body 
weight cisDDP (chronic group; n=10), whereas the control group received vehicle (n=10). All 
mice were again housed for 24-hours into metabolic cages to collect urine after which they 
were sacrificed to remove tissue and blood (both chronic and control group). The body 
weight of the chronic group was significantly decreased compared to the control group as 
well as to the acute group (Table 2). In particular, 3 mice were omitted from further analysis, 
as they were visually sick following the chronic treatment with cisDDP. Next to the observed 
weakness, these mice featured a mixed phenotype including green/yellow faeces, a small 
spleen and light-colored kidneys.
Table 2: Serum levels and urinary excretion in mice following acute and chronic cisDDP treatment.
4 days (1 injection): 11 days (2 injections):
Control Acute Control Chronic
Bodyweight (g) 19.1 ±0.4 18.0±0.4a 20.5±0.2 16.610.6ab
Serum:
[Mg2*] (mmol/L) 1.41±0.05 1.24l0.03a 1.46±0.03 1.27l0.05a
[Ca2*] (mmol/L) nd 2.2±0.1 2.3±0.1 2.210.1
[Na*] (mmol/L) nd 113.4±1.0 111.510.7 113.411.1
[K*] (mmol/L) nd 4.9l0.2a 7.4±0.2 5.410.33
Urine:
Volume (ml/24 h) 1.1±0.1 1.1±0.1 1.210.1 1.210.2
[Creatinine] (mmol/L) 2.0±0.1 1.910.1 2.010.1 1.3±0.1a
Mg2* excretion (pmol/g/24 h) 1.810.1 1 .610.1 1.910.2 2.510.4
Mg2*/creatinine 16.1 ±1.1 17.1 ±1.8 18.8H.5 29.715.1
Ca2* excretion (pmol/g/24 h) 0.53±0.05 0.31±0.04a 0.4210.11 0.4910.08
Ca27creatinine 4.8±0.3 3.1±0.4a 3.810.2 5.911.1a
Na* excretion (pmol/g/24 h) 9.610.8 7.1 ±1.0 10.611.4 8.911.0
Na*/creatinine 88±3 80±12 97±13 98112
K* excretion (pmol/g/24 h) 4.510.3 3.110.2 4.810.5 3.710.5
KVcreatinine 42±2 38±5 4515 4218
Controls: mice receiving vehicle only; Acute: one injection cisDDP (7.5 mg/kg body weight); Chronic: second 
injection one week later. Data are presented as average ± SEM. aP<0.05 compared to control; bP<0.05 compared 
to acute; nd: not determined.
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The urinary creatinine levels were significantly reduced in the chronic group (Table 2), which 
may indicate decreased renal function in these animals. Additionally, mice in the chronic 
group displayed lower serum Mg2+ (Figure 1A) and K+ levels (Figure 1C) and normal Ca2+ 
(Figure 1B) and Na+ levels (Figure 1D), which is similar to the serum electrolyte levels 
observed after one injection of cisDDP (acute group). A second dose of cisDDP significantly 
increased the urinary Ca2+ excretion (Figure 2D), which is in contrast with the decreased 
excretion observed in the acute group The urinary excretion of Mg2+, K+ and Na+ (Figure 2B, 
F igure 2F and F igure 2H) did not differ from those observed in the control animals.
Figure 1: Effect of cisDDP vs. vehicle treatment on serum electrolyte levels, including Mg2+ (A), Ca2+ (B), K+ (C) 
and Na+ (D). Mice received vehicle (Control), 1 dose (acute) or 2 doses of 7.5 mg/kg body weight cisDDP 
(chronic). Data are presented as average ± SEM. P<0.05 is considered statistically significant.
The effect o f cisDDP on mRNA expression o f renal e lectro ly te  transporte rs
The mRNA expression levels of Mg2+ and Na+ transporters were determined by real-time 
quantitative PCR analysis. Both the acute and chronic group showed significantly lower 
expression levels of NCC (45±5% and 51 ±7% versus 100±4%, acute and chronic versus 
control, respectively, P<0.05) (Figure 3A) and TRPM6 (32±6% and 45±4% versus 100±3%, 
acute and chronic versus control, respectively, P<0.05) (F igure 3B).
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Figure 2: Effect of cisDDP vs. vehicle treatment on the creatinine (Cr) corrected excretion of electrolytes including 
Mg2+ (A+B), Ca2+ (C+D), K+ (E+F) and Na+ (G+H). Mice received vehicle (Control; white bars; A-H), 1 dose 
(Acute; black bars; A+C+E+G) or 2 doses (Chronic; grey bars: B+D+F+H) of 7.5 mg/kg body weight cisDDP. Data 
are presented as average ± SEM. *P<0.05 is considered statistically significant.
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Figure 3: Effect of Acute (black bars) and Chronic (grey bars) cisDDP treatment on mRNA expression levels of 
renal transport proteins, which reside in the distal convoluted tubule (DCT), such as the Na+-Cl- cotransporter 
(NCC) (A) transient receptor potential member 6 (TRPM6) (B) and parvalbumin (PV) (C) or are located in other 
tubule segments, including the Na+-H+ exchanger 3 (NHE3) (D), epithelial Na+ channel (ENaC) (E) and Na+-K+-Cl- 
cotransporter (NKCC2) (F). Expression levels are shown as percentage of control (white bars). Data is presented 
as means ± SEM. * P<0.05 is considered statistically significant. WT: Wild type.
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Additionally, parvalbumin (PV), a DCT specific Ca2+-and Mg2+-binding protein, was markedly 
downregulated in cisDDP-treated mice (16±5% and 19±9% versus 100±4%, acute and 
chronic versus control, respectively, P<0.05) (Figure 3C). The level of NHE3 mRNA 
expression, which is exclusively expressed in the PT, was not affected by cisDDP treatment 
(98±9% and 85±7% versus 100±6%, acute and chronic versus control, respectively, P>0.05) 
(Figure 3D). The ENaC mRNA levels, which localizes to the CNT and CD, were not 
significantly changed either (93±5% and 104±13% versus 100±4%, acute and chronic versus 
control, respectively, P>0.05) (Figure 3E). Additionally, the thick ascending loop (TAL) 
segment was not affected by cisDDP, as the NKCC2 expression level was not significantly 
changed (68±14% and 100±8% versus 100±8%, acute and chronic versus control, 
respectively, P>0.05) (Figure 3F).
Control Acute Chronic Control Acute Chronic
OCT2 CTR1
Figure 4: Effect of Acute (black bars) and Chronic (grey bars) cisDDP treatment on mRNA expression levels of 
proteins that transport cisDDP such as organic cation transporter 2 (OCT2) A: and copper transporter 1 (CTR1) 
B: Expression levels are shown as percentage of Control (white bars). Data is presented as means ± SEM. * 
P<0.05 is considered statistically significant. WT: Wild type.
The effect o f cisDDP on mRNA expression o f known cisDDP transporte rs
Previous studies suggested that the uptake of cisDDP is mediated by a specific transport 
mechanism [26, 27]. Exclusive expression of cisDDP transporters to the DCT may explain 
the damage to this tubule segment. Compared to the control group, the mRNA expression 
level of OCT2 was not changed in the acute mice group, while the chronic cisDDP mice 
group was significantly reduced (90±7% and 67±9% versus 100±4%, acute and chronic
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versus control, respectively, P<0.05 chronic versus control) (Figure 4A). Both the acute and 
chronic mice group did display significantly altered CTR1 mRNA levels (69±9% and 65±4% 
and 100±4%, acute and chronic versus control, respectively, P<0.05) (Figure 4B).
D iscussion
Our study demonstrated that cisDDP treatment in mice induces several electrolyte 
disturbances including hypomagnesemia, hypokalemia and hypocalciuria within 4 days after 
the first dose (acute group). The chronic mice group, who received a second dose of cisDDP 
at day 7, displayed similar decreased serum Mg2+ and K+ levels at day 11, while the renal 
excretion of Ca2+ was increased. Next, the mRNA expression level of Na+ entry mechanisms 
NHE3, NKCC2, NCC and ENaC as well as the Mg2+ channel TRPM6 was investigated. Of all 
studied transport proteins, only the expression of NCC and TRPM6 was significantly reduced 
in the acute and chronic cisDDP-treated mouse group.
In this study we showed that acute cisDDP treatment causes hypomagnesemia, hypokalemia 
and hypocalciuria. Interestingly, similar clinical findings were observed in patients suffering 
from Gitelman syndrome (GS) [20, 22, 28]. GS results from homozygous loss-of-function 
mutations in NCC [29], which localizes to the luminal membrane of the DCT where it 
cotransports Na+ and Cl- from the pro-urine to the intracellular compartment. Interestingly, 
severe hypotrophy of the DCT has been observed in NCC-deficient mice and in rats following 
chronic thiazide treatment [30, 31]. Impaired function of the DCT may also be the mechanism 
that causes the observed electrolyte disturbances following treatment with cisDDP. Absence 
of the NCC causes renal NaCl wasting and activation of the renin-angiotensin-aldosterone 
system [32, 33]. This likely leads to the observed hypokalemia as a result of increased Na+ 
load and compensatory reabsorption in the connecting tubule (CNT) and collecting duct (CD) 
region in exchange for K+ [34]. As a consequence, the urinary excretion of K+ could be 
increased, which was not observed in either of the cisDDP-treated mice groups. Perhaps, the 
excretion of K+ can be corrected by other compensatory transport systems that are not 
affected by cisDDP-treatment.
Next to the transport of NaCl, the DCT plays a key role in determining the final plasma Mg2+ 
concentration, as the more distal parts of the tubule are largely impermeable to Mg2+. In 
DCT, Mg2+ reabsorption occurs in an active transcellular manner via TRPM6 [35]. TRPM6 
localizes to the luminal membrane where it facilitates transport of Mg2+ from the pro-urine into 
the cell [36]. The importance of Mg2+ in cisDDP-induced renal injury has been underlined by 
several studies. A recent study demonstrated that cisDDP induced nephrotoxicity is
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enhanced due to Mg2+ depletion [37]. In addition, nephroprotection can be attained in patients 
who are supplemented with Mg2+ during and between courses of cisDDP treatment [38]. 
Another characteristic of impaired DCT function is hypocalciuria. Previously, a study by 
Nijenhuis et al. demonstrated that hypocalciuria in NCC-deficient mice is caused by 
increased Ca2+ reabsorption in the PT [39]. A similar mechanism may be applicable for the 
observed low urinary Ca2+ levels in our acute cisDDP-treated mice group. Surprisingly, 
chronic cisDDP treatment causes hypercalciuria. This transition from hypocalciuria in the 
acute group into hypercalciuria in the chronic group may be caused by cisDDP time- or dose- 
dependent effect on (a part of) the proximal tubule (PT). Several studies in which rats were 
treated with cisDDP demonstrated specific injury to the S3 segment of the PT [6, 7]. This 
study demonstrated significantly lowered mRNA expression of OCT2 in the PT caused by 
chronic, but not acute cisDDP treatment. So, DCT injury may cause compensatory Ca2+ 
reabsorption by the PT, which will be lost following PT damage. The mRNA levels of proteins 
expressed in the DCT like NCC, PV and TRPM6 were significantly reduced following cisDDP 
treatment in both the acute and chronic group. These results suggest a specific 
downregulation of proteins that reside in the DCT. To our knowledge, this is the first study 
that investigates the expression levels of transport proteins in the DCT following cisDDP 
treatment. Next, the effect of cisDDP on other tubule segments, including the PT, TAL, CNT 
and CD was investigated. NHE3 is expressed in the medullary TAL and the PT, of which the 
latter can be severely affected by cisDDP treatment. The expression of NHE3 was similar in 
kidneys of control and both cisDDP-treated groups. Perhaps, NHE3 is expressed in a part of 
the PT that is not directly affected by cisDDP. Furthermore, we were unable to detect 
expression differences for CNT and CD marker ENaC, suggesting that these tubular 
segments are not affected in our study. Additionally, the mRNA expression of NKCC2 was 
unchanged following acute and chronic cisDDP treatment. These observations are in line 
with a study by Ecelbarger et al., who showed normal protein expression of NKCC2 in the 
inner medullary (IM) TAL segment [40]. The same study also demonstrated that the protein 
abundance of NHE3, ROMK (TAL and CNT) and the a-subunit of the Na+/K+ ATPase (a- 
Na+/K+ ATPase) were not affected. On the other hand, the expression of IMCD proteins 
aquaporin (AQP) 2 and 3 and urea transporters (UT-A) was reduced. In contrast, a study by 
Lajer et al., displayed lower protein abundance for all investigated proteins, including the a- 
Na+/K+ ATPase, NHE3, NKCC2, AQP1 and AQP2 [37]. It is important to note that these 
discrepancies may result from a time and/or cumulative effect as the latter study (rats: 2.5 
mg cisDDP/kg body weight) lasted for three weeks, while our study (mice: 7.5 mg cisDDP/kg 
body weight) and the study performed by Ecelbarger et al. (rats: 5 mg cisDDP/kg body 
weight) were carried out for 11 and 7 days, respectively.
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Taken together, the previous observations suggest a specific effect on DCT function that 
may originate from either downregulation of DCT Na+ and Mg2+ transport proteins or a 
mechanism that induces DCT cell death. The procedure for cisDDP-mediated cell death is 
still unknown. Apoptosis can be induced by the formation of chromosomal DNA/cisDDP 
adducts and/or mitochondria-induced pathways [41, 42]. Mitochondria induced apoptosis is 
of interest as DCT cells are characterized by large size and a high density of mitochondria 
[43]. For that reason, the DCT may be more susceptible to mitochondria-induced apoptosis. 
Detailed insight in these pathways could increase our knowledge of how to threat patients 
with cisDDP.
It is of key importance to identify a way to prevent the renal side effects. A lot of research 
focuses on the identification of cisDDP transport mechanisms contributing to its 
nephrotoxicity and ways to block these in a competitive manner. The OCT2 transporters are 
expressed on the basolateral membrane of S3 segment of PT cells [44, 45], where they 
facilitate transport of organic cations like cisDDP from the interstitium to the inside of the cell 
[13]. Interestingly, cisDDP toxicity is suppressed when incubated with a competing substrate 
(Cimetidine) [13]. Some studies assume that OCT2 also localizes to the luminal side of DCT 
cells [46]. The mRNA expression of OCT2 in total kidney samples was only affected by 
chronic cisDDP treatment. Additionally, we studied the expression levels of OCT2 in DCT 
cells, which were specifically isolated from mice that selectively express enhanced green 
fluorescence protein (eGFP) by a PV promoter. The expression was ~20 lower in DCT cells 
compared to cells of the total kidney (data not shown), which indicates higher levels of OCT2 
expression in other segments of the kidney. Additionally, following cisDDP treatment the 
expression level of OCT2 was not lowered to the same extent as TRPM6, PV and NCC. 
Another transporter with a proposed role in cisDDP uptake is CTR1 [14], which in the kidney 
localizes to the basolateral membrane of both PT and TAL/DCT region [47]. Compared to 
control, the expression of CTR1 was significantly decreased in the kidneys of both cisDDP 
treated groups. Altogether, future studies are needed to confirm the role of CTR1 in the entry 
of cisDDP in DCT cells and to elucidate the exact mechanism that is responsible for the 
observed DCT-specific nephrotoxicity.
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In the last decade, positional candidate approaches in families with monogenetic forms of 
NaCl wasting and hypomagnesemia allowed the identification of new genes and derived 
proteins. Many of these proteins reside in the distal convoluted tubule (DCT). The thiazide­
sensitive NaCl cotransporter (NCC) [1] and the chloride channel, subunit b (ClC-Kb) [2] are 
affected in the K+ and Mg2+ wasting disorder Gitelman Syndrome (GS). Proteins that are 
involved in active renal Mg2+ handling include the epithelial Mg2+ channel transient receptor 
potential ion channel, member 6 (TRPM6) [3, 4], the y-subunit of the Na+,K+-ATPase 
(FXYD2) [5], and the hormone epidermal growth factor (EGF) [6]. TRPM6 is located at the 
luminal membrane of the DCT where it facilitates transport of Mg2+ from the pro-urine into the 
cell (F igure 1). EGF was discovered as the hormone that regulates active Mg2+ reabsorption 
via TRPM6 (Figure 1). The Na+,K+-ATPase, situated in the basolateral membrane, provides 
the Na+ gradient that is used by NCC to facilitate transport of Na+ and Cl- from the tubular 
lumen into the cell (Figure 1). The efflux of Cl- to the interstitium occurs through ClC-Kb, 
while the y-subunit of the Na+,K+-ATPase may regulate the function of the a  and/or p 
subunits of the Na+,K+-ATPase; the exact function of the prior subunit is still unknown 
(Figure 1). Despite these important discoveries, the mechanisms responsible for the 
transport of NaCl and Mg2+ in the DCT are not completely understood. This thesis 
incorporates novel aspects, which will be discussed in this chapter.
Identifica tion  and characterization o f NCC m uta tions
Gitelman syndrome (GS) is a frequently observed (1:40.000) tubulopathy, which is caused by 
mutations that affect NCC activity. Furthermore, NCC is the target for thiazide-type diuretics, 
which are currently recommended as the first line pharmacological treatment of hypertension 
[7] (Figure 1). Extensive study of NCC is essential to improve the diagnosis and treatment of 
GS and/or hypertensive patients. Analysis of individual mutations and corresponding amino 
acid residues provides insight into mechanisms by which NCC is regulated. The Xenopus 
laevis oocyte expression system is used to study the effect of NCC mutations on the activity 
and plasma membrane localization. Unfortunately, it is not yet feasible to use mammalian 
cells since NCC-transfected or NCC-expressing stable cell lines do not exhibit Na+ transport. 
In recent years, ~30 papers have described the identification of in total 180 different 
mutations, affecting 145 of the 1030 NCC amino acids [1, 8-40].
Introduction: electrolyte handling by the DCT
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Figure 1: Electrolyte handling in the DCT. Transient receptor potential ion channel member 6 (TRPM6) is located 
at the luminal membrane of the distal convolute tubule (DCT) where it facilitates transport of Mg2+ from the pro­
urine into the cell. Mg2+ reabsorption is primarily driven by the luminal membrane potential established by the 
voltage-gated K+ channel, Kv1.1. The epidermal growth factor (EGF) was discovered as a hormone that via 
interaction to the basolateral EGF receptor (EGFR) induces active Mg2+ reabsorption through increased trafficking 
of TRPM6. The Na+,K+-ATPase, situated in the basolateral membrane, provides the Na+ gradient that is used by 
NaCl cotransporter (NCC) to facilitate cotransport of Na+ and Cl- from the pro-urine into the cytoplasm. K+ is 
supplied to the Na+,K+-ATPase through Kir4.1 whereas the efflux of Cl- to the interstitium occurs through the 
chloride channel, subunit b (ClC-Kb). The y-subunit of the Na+,K+-ATPase may regulate the function of the a 
and/or p subunits, however, the exact function is unknown. Transcription factor HNF1B (hepatocyte nuclear factor 
1 homeobox B) is proposed to regulate the expression of the y-subunit of the Na+,K+-ATPase. Several drugs 
interfere with transport processes in the DCT. Cisplatin (cisDDP) is an anti-cancer agent, which causes injury to 
DCT cells. Immunosuppressive drug cyclosporin A down-regulates the expression of TRPM6. 
Hydrochlorothiazide and related compounds are widely used against hypertension as they block NCC-mediated 
NaCl transport. Anti-cancer drug Cetuximab induces hypomagnesemia because trafficking of TRPM6 channels is 
reduced as a result of its EGFR blocking effect.
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The study presented in Chapter 2 of this thesis contributed a large amount, including 30 
missense mutations and 4 nonsense mutations. Detailed information concerning all known 
NCC mutations is given in F igure 2. In addition to identification, the latter study and 4 other 
studies [12, 29, 41, 42] have characterized the effect of mutations on the glycosylation state, 
NCC activity and NCC plasma membrane expression using the aforementioned Xenopus 
laevis oocyte expression system (Table 1). Based on these observations each NCC mutant 
was categorized according to the nomenclature as shown in F igure 3. In the next 
paragraphs an insight into the spatial distribution of all identified mutants is given and the 
mechanisms by which mutants (from each class) impair NCC function are discussed.
Spatial distribution of NCC mutations
The identified mutations are randomly distributed throughout the NCC proteins, although 
some large regions seem to be unaffected. Amino acids in these regions are less susceptible 
to the introduction of mutations or not essential for NCC function. For instance, the carboxy- 
terminus includes a region of 82 amino acids (between NCC residues 751-833) that is not 
affected by a mutation (F igure 2). This region includes a potential PKA phosphorylation site 
at position 811 (Ser811). PKA phosphorylation may be a mechanism to regulate NCC 
function. Interestingly, the Ser811 residue does not occur in each of the known NCC splice 
variants.
There are 3 known splice variants: compared to the NCC 1030 and 1029 (absence residue 
Gln95) variant, NCC 1021 lacks residues 807-816 including the presumed Ser811 
phosphorylation site. At this moment, little is known about the function and tissue localization 
of the different isoforms and whether this PKA phosphorylation site is essential for the 
regulation of NCC activity.
Functional characterization of NCC mutations
To date, the effect of the mutation on the subcellular localization and function of the NCC 
transporter has been fully studied for 33 sequence variants [12, 29, 41, 42] (including the 7 
mutants presented in Chapter 2). The transport activity of 3 sequence variants is not 
significantly different from wild-type NCC. The Ala728Thr and Arg913Gln mutants 
demonstrated equal NaCl transport, while the Arg928Cys mutation showed even increased 
NCC function [43]. These, but also other identified non-synonymous mutations, occur in the 
general population and can, therefore, not be directly linked to the GS phenotype (Table 1). 
The Gly264Ala and Arg913Gln sequence variants appear in hypertensive (HT) patients and 
the latter variant is even associated with increased risk for the development of hypertension 
(Table 1) [22, 44].
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Figure 2: Predicted schematic topological model of the NaCI cotransporter (NCC), including all identified NCC 
mutations in Gitelman syndrome (GS) patients. The NaCl cotransporter consists of large intracellular amino -and 
carboxy-termini, which presumably are located within the cell, 12 transmembrane segments (S) and a large 
hydrophilic extracellular loop between S7 and S8 comprising two glycosylation sites. Every dot represents one 
amino acid and the localization of the newly identified NCC mutations is denoted by a red dot.
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# Mutation Ref, # Mutation Ref, # Mutation Ref,
1 p. Met 1 Leu 20 51 p.Trp381X 26 « p.Arg642Gly 38
2 p/Thr60Met 20 52 p.Thr3S2Met 26 100 p.Pro643Leu 26
3 p.Asp62His 21 53 p.Thr3S3Met 11 101 p.Vai647Met this thesis
4 p.Glu68Lys 13 54 p.Tyr386Cys 27 102 p.Thr649Arg 18
5 prHis69Asn 13 55 p,Thr392lle 11 p.Thrf349Met 17
6 p.Arg83Trp this thesis 56 p.Arg399Cys 38 103 p,Gly650Arg 11
p.Arg83Gin 26 57 p.Ser402Phe 28 104 p,Arg655Cys 18
7 p,His90Tyr 40 58 p.Asn406His 35 p.Ang655His 1
8 p,G!u112X 36 59 p.Cys421X 11 p.Arg655Leu 21
9 p.Glu121Asp this thesis ■■ p.Cys421Gly 11 105 p.Met672Ue 33
10 p.Arg135CyS this thesis ■■ p,Cys421Arg 1 106 p.Val677Met 31
11 p .Arg 145 His 13 p.Cys421Phe 27 p,Vai677Leu 13
+t p.Arg145Cys 29 60 p.Trp425X 11 107 p.Trp699Arg 11
12 p,Cys146Phe 23 61 p.Asn426Lys 10 108 p.Ser710X 40
13 p.lie150Met this thesis 62 p.Cys430Gly 30 109 p.Gly722X this thesis
14 p.Val153Met 13 §3 p.Gly439Ser 21 110 p.Aia728Thr 1
15 p.lle154Phe 38 ■■ p.Gly439Val 30 111 p,Gly729Vai 38
16 p.Leul57Pro this thesis 64 p.Asn442Lys 9 112 p,Gly731Arg 21
17 p.ArglSSGIn 31 » p.Asn442Ser this thesis 113 p,Pro735Arg this thesis
» prArg158Leu this thesis 65 p.Ala459Asp 38 114 p. Leu738Arg 18
10 p.Thrl 63 Met 31 66 p.Gly463Arg 26 115 p.Gly741Arg 1
19 p.Aia166Val this thesis p.Gly463Glu 31 116 p.Pro751Leu this thesis
20 p.Trp172Arg 31 67 p.Ala464Thr 31 117 p.Ser833Thr this thesis
21 p.Serl78Leu 38 68 p.Thr465Pro 23 118 p.Trp844X 40
22 p.Thrl 80Lys 24 69 p.Ser475Cys this thesis 119 p.Asp848Asr 11
23 p.G ¡y 186 Asp 21 70 p.Lys478Glu 21 120 p.Gly850Arg this thesis
24 p.lie192Thr this thesis 71 p.Cys484Trp 29 121 p.Tyr857Cys 23
25 p.Thrl 94 tie this thesis 72 p.Asp486Asn 1 122 p,Leu858His 24
26 p.Gly196Val 30 73 p.Tyr489His this thesis p.Leu858Phe this thesis
27 p.Arg209Trp 1 74 p.Gly496Cys 1 123 p.Leu859Pro 1
p.Arg209Gin 38 75 p.Lys497X 38 124 p.Ang861Cys 18
28 p.Leu215Pno 18 76 p.Arg507Cys this thesis p.Arg861 His 8
29 p.Ala226Thr 18 77 p Ala523Thr 29 p.Arg86l Ser 31
30 p,Gly230Asp 13 78 p.Asn534Ser this thesis 125 p,Arg871Pro 11
31 p.Thr235Arg this thesis 79 p.Phe536Leu 12 p,Arg871His 40
32 p.Asp259Asn this thesis 80 p.Leu542Pro 21 126 p.Gly876Ser 13
33 p.Arg261Cys 39 81 p.Ser546Gly this thesis 127 p.Met881Thr this thesis
p.Arg261Hïs 18 82 p.Ser555Leu 38 128 pJArg896X 38
34 p.Giy264Arg 34 83 p.Pro556Leu 23 « p,Arg896Gfn this thesis
» p.Gly264Aia 26 84 p,Pro560Leu 18 129 p.lle904Phe 11
35 p. Leu 2 72 Pro this thesis p.Pro560Arg this thesis 130 p,Arg913Gtn 18
36 p.Ser283Tyr 40 85 p A!a569Va! 20 131 p,Arg928Cys 18
37 p.Lys284Arg 38 p.A!a569Giu 24 132 p.Glu94lX this thesis
36 p,Ser296Ala 26 85 p,Ala570Val 37 133 p.Ang943Trp 26
39 p.Thr304Met 22 87 p Leu571 Pro 30 134 p.Cys944Tyr 29
** p.Thr304pro this thesis 88 pVa!578Met 24 135 p.Lys957X this thesis
40 p.Ala313Val 38 89 p.Met581Lys 11 136 p,Ang964Gfn 1
41 p.Ser314Phe 27 90 p.Ala588Val 1 : ht p,Arg964Trp 11
42 p,Gly316Ala 26 91 p.Asn611Thr 23 137 p.Arg967Giy 1
p,Gly316Val 31 ■■ p.Asn611Ser 29 138 p.Arg977X this thesis
43 p.Arg321Trp 38 92 p Trp612Cys 26 p.Arg977Gln 29
44 p.Arg334Trp 38 93 p Gly613 Ser 18 139 p,Cys994tyr 12
45 p.Thr339lie 27 94 p.Ser615Leu 38 140 p.Gly989Arg 38
46 p.Gly342Ala 13 ■■ p.Ser615Trp 31 141 p,Arg10l8X 14
T prGly342X this thesis 95 p,Ala618Ser 26 fT p.Arg1018Gln 35
47 p.Pro349Leu 1 96 p.Leu623Pro 32 1T p.Arg1018Cys this thesis
48 p.Ser350Leu 29 97 p.Arg628Ser 18 142 p. Asn 1023Lys 35
49 p. As n 3 59Asp 23 98 p.Gly630Val 1 143 p.Vai1024Met 41
p.Asn359Lys 27 99 p.Arg642Cys 24 144 p,Thr1026l!e 38
50 p.Giy374Val 31 M p.Arg642His 18 145 p.Gln1030Arg this thesis
# corresponds to its location in the topological model shown on the previous page.
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Figure 3: Overview of 
the NCC mutant 
classes. NaCl entry 
from the tubular lumen 
into the distal 
convoluted tubule 
(DCT) cell occurs via 
the NaCl cotransporter 
(NCC), following
basolateral extrusion of 
Na+ and Cl- to the blood 
via the Na+,K+ ATPase 
and chloride channel, 
subunit b (ClC-Kb), 
respectively. NCC 
function can be 
impaired as a result of 
5 different mechanisms 
(Class 1-5) as shown in 
the figure. ER: 
Endoplasmic reticulum.
21 NCC sequence variants are not present on the plasma membrane and for that reason 
unable to transport NaCl (Table 1). In 8 cases, NCC presumably resides in the endoplasmic 
reticulum (ER) as a consequence of improper folding of the protein. Compared to water- 
injected oocytes, these mutants showed reduced transport capacity and plasma membrane 
expression (Table 1; F igure 3:class 2). Most of the class 2 mutations (6/8) specifically affect 
amino acids in the regions that are in or near to the membrane (TMs and intra- and 
extracellular loops regions) that comprise only ~40% of the predicted topological model of 
NCC (F igure 2). This is also the case for the class 2 Thr392Ile mutation presented in this 
thesis (Chapter 2). Hydrophobic segments like TMs are important for protein folding and 
membrane insertion [45]. Mutations that affect amino acids in TMs may, therefore, cause 
protein misfolding, which would explain the ER retention that characterizes class 2 
mutations.
13 sequence variants partially localize to the cell surface and the cytoplasm, explaining why 
the transport is higher than water-injected oocytes, but lower than wild-type NCC-expressing 
oocytes (Table 1; F igure 3:class 3). These class 3 mutations are randomly distributed 
throughout the NCC protein (F igure 2). 9 NCC sequence variants are expressed on the cell 
membrane, but not able to transport NaCl (Table 1; Figure 3:class 4). These mutants (8 out 
of 9) localize to amino- and carboxy-terminus in the intracellular compartment. Of these, 2 
mutations locate in the amino-terminus, 4 reside in the carboxy-terminus and 2 exist in the 
fourth and largest intracellular loop (Figure 2). The amino- and carboxy-termini often
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comprise domains that are important for the regulation of a protein, which may also be the 
case for the NCC cotransporter. Detailed analysis of NCC amino acids can provide insight 
into NCC function or regulation, which may ultimately provide tools to predict, prevent and 
treat hypertension and/or GS. The following paragraphs will discuss how the various (classes 
of) mutations interfere with NCC function.
Table 1: Overview of all NCC mutations that are functionally characterized
# Genotype NCC Functional analysis:
Conser- Glyco- Na+ 
ved svlated Transport
cell surface 
localization
Mutant
Class
Loalization 
in NCC
Occurrence
in
population
Reference
2 p.ThrôOMet + + 1 5 4 NT GS 23
9 p.Glu121Asp + + 2 5 4 NT GS this thesis
11 p.Arg145Cys + + 2 3 3 NT GS 29
27 p.Arg209Trp + - 1 nd ? IL1 GS NT 42
28 p Leu215Pro + - 2 2 3 TM 3 GS 12
2d p.Ala226Thr + + nd nd 7 TM3 GS 41
39 p.Thr304Met + - 1 1 2 TM5 GS 23
42 p.Gly316Val + +/- 1 1 2 EL2 GS 29
47 p.Pro349Leu + - 1 nd ? TM6 GS 41,42
55 p.Thr392lle + - 2 2 3 TM7 GS this thesis
56 p.Arg399Cys + +/- 1 1 2 EL3 GS 29
58 p.Asn406His + - 2 2 3 EL3 GS 46
59 p.Cys421Arg + - 1 nd 7 EL3 GS NT 42
61 p.Asn426Lys - - 2 2 3 EL3 GS 46
63 p.Gly439Ser + - 1 2 2 EL3 GS 12
64 p.Asn442Ser + +/- 3 2 3 EL3 GS this thesis
68 p.Thr465Pro + - 1 1 2 TM8 GS 23
69 p.Ser475Cys + + 3 5 4 IL4 GS this thesis
73 p.Tyr489His + + 3 4 4 IL4 GS this thesis
79 p.Phe536Leu + + 1 4 4 TM10 GS 12
82 p.Ser555Leu + + 1 2 2 IL5 GS 29
90 p.Ala588Val + + 2 2 3 TM12 GS 29,41
91 p.Asn611Thr + + 3 3 3 CT GS 23
91 p.Asn611Ser + + 3 4 4 CT GS 29
93 p.Gly613 Ser + + 2 3 2 CT GS 41
98 p Gly630Val - - 3 3 3 CT GS NT 41
102 p.Thr649Arg - - 1 2 2 CT GS 12
110 p.Ala728Thr - nd 5 nd - CT GS NT HP 43
114 p.Leu738Arg + - 2 nd 7 CT GS 42
115 p.Gly741Arg + - 2 2 3 CT GS 12,42
116 p.Pro751Leu + + 3 5 4 CT GS this thesis
123 p.Leu859Pro + - nd nd 7 CT GS 41
124 p.Arg861Cys - + nd nd 7 CT GS 41
130 p.Arg913Gln - nd 5 nd - CT GS NT HP 43
131 p.Arg928Cys + + >5 5 • CT GS NT HP 41
136 p.Arg964Gln + + 2 2 3 CT GS 12,41
138 p.Arg977X del del 1 nd ? CT GS 41,42
139 p.Gly989Arg + + 2 4 4 CT GS NT 12
140 p.Cys994tyr + + 3 4 4 CT GS 12
141 p.Arg1018X del del 1 nd 7 CT GS 41,42
143 p.Val1024Met + + 2 2 3 CT GS 41
144 p.Thrl 026lle + - 2 nd 7 CT GS 41,42
145 p.Gln1030Arg + + 3 3 3 CT GS this thesis
#: Relates to numbering in Figure 2; The Na+ transport and cell surface localization columns display numbers, 
which correspond to the percentage of NCC activity and percentage of NCC on the plasma membrane, 
respectively (1: 0%; 2: 1-25%; 3: 26-50%; 4: 51-75%; 5: 76-100%); del: premature deletion; nd: not defined; ?: 
unknown due to incomplete characterization; NT: N-terminus; TM: transmembrane; CT: C-terminus; GS: Gitelman 
syndrome; NT: normotensive; HP: hypertensive.; IL: intracellular loop; EL: extracellular loop.
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Effect of mutations on NCC glycosylation
NCC contains 2 N-linked glycosylation sites (human Asn406 and Asn426) in the large 
extracellular loop. The Asn442Ser mutant (Chapter 2) affects a residue that is situated close 
to the NCC glycosylation sites (Figure 2). The glycosylation is partially abolished for the 
Asn442Ser NCC mutant, suggesting that glycosylation of either the Asn406 or Asn426 
residues is hampered (Table 1). Mutation of either glycosylation site causes reduced Na+ 
transport activity, which results from decreased expression at the cell surface (Table 1) [46]. 
GS patients with a mutation that directly affects one of the NCC glycosylation sites were 
proposed to have a more severe phenotype. Indeed, the Asn426Lys mutation was identified 
in a patient with profound hypokalemia (1.8 mmol/L), which is usually milder in GS [10]. 
Unfortunately, the clinical data of a Chinese male with the Asn406His mutation [35] were not 
described in the paper. Therefore, a direct link between impaired glycosylation and a more 
severe GS phenotype cannot yet be made.
Effect of mutations on NCC phosphorylation
The NCC amino-tail contains 3 phosphorylation sites (human Thr46, Thr55 and Thr60), 
which are important mechanisms for the regulation of NCC function. A study using the 
Xenopus laevis oocyte expression system showed that the NaCl transport activity was 
increased upon Thr60 phosphorylation of the NCC. Maki et al. described a NCC mutation in 
a GS patient, affecting the Thr60 NCC residue (Thr60Met) (Figure 2) [20]. In contrast, this 
mutant NCC transporter was expressed at the cell surface, but the transport activity was 
reduced (class 4) (Table 1). Like the Thr60Met mutation, the identified Glu121Asp mutant 
(Chapter 2) displayed class 4 NCC characteristics (Figure 3) and both affected residues 
reside in the amino-tail.
Phosphorylation of the human Thr46, Thr55 and Thr60 residues occurs in case of hypotonic 
low Cl- conditions [47], angiotensin II (AngII) [48] and aldosterone [49]. It is now evident that 
Ste20-related proline-alanine-rich kinase (SPAK) and oxidative stress response 1 (OSR1) 
are responsible for the phosphorylation of Thr60, which further initiates the phosphorylation 
of other residues in the NCC N-terminus, namely Thr46 and Thr55 [50]. So far, mutations 
that affect the Thr46 and Thr55 residues have not been discovered in GS patients. 
With-no-Lysine kinases (WNK) 1 and 4 suppress SPAK/OSR1 phosphorylation, which as a 
consequence reduces NCC activity [51]. Mutations in WNK1 and 4 are associated with 
hyperkalemic hypertension and metabolic acidosis (FHH) or Gordon syndrome) (OMIM 
145260); which is the mirror image of the GS phenotype [52]. Mutations in WNK1 and WNK4
Effect of NCC mutations on function and regulation
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presumably reduce the usual inhibitory effect, increasing NCC activity [53, 54]. In line with 
these observations, WNK4 knockout (KO) mice display increased phosphorylation of 
SPAK/OSR1 and NCC, increasing the activity of NCC [55]. Even though additional 
experiments are required to confirm its involvement, mutations of the Glu121 residue may 
disrupt the interaction between NCC and OSR1, SPAK or WNK1, resulting in decreased 
NCC phosphorylation and therefore activity.
Effect of mutations on ion affinity, thiazide sensitivity and trafficking of NCC 
Recent studies have revealed the critical domains and/or residues that define the specificity 
for NCC ion translocation and thiazide inhibition [56]. The NCC affinity-modifying residues for 
Cl- and for thiazides are located within the TM1-7 and TM8-12 region, respectively, whereas 
both segments seem to be implicated in defining Na+ affinity. The Ser475Cys and Tyr489His 
mutants (Chapter 2) are not functional, but expressed at the cell surface (Table 1). 
Additionally, the affected residues are located in the intracellular loop between TM8 and 
TM9. Perhaps, reduced affinity for Na+ can explain impaired NCC function of these mutants. 
Another interesting non-functional mutant of NCC is Pro751Leu, which like the Ser475Cys 
and Tyr489His mutants, is expressed at the plasma membrane (Table 1). The Pro751 
residue is situated in the C-terminus and possibly part of a mechanism that regulates NCC 
function at the cell surface. Mutant Gln1030Arg transporters (Chapter 2) to some extent 
localize to the plasma membrane and consequently show reduced activity (Table 1). 
Interestingly, the Gln1030Arg mutation changes the last amino acid of NCC. Possibly, the 
Gln1030 amino acid is part of a protein-protein interaction motif, which is essential for 
trafficking.
Phenotype-genotype association study for NCC
Next to the obtained clues about the role of certain amino acids in NCC activity and 
regulation, identified mutations can potentially be used to predict the clinical outcome of GS 
patients. A recent study showed a high prevalence of splicing mutations in a subgroup of 
patients who displayed a severe phenotype. However, the number of patients in the severe 
phenotype group was limited [29] and for that reason these associations should be 
confirmed. A recently started European study that investigates a large cohort of GS patients 
will hopefully identify NCC genotype-phenotype correlations (Eunefron).
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Kv1.1: a new regu la tor of Mg2+ entry via TRPM6
Identification of a novel mutation in the gene encoding Kv1.1 in a family with renal 
hypomagnesemia
In Chapter 3 of this thesis the identification of a novel protein called Kv1.1, which was shown 
to have a key role in Mg2+ handling in the DCT is described (F igure 1). A mutation in the 
KCNA1 gene, coding for the voltage-gated K+ channel Kv1.1 (OMIM 176260), was the cause 
for autosomal dominant hypomagnesemia (0.28-0.37 mmol/L) in a large Brazilian family [57]. 
The phenotype present from infancy consisted of recurrent muscle cramps, tetany, tremor, 
muscle weakness, cerebellar atrophy and myokymia. Kv1.1 colocalizes with TRPM6 along 
the luminal membrane of the DCT. Functional Kv1.1 channels are composed of 4 subunits 
that form homo- or heterotetramers in assembly with other Kv channel subunits. Functional 
analysis showed that the mutation results in a non-functional channel with a dominant 
negative effect on wild-type channel function, in line with the pattern of inheritance observed 
in the family. The Mg2+ influx via TRPM6 is energized by the local electrochemical gradient. 
Importantly, the DCT cell lacks a substantial chemical gradient for Mg2+. The Mg2+ 
concentration in the pro-urine is likely around 1.1 mmol/L, while the free intracellular Mg2+ 
concentration has been estimated to be 0.5-1.0 mmol/L [58]. The luminal membrane 
potential in the DCT is approximately -70 mV [59], favouring luminal Mg2+ influx. Thus, the 
movement of Mg2+ into the DCT cell seems mainly driven by the electrical gradient. The 
Renal Outer Medullary Potassium channel (ROMK) was proposed to generate the luminal 
membrane potential via K+ efflux. Nevertheless, immunolocalization studies show specific 
ROMK staining in the TAL and connecting tubule (CNT), but not the DCT [60]. Alternatively, 
Kv1.1 has been identified as luminal K+ channel in DCT that establishes a favourable luminal 
membrane potential to control TRPM6-mediated Mg2+ reabsorption (Figure 1). 
Consequently, mutation of Kv1.1 residue Asn255 leads to impairment of renal Mg2+ handling 
[57] (Chapter 3).
Functional consequence of the Kv1.1 Asn255Asp mutation
The occurrence of a complicated hydrogen-bonded network in Kv1.1 together with the 
introduction of an additional charge, led to the hypothesis that the Asn255Asp mutation 
interferes with the voltage sensor characteristics of Kv1.1 (Chapter 4). Therefore, the tertiary 
structure of Kv1.1 was modeled by the WHAT-IF server, based on 75% sequence identity 
with the crystallized Kv1.2-Kv2.1 chimeric channel [61, 62]. Additionally, six mutations were 
introduced in Kv1.1 at position Asn255 to study the amino acid substitution in relation to 
channel function. In general, mutations can affect channel activity via loss-of-function at the
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plasma membrane, protein instability or lack of plasma membrane targeting. Importantly, cell 
surface biotinylation studies showed that all Kv1.1 mutants (Asn255Glu, Asn255Gln, 
Asn255Ala, Asn255Val, Asn255Thr, Asn255His) were expressed at the plasma membrane. 
These amino acids have a different hydrophilic or hydrophobic character depending on the 
polarity of the side chain [63]. These properties determine the protein structure, as well as 
the physical properties of the side chains, which influence the interactions within the protein 
and between proteins. The hydrophilic Asn255 residue could be important for structural 
rearrangements within the channel in response to voltage changes. This may be hampered 
by the introduction of a negative residue in case of the Asn255Gln mutation. To investigate 
this possibility, the negative residue glutamic acid (Asn255Glu) was introduced, which is one 
CH2-group longer than the aspartic acid and asparagine side chain. As a control for steric 
hindrance, the non-charged glutamine (Asn255Gln) was also investigated, which has the 
same size as glutamic acid. However, both Asn255Glu and Asn255Gln channels were non­
functional. This indicates that there is no correlation with the addition of charge at position 
255, which is line with the finding that substitution by a positive charged histidine 
(Asn255His) results in normal channel activity. Alternatively, introduction of the Asn255Asp 
may block the formation of hydrogen bonds, which would reduce the stability of the Kv1 .1 
channel. Therefore, alanine (Asn255Ala), valine (Asn255Val), threonine (Asn255Thr) were 
introduced. Alanine and valine are both non-polar side chains that cannot participate in 
hydrogen bonds, whereas threonine has an alcoholic group in its side chain and is, therefore, 
able to contribute to hydrogen bonds. These mutations stabilized the open state of the Kv1.1 
channel, measured as negative shifts in the voltage dependence of channel activation. The 
voltage-dependence and kinetics of channel gating was further examined for all functional 
mutants (Asn255Ala, Asn255Val, Asn255Thr, Asn255His). But, there was no obvious 
correlation between the size, loss of hydrogen bond or charge and the magnitude of the shift 
in V1/2 for activation or inactivation. Taken together, Asn255 is essential for normal channel 
function, since substitution by other amino acids significantly altered channel activity, 
voltage-dependence and kinetics of Kv1.1 channels, but more detailed structural information 
is necessary to specify the involvement of this residue in voltage-sensing and channel 
opening (Chapter 4).
Possibly the Asn255 residue is essential to keep the channel in the plasma membrane. The 
S2-S3 turn, nearby the Asn255 amino acid, is involved in the anchoring of the channel into 
the plasma membrane. Mutations within that region could result in the inability of the channel 
to remain in the plasma membrane. Alternatively, affected interaction with other Kv channels 
or other binding partners may be the underlying molecular defect. The latter possibility can 
be studied using immunoprecipitation techniques followed by mass-spectrometry.
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O  Marking every 50 amino adds
# Genotype
Conser­
ved
Phenotype
EA1 Myo­
kymia
Myo­
tonia
Epilepsy Senjm [Mg'] 
mmol/L
Other
Reference
1 p.Val173F ♦ + + . _ nd 65
2 p.lle176Arg + ■f ♦ - - nd 77
3 p.Phe184Cys ♦ ♦ + - - nd 64
4 p.Thr226Ala + 4- - - - nd 77
5 p.Thr226Lys + -  + - - nd 66
6 p.Thr226Arg + +/- + ♦/- ♦/- nd Skeletal deformities 70.74
7 p.Arg239Ser + + + - - nd 65
8 p.Ala242Pro + - + + nd 68
9 p.Pro244His + + - nd 68
10 p.Phe249lle + + + - - nd 65
11 p.Phe250del + + + + - nd Breathing problems 73
12 p Asn255Asp + -  +/- - - 0.37 this thesis
13 p.lle262Thr ♦ + -f + - 0.76 71
14 p Val299lle ♦ + ♦ + - nd 75
15 p.Leu305Pro ♦ +/- +/- +/- 0 80 72
16 p.Glu325Asp + + + - - nd 64
17 p.Leu329lle + ♦ +/- - - nd 76
18 p Ser342lle + + - - - nd Severe EA 78
19 p.VaW04lle ♦ ■f + - - 0.73 68.77
20 p.Val408Ala ♦ + + - - nd 65
21 p.Val408Leu ♦ ♦ + + + nd Cerebellar atrophy 67
22 p.Phe414Cys + + ♦ +/- +/- nd 69
23 p.Arg417X + + + - - nd Drug resistance 68
Figure 4: Phenotypic overview associated with Kv1.1 mutations (refs 64-77) and predicted schematic topological 
localization of each identified Kv1.1 mutations. Patients with Kv1.1 mutations display a mixed phenotype, 
including episodic ataxia 1 (EA1), myokymia, neuromyotonia, epilepsy and hypomagnesemia. Kv1.1 consists of 
large intracellular amino -and carboxy-terminal domains, which presumably are located within the cell, 6 
transmembrane segments (S) and a pore region between S5 and S6. Every dot represents one amino acid and 
the localization of the identified Kv1.1 mutations is denoted by a white or red (this thesis) dot. nd: not defined.
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Other phenotypes associated with mutations in KCNA1
Previously identified mutations in the KCNA1 gene are characterized by episodic ataxia 1 
(EA1; OMIM 160120), which manifests during the first or second decade of life [64-78]. 
Attacks of ataxia are in some cases accompanied by myokymia [64-75, 77], neuromyotonia 
[67-73, 75] and epilepsy [67, 68, 74]. The diverse phenotype is nicely illustrated by the 
mutation of the Kv1.1 residue Thr226, which dependent on the mutation causes isolated EA1 
(Thr226Ala), isolated myokymia (Thr226Lys) or a mixture of EA1, myokymia and epilepsy 
(Thr226Arg). The latter phenotype can vary between families and even among family 
members affected by the same mutation (Figure 4). These intra -and interfamilial differences 
suggest that other genetic or environmental factors contribute to the phenotypic variability.
We identified a new KNCA1 genotype that results in a different phenotype including renal 
hypomagnesemia (0.37 mmol/L) and myokymia (Chapter 3) [57]. As it was not known 
whether renal Mg2+ handling is also affected in patients with other KCNA1 mutations, plasma 
Mg2+ levels were evaluated. Three EA1 patients have been analyzed [71, 72, 77] and their 
serum Mg2+ levels (Ile262Thr: 0.76 mmol/L; Leu305Pro: 0.80 mmol/L; Val404Ile: 0.73 
mmol/L) are within the normal range (0.7-1.1 mmol/L) (unpublished data) (Figure 4). 
Possibly, as observed for EA1, the hypomagnesemia is transient and should, therefore, be 
measured at different points in time. Additionally, it would be interesting to investigate serum 
Mg2+ levels of patients with myokymia, neuromyotonia and epilepsy (Ala242Pro and 
Pro244His mutations), but not EA1. The hypomagnesemic patients with the Asn255Asp 
mutation suffer from tetany, spontaneous muscle cramps and muscle weakness, a 
phenotype that resembles myokymia/neuromyotonia (F igure 3) [65].
For that reason, hypomagnesemia may have been missed in these patients. In addition, like 
the phenotype associated with Kv1.1 mutations and the Kv1.1 knockout mouse [79], 
hypomagnesemia has also been associated with seizures [80]. Kv1.1 residues Ala242 and 
Pro244 are positioned in the first intracellular loop, while the Asn255 residue is situated in the 
third transmembrane region (Figure 4). Therefore, a role in the same regulatory process for 
these residues is not likely. Yet, a defect in distinctive processes that are important for NCC 
function can still lead to similar patient phenotype. Additional experiments have to be 
performed to find out whether the Kv1.1 Ala242 and/or Pro244 or any other residue is 
important for Kv1.1 function in the kidney as shown for the Asn255 residue.
Several mechanisms can explain the kidney-associated phenotype, which so far has only 
been observed for the Kv1.1 Asn255Asp mutation. For instance: i) the expression of an 
alternative tissue-specific Kv1.1 coding sequence. Until now, most studies have focused on 
the brain and as a consequence other transcripts may have been missed. For that reason, it 
is interesting to investigate whether other Kv1.1 transcripts exist within the kidney; ii) post-
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translational modification processes differ between tissues such as the brain and kidney. In 
combination with the mutation, this may give rise to a tissue-specific phenotype; iii)  in brain 
Kv1.1 subunits are known to assemble with other pore-forming subunits such as of auxiliary 
p-subunits or other Kv1 subunits. The assembly of these subunits determine the functional 
characteristics of the channel. In the kidney, Kv1.1 may have an interaction partner, which is 
not expressed in brain. The Kv1.1 Asn255Asp mutation possibly has a dominant effect on 
the function of this unidentified interaction partner, but not its interaction partners in the brain. 
Importantly, further experiments are necessary to identify the mechanism that underlies the 
kidney-specific phenotype.
A key role for K+ channels in the DCT
Interestingly, Kv1.1 is not the only example of a K+ channel with an important role in the 
distal parts of the nephron. In contrast to renal K+ secretion or reabsorption, renal outer 
medullary K+ channel (ROMK) and KIR4.1 support other transport functions. ROMK is known 
to recycle K+ from the intracellular compartment to the tubular lumen to drive NaCl 
reabsorption via the Na+-K+-Cl- cotransporter 2 (NKCC2) in TAL cells. Also, more recently 
KIR4.1 was revealed as the affected protein in a new syndrome closely resembling the GS 
phenotype, accompanied by epilepsy, ataxia, sensorineurol deafness (EAST (also referred to 
as SeSAME); OMIM 612780 [81]. KIR4.1 is expressed at the basolateral membrane of DCT 
cells [82], together with the Na+,K+-ATPase (F igure 1). The Na+,K+-ATPase facilitates 
transport of Na+ to the interstitium and K+ to the intracellular compartment against their 
respective chemical gradients, generating a driving force for luminal NaCl influx via NCC and 
basolateral Cl- transport via ClC-Kb (Figure 1). KIR4.1 is suggested to recycle K+ into the 
interstitium to allow a sufficient supply of K+ for optimal Na+,K-ATPase activity. Importantly, as 
reflected by the high density of mitochondria in the DCT, the Na+,K+-ATPase activity is here 
the highest of all nephron segments [83]. In DCT, a high Na+,K--ATPase activity may be 
necessary to support the substantial active transport processes, which are necessary to 
reabsorb NaCl and Mg2+. Altogether, the emerging role for particularly K+ channels in 
mediating the reabsorption of other electrolytes and their localization to the same tubule 
segments is fascinating. The similar roles for these proteins suggest the earlier existence of 
one protein that in time evolved into distinctive proteins with similar functions. Alternatively, 
similar processes were introduced in parallel, as they are favourable for the function of the 
cell like for instance the conservation of energy.
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Other m echanism s tha t regulate Mg2+ handling by the DCT
Intracellular regulation of TRPM6 via its a-kinase domain
The a-kinase domain is proposed to function as a sensor of the intracellular Mg2+ 
concentration. As a consequence, the Mg2+ influx via TRPM6 is tightly regulated to prevent 
overload of intracellular Mg2+. Recently, a Receptor for Activated C-Kinase (RACK1) and 
Repressor of Estrogen receptor Activity (REA) were identified as the TRPM6 a-kinase 
domain interacting proteins. RACK1 and REA were shown to function as a dynamic switch 
controlling TRPM6 channel activity via the a-kinase domain [84, 85]. Moreover, TRPM6 is 
inhibited upon interaction of adenosine-5'-triphosphate (ATP) with a specific motif in the a- 
kinase domain [86]. Additionally, Mg2+ handling by the DCT is regulated from the extracellular 
compartments by the action of hormones.
Systemic and hormonal regulation of TRPM6
The renal Mg2+ excretion and TRPM6 expression are strongly regulated by the Mg2+ intake. 
Mice studies showed that reduction in dietary Mg2+ results in hypomagnesemia, and renal 
Mg2+ and Ca2+ conservation, whereas a high dietary Mg2+ content has the opposite effect. A 
Mg2+ restricted diet led to a significant increase in renal TRPM6 abundance, while an 
enriched Mg2+ diet tended to decrease renal TRPM6 mRNA levels [87]. Variation in dietary 
Mg2+ content did not alter the mRNA expression level of the ubiquitous TRPM7 protein. 
These data support the idea of TRPM6 being the gatekeeper of transepithelial Mg2+ 
transport.
Several hormones have been proposed to regulate renal Mg2+ reabsorption, including 
parathyroid hormone (PTH) [88], 1,25-dihydroxyvitamin D3 [89], insulin [90], aldosterone [91], 
arginine vasopression (AVP) [92] and glucagon [92]. Importantly, these effects were shown 
in an immortal mouse TAL cell line [88] with DCT characteristics. For that reason it is unsure 
whether these hormones regulate Mg2+ reabsorption by the TAL or the DCT. Groenestege et 
al. demonstrated that TRPM6 expression levels were significantly decreased in 
ovariectomized rats, while the effect was normalized after 17p-estradiol, but not 1,25- 
dihydroxyvitamin D3 or PTH treatment [87].
EGF: a key regulator of Mg2+ handling in DCT
Recently, the Epidermal Growth Factor (EGF) was identified as a novel magnesiotropic 
hormone [6]. The EGF gene encodes pro-EGF, a small peptide autocrine hormone that is 
synthesized and secreted by DCT cells [6, 93]. Pro-EGF is a type-1 membrane protein that is
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sorted to basolateral membrane [94]. The extracellular part of pro-EGF is processed by 
proteases into a functional EGF peptide hormone, which activates the EGF Receptor (EGFR) 
on the basolateral membrane. EGFR-activation in turn stimulates TRPM6 expression [95] 
and trafficking to the luminal membrane [96], which consequently increases the reabsorption 
of Mg2+ via TRPM6 (F igure 1). The mutation, observed in the family with isolated recessive 
hypomagnesemia (IRH), disrupts the basolateral-sorting motif in pro-EGF. For that reason, 
the trafficking of pro-EGF to the basolateral membrane is impaired leading to diminished 
stimulation of the EGFR and subsequent reduced Mg2+ transport by TRPM6. Additional 
evidence for a role of EGF in the regulation of Mg2+ homeostasis was provided by colorectal 
cancer patients treated with antibodies raised against the EGFR, such as cetuximab. 
Treatment with this EGFR monoclonal antibody has been shown to result in 
hypomagnesemia in a significant number of patients (Figure 1) [97, 98].
What is the function of FYXD2?
The first protein that was implicated in active Mg2+ reabsorption in DCT cells is the y-subunit 
of the basolateral Na+,K+-ATPase. At present, the exact function of this protein and its role in 
Mg2+ handling are still unknown. Mutations in the FYXD2 gene, encoding the y-subunit of the 
Na+,K+-ATPase, were found in patients with isolated dominant hypomagnesemia with 
hypocalciuria (IDHH) [5, 99]. This protein is primarily expressed in the kidney with highest 
expression levels at the basolateral membrane of DCT and medullary TAL (Figure 1) [100]. 
A role for the y-subunit in the regulation of the ap-subunit Na+,K+-ATPase has been 
suggested. Further evidence for an instrumental role of the y-subunit in Mg2+ reabsorption 
was provided by a recent study showing that the transcription factor HNF1B is linked to the 
regulation of the FXYD2 gene. Hypomagnesemia, hypermagnesuria and hypocalciuria were 
observed in 44% of the HNF1B mutation carriers (OMIM 137920). By analysis of the FXYD2 
promoter region a highly conserved HNF1B recognition site was identified. By subsequent 
use of luciferase reporter assays, the authors demonstrated the control of FXYD2 gene 
expression by HNF1B [101]. A chromatin immunoprecipitation with microarray technology 
(ChIP-on-chip) can be performed to confirm the role of HNF1B in the regulation of FXYD2 
and to identify other components of the molecular machinery involved in renal Mg2+ handling 
(Figure 1).
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Other patho log ies tha t cause hypom agnesem ia
In addition to the aforementioned inherited forms, hypomagnesemia is also observed under 
conditions, which not necessarily result from inherited defects. A representative study 
showed that a high percentage of hospitalized patients (acute 26% and chronic 4%) are 
diagnosed with hypomagnesemia [102]. Some examples of other mechanisms that cause 
hypomagnesemia are: i) the use of immunosuppressive agent cyclosporine [103], ii) of anti- 
acidic drugs like omeprazol and esomeprozol [3, 4]; iii) of anticancer drugs cetuximab [5, 6]; 
iv) and of cisplatin (cisDDP) [104]; v) secondary to other medical conditions like diabetes 
mellitus.
Cisplatin-induced hypomagnesemia
In Chapter 5 of this thesis, the effect of cis-Diamminedichloroplatinum(II) (cisplatin; cisDDP) 
on electrolyte handling by the DCT was examined. CisDDP is used to treat a broad range of 
solid tumors [105]. Despite its effect as an anti-cancer agent, clinical use is limited as ~20% 
of the patients who receive high-dose cisDDP have severe renal dysfunction, which 
frequently results in acute renal failure (ARF) [106-108]. Acute cisDDP treatment in mice 
caused hypomagnesemia, hypokalemia and hypocalciuria. This phenotype overlaps the 
mixed phenotype observed in humans, who suffer from hypomagnesemia [104, 109], often 
associated with a reduced glomerular filtration rate (GFR), polyuria and electrolyte 
disturbances such as Mg2+ and Na+ wasting, hypocalcemia and/or hypokalemic alkalosis 
[110-113].
The cisDDP mouse group displayed decreased mRNA expression of the DCT proteins NCC, 
TRPM6 and parvalbumin (PV), which likely explains the observed phenotype (Chapter 5). 
Decreased mRNA expression of TRPM6 may cause renal Mg2+ wasting and consequently 
hypomagnesemia. In addition, as shown in GS, decreased NCC function explains the 
hypokalemia and hypocalciuria. Yet, mRNA data can give an incorrect view of the protein 
expression in the DCT segment. For that reason it is essential to perform additional Western 
blotting experiments and/or immunohistochemistry. Decreased expression of DCT-specific 
proteins is also observed in NCC KO mice as well as in rats after chronic treatment with 
thiazides, a blocker of NCC. At this point it is not known whether the decreased expression is 
caused by selective down-regulation of the NCC, TRPM6 or PV mRNA levels in the DCT or a 
result of hypotrophy of DCT cells. A morphological study in which the DCT cell quantity is 
analyzed using electron microscopy would give insight in the underlying mechanism of 
cisDDP treatment. Moreover, tubular damage can be investigated by the quantification of 
proximal and distal tubular injury via markers GSTA1-1 and GSTP1-1, respectively, in the
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urine of cisDDP-treated patients. Additionally, tubular cells can be isolated from the urine of 
cisDDP and control patients to investigate the mRNA expression of specific DCT proteins via 
quantitative PCR analysis.
The ultimate goal is to identify the mechanism that mediates the entry of cisDDP in DCT 
cells. CisDDP enters cells via passive diffusion and active uptake by transport mechanisms. 
Recent studies identified the Organic Cation Transporter 2 (OCT2) [114] and the Copper 
Transporter 1 (CTR1) [115] as cisDDP-transporting proteins. Interestingly, both OCT2 and 
CTR1 are expressed in the kidney as well as in malignant tissues [116-118]. CTR1 partially 
localizes to the DCT region while OCT2 does not (Chapter 5; unpublished results). The 
DCT-specific toxicity suggests an exclusive localization of the elusive entry mechanism to 
this segment. NCC is selectively expressed in the DCT segment and may be the entry 
mechanism for cisDDP and, therefore, causative for the DCT-specific tubulotoxicity. It is 
important to study the existence of a DCT cisDDP transporting protein as competitive 
blockage could help many patients that deal with the kidney-related side effects following 
cisDDP treatment. An alternative cause for cisDDP-mediated cell injury is presumed to be 
mitochondria-induced apoptosis. DCT cells are characterized by their high number and large 
size mitochondria, which could explain its cisDDP sensitivity.
Diabetes mellitus type II, cyclosporin A, omeprazol and cetuximab
Streptozotocin (STZ)-induced diabetic rats displayed increased renal TRPM6 mRNA 
expression, which may represent a compensatory mechanism for the increased Mg2+ load to 
the DCT. Insulin administration reversed this increased abundance in TRPM6 and corrected 
the hypermagnesiuria in these rats [119]. Thus, diabetes is associated with renal Mg2+ 
wasting, but the responsible molecular mechanism is unknown.
Despite the elusive mechanism for omaprazol -or esomeprozole-induced hypomagnesemia, 
measurements of the fractional excretion for Mg2+ have pointed towards an intestinal defect. 
Cyclosporin A- and cetuximab-induced hypomagnesemia, however, likely result from 
defective transport processes in DCT. For instance, cyclosporine A has been shown to 
downregulate renal TRPM6 expression [120] (Figure 1). Furthermore, cetuximab has been 
demonstrated to block EGFR-signalling, which consequently hampers trafficking of TRPM6- 
containing vesicles towards the luminal membrane [96] (Figure 1). Detailed study of these 
pathologies is important to provide further insight in the mechanisms of Mg2+ handling in 
general and more specifically in DCT.
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Related to the studies presented in this thesis
The general aim of the research presented in this thesis was the elucidation and further 
characterization of the molecular mechanisms of electrolyte handling by the DCT. It 
describes the discovery of novel mutations in the NCC (Chapter 2), which is the main target 
in the treatment of hypertension. The identification of these novel mutations may provide 
insight in the mechanisms that regulate NCC function. It is attractive to investigate the 
phenotype (electrolyte values, age of onset, etc) of the GS patients in more detail. Further 
characterization of the corresponding genotype (mutation class) should ultimately allow to 
predict, prevent or treat GS. Furthermore, drugs that assist protein folding (chemical 
chaperones) have been successfully used to restore trafficking and thereby function of class 
II mutant proteins of V2R and CFTR [121, 122]. Studies that investigate chaperone-induced 
trafficking of mutant NCC proteins should be performed, to ultimately use them as potential 
therapeutic agents.
Kv1.1 was identified as the affected protein in a family with primary renal hypomagnesemia 
and a role for Kv1.1 in setting a favourable membrane potential in DCT cells to facilitate 
TRPM6-mediated Mg2+ entry was postulated (Chapter 3). As discussed, the Kv1.1 
Asp255Asn mutant is able to reach the plasma membrane, but is not functional. The reason 
why this mutation interferes with Kv1.1 channel functioning is still unknown and should be 
addressed in the coming years. Detailed modelling and functional analysis of the Kv1.1 
Asp255 residue demonstrated that the channel defect does not result from the introduction of 
charge, failure to form hydrogen bridges or steric hindrance (Chapter 4). In addition, the role 
of the Kv1.1 Asp255Asn mutation in the generation of a kidney-associated phenotype should 
be studied.
Identification novel proteins involved in DCT electrolyte handling
The recent decade has witnessed the identification of many proteins that are important in 
electrolyte handling by the DCT segment (Figure 1). However, several proteins remain 
unidentified. Examples of these are the basolateral extrusion mechanism for Mg2+, 
associated proteins of NCC/TRPM6/Kv1.1 and hormones that regulate electrolyte handling 
by DCT cells. The following methods are options to identify these elusive proteins: i) several 
unrelated small families and isolated patients with hypomagnesemia have been collected 
over the previous years. In some cases these families display other electrolyte disturbances 
or phenotypic characterises such as mental retardation. Detailed phenotyping may provide 
patients with the same pattern of disturbances, which can be used to identify the affected
Future perspectives
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gene using next generation techniques, such as exome sequencing; ii) little is known about 
the proteins that regulate the identified DCT-transporting proteins like NCC, KIR4.1, TRPM6 
and Kv1.1. The identification of associated proteins via yeast two-hybrid assays and 
glutathione S-transferase (GST)-pull-down approaches and subsequent analysis of their role 
in the regulation of their binding partner is interesting; iii) by use of an automated tubule 
sorter it has become possible to specifically isolate DCT tubules from mice that express 
eGFP under control of a parvalbumin promoter. These tubules can be used to collect and 
detect the total DCT protein fraction by use of mass spectrometry. Additionally, the effect of 
certain stimuli such as low Mg2+ diets, K+ diets or for instance thiazides can be studied; iv) 
isolated mouse DCT cells can be used to generate a cDNA library for an expression cloning 
approach to identify the basolateral Mg2+ extrusion mechanism. Following, injection of 
oocytes and the use of stable Mg2+ isotopes should provide the opportunity to select positive 
clones for Mg2+ transport.
Altogether these investigations will further improve our understanding of the electrolyte 
transport processes that occur in the DCT (Figure 1). This may ultimately provide tools to 
prevent or treat DCT-related diseases such as hypomagnesemia, salt wasting and 
hypertension.
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The kidneys are multifunctional organs, which play a prominent role in the determination of 
serum electrolyte levels by excretion via the urine. The human adult kidney contains 
approximately 1 million so-called nephrons. Each nephron consists of a glomerulus and 
tubular system that, after filtration of blood, produces the tubular fluid. Electrolytes are 
reabsorbed and/or secreted at specialized segments of the tubular system. This thesis 
focuses on one of these segments named the distal convoluted tubule (DCT), which is 
characterized by the reabsorption of NaCl and Mg2+. The DCT is important for the following 
reasons: i) thiazides and related compounds are currently recommended as the first-line 
pharmacological treatment of hypertension. These thiazides are known to specifically block 
the entry of NaCl via the luminal NaCl cotransporter (NCC) in the DCT, which consequently 
lowers the blood pressure; ii) a common inherited disorder named Gitelman Syndrome (GS) 
results from mutations in the gene encoding NCC, reducing the reabsorption of NaCl by the 
DCT; iii) in the DCT, the final plasma Mg2+ concentration is determined. Low serum Mg2+ 
levels are observed in ~3% of the population, causing tetany, cardiac arrhythmias and/or 
seizures.
Detailed knowledge of DCT transport processes is essential to understand and treat GS, 
hypertension and hypomagnesemia. In the last decade the study of families with inherited 
forms of NaCl and Mg2+ wasting has facilitated the identification of several proteins that play 
a key role in the reabsorption of these electrolytes by the DCT. Here, NCC regulates the 
cotransport of Na+ and Cl- from the tubular lumen into the cytoplasm. The Na+ gradient that 
drives the NaCl cotransport via NCC is provided by the Na+-K+-ATPase, which is situated at 
the basolateral membrane. The K+ channel Kir4.1 supplies the K+ to facilitate high Na+-K+- 
ATPase pump activity, while Cl- is transported across the basolateral membrane via the 
chloride channel ClC-Kb. Mg2+ entry from the tubular lumen into DCT cells is facilitated by the 
transient receptor potential channel melastatin subtype 6 (TRPM6). TRPM6 trafficking and 
consequently the transport of Mg2+ is regulated by the hormone epidermal growth factor 
(EGF). A mutation in the FXYD2, which is the gene that codes for the Na+-K+-ATPase y- 
subunit, causes familial isolated dominant hypomagnesemia. The molecular mechanism by 
which the Na+-K+-ATPase y-subunit is involved in DCT Mg2+ handling remains unknown. DNA 
binding domains for the renal transcription factor hepatocyte nuclear factor 1 homeobox B 
(HNF1B) exist in the promoter region of FXYD2. Interestingly, a high percentage of patients 
with mutations in the HNF1B gene develop hypomagnesemia.
Despite these discoveries, several aspects of Mg2+ and NaCl transport processes in the DCT 
are poorly understood. Important unresolved issues that have been studied in this thesis
Chapter 1: Introduction
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include: i) the genetic and molecular characterization of NCC; ii) identification of Kv1.1 as a 
novel regulator of TRPM6 activity; iii) the effect of anti-cancer agent cisplatin (cisDDP) on 
DCT electrolyte handling.
Chapter 2: Identifica tion  and characterization o f novel m utations in NCC
Loss-of-function mutations are the cause of GS, which is characterized by hypokalemic 
metabolic alkalosis, hypocalciuria and hypomagnesemia. Detailed analysis of the mutated 
NCC protein provides insight in its function and regulation, which may result in tools to treat 
GS or improve the use of thiazide diuretics. In this thesis, 50 novel mutations were identified 
in a cohort of 263 patients with clinical suspicion of GS. 7 missense mutations (Glu121Asp, 
Thr392Ile, Asn442Ser, Ser475Cys, Tyr489His, Pro751Leu, Gln1030Arg) were selected for 
functional characterization using the Xenopus laevis oocytes expression system. All selected 
mutant NCC proteins displayed significantly lower functional activity, as a result of different 
molecular mechanisms.
The Thr392Ile NCC transporter localized to the endoplasmic reticulum presumably as a 
result of misfolding. NCC transporters that carry the Gln1030Arg or the Asn442Ser mutation 
displayed reduced function, resulting from impaired plasma membrane expression. This 
could be explained by the fact that a mutation of the amino-terminal Gln1030 residue disturbs 
the function of another protein that mediates trafficking or plasma membrane internalization. 
The Asn442Ser mutant displayed incomplete NCC glycosylation. Mutation of the NCC 
Asn442 amino acid may hamper amino-linked glycosylation of the N404 or N424 site. The 
Glu121Asp, Ser475Cys, Tyr489His, and Pro751Leu mutant NCC proteins were expressed at 
the cell surface, but displayed decreased function. The residue(s) that determine the Na+ 
affinity localize somewhere between transmembrane (TM) segments 8 and 12. The Ser475 
and Tyr489 amino acids could be involved as they reside between TM8 and 9. The NCC 
amino-terminus contains three phosphorylation sites (Thr46, Thr55 and Thr60). Mutant 
Glu121Asp transporters exhibit reduced NCC activity, but no change in plasma membrane 
expression. This has also been observed in case of mutation of the Thr60 residue. Mutation 
of the amino-terminal Glu121 residue may hamper the interaction between NCC and the 
Ste20-related proline-alanine-rich kinase (SPAK), oxidative stress response 1 (OSR1) or 
With-no-Lysine kinase 1 (WNK1) kinases, which would consequently block the 
phosphorylation and, therefore, function of the NCC transporter. Finally, the Pro751Leu 
mutation is situated in the carboxy-terminus and may be part of a domain that regulates NCC 
function at the cell surface.
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Altogether, this study provides clues about the role of NCC residues in NCC stability, 
trafficking, regulation and ion affinity. Insights in NCC function and regulation will ultimately 
lead to possibilities to prevent, predict and treat GS. Additionally, these observations will help 
to identify better ways to regulate blood pressure in case of hyper- and/or hypotension.
Chapter 3: Kv1.1 fac ilita tes  TRPM6-driven Mg2+ transpo rt
Mutation of the KCNA1 gene, coding for the voltage-gated K+ channel Kv1.1 (OMIM 176260), 
is causative for autosomal dominant hypomagnesemia in a large Brazilian family. The 
phenotype detectable from infancy consisted of recurrent muscle cramps, tetany, tremor, 
muscle weakness, cerebellar atrophy and myokymia. Kv1.1 colocalizes with TRPM6 along 
the luminal membrane of the DCT. Functional Kv1.1 channels are composed of 4 subunits 
that form homo- or heterotetramers in assembly with other Kv channel subunits. Functional 
analysis showed that the mutation results in a non-functional channel with a dominant 
negative effect on wild-type channel function, in line with the pattern of inheritance observed 
in the family.
Importantly, the DCT cell lacks a substantial chemical gradient for Mg2+ influx. The Mg2+ 
concentration in the tubular lumen is around 1.1 mmol/L, while the free intracellular Mg2+ 
concentration presumably is 0.5-1.0 mmol/L. The luminal membrane potential in the DCT is 
approximately -70 mV, favouring luminal Mg2+ influx. Thus, the movement of Mg2+ into DCT 
cells seems mainly driven by the electrical gradient. Kv1.1 likely functions as the luminal K+ 
channel in DCT cells that establishes a favourable luminal membrane potential to control 
TRPM6-mediated Mg2+ reabsorption. Consequently, mutation of Kv1.1 leads to impairment of 
renal Mg2+ handling as observed in affected family members of the Brazilian family.
Chapter 4: Functional consequence o f the  Kv1.1 Asn255Asp m utation
As shown, the phenotype associated with the mutation in Kv1.1 (Asn255Asp) result from 
impaired function of the channel at the plasma membrane. Detailed structural modelling of 
the Kv1.1 Asn255 residue was performed to investigate the importance of this residue in 
channel function. In this regard, 6 mutations were introduced in Kv1.1 at position Asn255 to 
study the effect of charge, failure to form hydrogen bridges or steric hindrance in relation to 
channel activity. The change in amino acid at position 255 had no effect on channel 
trafficking as all mutant were expressed at the plasma membrane.
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The hydrophilic Asn255 residue could be important for structural rearrangements within the 
channel in response to voltage changes, which are possibly hampered by the introduction of 
a negative residue (Asn255Asp). To investigate this, another negative charged glutamic acid 
(Asn255Glu) or positive charged histidine (Asn255His) residue were introduced. Compared 
to Asp, the Glu residue contains an extra CH2-group. As a control for steric hindrance, the 
non-charged glutamine (Gln) was introduced (Asn255Gln), which is the same size as Glu. 
Whole-cell patch clamp analysis demonstrated that Asn255Glu and Asn255Gln channels 
were non-functional, while Asn255His functions as a normal channel. This indicates that next 
to the addition of a negative charge at position 255 also an additional CH2-group in the side- 
chain influences channel function, likely by conformational rearrangements.
Alternatively, introduction of the Asn255Asp mutation may block the formation of hydrogen 
bonds, which reduces the stability of the Kv1.1 channel structure. Therefore, alanine 
(Asn255Ala), valine (Asn255Val), and threonine (Asn255Thr) were introduced. Alanine and 
valine contain both non-polar side chains such that participation in hydrogen bounds is 
precluded, whereas threonine has an alcoholic group in its side-chain and is, therefore, able 
to contribute to hydrogen binding. These amino acid substitutions had no effect on Kv1.1 
channel activity as shown by patch clamp analysis. Furthermore, the voltage-dependence 
and kinetics of channel gating of these functional mutants (Asn255Ala, Asn255Val, 
Asn255Thr, Asn255His) was examined. There was no correlation between the size, loss of 
hydrogen bond or charge and the magnitude of the shift in V1/2 for activation or inactivation. 
Altogether, Asn255 is essential for normal channel function, since substitution by other amino 
acids significantly altered channel activity, voltage-dependence and kinetics of Kv1.1 
channels, but more detailed structural information is necessary to specify the involvement of 
this residue in voltage-sensing and channel opening.
Chapter 5: C isDDP-induced in ju ry  o f the  DCT
CisDDP and related compounds are widely used in the treatment of solid tumors. 
Unfortunately, the use of cisDDP is limited due to its toxicity to normal tissues, particularly 
the kidneys. The uptake of cisDDP in renal tubular cells is high, leading to accumulation and 
consequently tubular cell injury and death, possibly accumulating in acute renal failure. 
Patients treated with CisDDP show the first signs of renal problems early after treatment, 
including Mg2+, Ca2+ and Na+ wasting, hypokalemic alkalosis, reduced glomerular filtration 
rate (GFR) and polyuria. The phenotype is probably dependent on the cisDDP dose and time 
of treatment. In this regard, mice were treated with one or two dosages of cisDDP. Acute
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CisDDP treatment significantly reduced serum Mg2+ and K+ levels and the renal excretion of 
Ca2+. Chronic cisDDP treatment reduced serum Mg2+ and K+ levels. Surprisingly, in contrast 
with acute treatment, the renal excretion of Ca2+ was increased in the chronic mice group. 
The observed phenotype following cisDDP-treatment is highly similar to the GS phenotype, 
which suggests specific injury to DCT cells. In line with that hypothesis, mRNA expression 
levels of DCT proteins NCC and TRPM6 were significantly reduced in both cisDDP-treated 
groups. In contrast, the expression levels of proteins that reside in other tubule segments, 
like Na+/H+ exchanger 3 (NHE3; proximal tubule and thin ascending limp), Na+/K+/Cl- 
cotransporter (NKCC2; thick ascending loop) and Epithelial Na+ Channel (ENaC; connecting 
tubule and collecting duct) were not affected by cisDDP treatment in our mouse groups. 
These observations suggest a specific downregluation of the DCT proteins as the cause for 
the pattern of electrolyte imbalances observed following cisDDP treatment.
Chapter 6: D iscussion and fu tu re  perspectives
Despite many years of research including the present thesis, several aspects of DCT 
electrolyte handling are still unexplained. For instance, the mechanism responsible for Mg2+ 
efflux from DCT cells into the interstitium remains to be identified. Additionally, little is known 
about TRPM6, NCC, Kir4.1, Kv1.1 and ClC-Kb regulating mechanisms such as hormones 
and associated proteins. These processes may be clarified by the use of recently established 
techniques, such as: i) an automated tubule sorter to isolate DCT cells that can be used to 
characterize DCT protein content; ii) cell surface biotinylation of TRPM6, NCC, Kir4.1, Kv1.1 
and ClC-Kb following mass spectrometry analysis to identify associated proteins; iii) whole 
exome sequencing to discover novel genes in hypomagnesemic patients. Furthermore, 
detailed investigation of the phenotype (serum and urinary electrolyte values, age of onset, 
etc) of well-characterized patients with NCC, TRPM6, and ClC-Kb mutations in relation to the 
genotype may give the opportunity to ultimately predict or prevent the pathology. Ultimately, 
better insight into the processes that facilitate NaCl and Mg2+ handling will pave the way to 
treat pathologies that originate from defective processes in the DCT.
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H oofdstuk 1: In troductie
De nieren spelen een belangrijke rol bij het bepalen van de eindconcentratie van electrolyten 
in het plasma doordat ze de uitscheiding van deze stoffen in de urine regelen. Een 
volwassen humane nier is opgebouwd uit ongeveer 1 miljoen nefronen. Elk nefron bestaat uit 
een glomerulus en een nierbuisje. Het nierbuisje transporteert de voorurine die gevormd 
wordt tijdens het filtratieproces in de glomerulus. De elektrolyten worden geresorbeerd en 
gesecreteerd via de verschillende segmenten van het nierbuisje. In dit proefschrift is de 
focus gelegd op één van deze segmenten, namelijk het distaal convoluut, dat een essentiële 
rol speelt bij de resorptie van NaCl en Mg2+. Het distaal convoluut is om de volgende 
redenen belangrijk: i) thiazide-diuretica en gerelateerde geneesmiddelen worden met grote 
regelmaat voorgeschreven bij de behandeling van hoge bloeddruk. Deze thiaziden blokkeren 
de luminale NaCl cotransporteur (NCC) in het distaal convoluut en daardoor de opname van 
NaCl. Het uiteindelijke gevolg hiervan is dat de bloeddruk wordt verlaagd; ii) mutaties in NCC 
veroorzaken een erfelijke ziekte genaamd Gitelman syndroom (GS). Dit syndroom wordt 
gekenmerkt door een verminderde resorptie van NaCl in het distaal convoluut; iii) het distaal 
convoluut is het laatste segment van het nierbuisje waar Mg2+ transport plaatsvindt en 
bepaalt daarmee de uiteindelijke Mg2+ uitscheiding via de urine. In ongeveer 3% van de 
humane populatie wordt een lage Mg2+ waarde in het plasma (hypomagnesiëmie) 
waargenomen, hetgeen kan leiden tot tetanie, hartritme stoornissen en epilepsie.
Het is belangrijk om een beter inzicht te krijgen in de transportprocessen die plaatsvinden in 
het distaal convoluut. De laatste jaren is er veel genetisch onderzoek verricht aan families 
met erfelijke vormen van NaCl- en Mg2+-verlies door de nieren. Dit onderzoek heeft geleid tot 
de identificatie van nieuwe eiwitten die betrokken zijn bij de NaCl en Mg2+ resorptie in het 
distaal convoluut. NCC transporteert NaCl vanuit de voorurine naar het cytoplasma van de 
distaal convoluutcel. De Na+ gradiënt die nodig is voor NaCl transport via NCC wordt 
gegenereerd door het Na+-K+-ATPase die aanwezig is op de basolaterale membraan van de 
cel. Op deze basolaterale membraan bevindt zich tevens het kaliumkanaal Kir4.1 alwaar het 
de werking van het Na+-K+-ATPase stimuleert door het rondpompen van K+ mogelijk te 
maken. Daarnaast treffen we hier ook het chloridekanaal ClC-Kb aan dat verantwoordelijk is 
voor het Cl- transport over de basolaterale membraan. De distaal convoluutcellen nemen 
Mg2+ vanuit de voorurine op via het magnesiumkanaal TRPM6. Het hormoon epidermale 
groeifactor (EGF) bepaalt de opname van Mg2+ via regulatie van het aantal TRPM6 kanalen
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op het plasmamembraan. De Na+-K+-ATPase y-subunit is een ander voorbeeld van een eiwit 
dat onvoldoende functioneert bij patiënten met hypomagnesiëmie. Het moleculaire 
mechanisme dat dit defect veroorzaakt is echter nog niet bekend.
Ondanks deze bevindingen bestaan er nog veel onduidelijkheden over de 
transportprocessen van NaCl en Mg2+ in het distaal convoluut. Voorbeelden van de 
onderdelen die zijn bestudeerd en beschreven in dit proefschrift: i) de ontdekking en 
bestudering van nieuwe mutaties in NCC; ii) de identificatie van Kv1.1 als een nieuwe 
regulator van TRPM6 activiteit; iii) het effect van het anti-kanker geneesmiddel cisplatine op 
het transport van elektrolyten in het distaal convoluut.
H oofdstuk 2: O ntdekking en bestudering van nieuwe m utaties in NCC
Mutaties in NCC zijn de oorzaak van GS, een ziekte die gekarakteriseerd wordt door 
hypokaliëmie, metabole alkalose, hypomagnesiëmie en hypocalciurie. Een gedetailleerde 
studie van gemuteerde NCC transporteur eiwitten geeft meer inzicht in de functie en de 
manier waarop NCC wordt gereguleerd.
In dit hoofdstuk zijn 50 nieuwe mutaties beschreven. Hiervan werden 7 missense mutaties 
(Glu121 Asp, Thr392Ile, Asn442Ser, Ser475Cys, Tyr489His, Pro751Leu, Gln1030Arg) 
geselecteerd voor studie naar de functie van de transporteur. De aanmaak en/of vouwing 
van nieuwe transporteurs was verstoord in het geval van de NCC Thr392Ile mutant waardoor 
de NCC eiwitten vermoedelijk worden vastgehouden in het endoplasmatisch reticulum. De 
NCC mutanten Gln1030Arg en Asn442Ser kwamen verminderd op het plasmamembraan 
wat vervolgens zorgt voor een beperkt transport van NaCl. Mutatie van het NCC Gln1030 
aminozuur verstoort wellicht de functie van een ander eiwit dat NCC naar het 
plasmamembraan brengt. Biochemische experimenten toonden een onvolledige 
glycolysering van de NCC mutant Asn442Ser. Mogelijk zorgt een mutatie van het NCC 
Asn442 aminozuur voor verminderde glycosylering van het Asn404 of Asn424 aminozuur in 
NCC. De NCC mutanten Glu121Asp, Ser475Cys, Tyr489His en Pro751Leu waren allen 
aanwezig op het plasmamembraan, maar konden geen NaCl transporteren. Vermoedelijk 
zorgen deze mutaties voor een directe vermindering van het NaCl transport door het NCC 
eiwit. Zo zijn er aminozuren tussen transmembraan (TM) segmenten 8 en 12 die de Na+ 
gevoeligheid voor NCC bepalen. De Ser475 en Tyr489 aminozuren bevinden zich tussen 
TM8 en 9 en zouden daarom belangrijk kunnen zijn voor de Na+ gevoeligheid in NCC. De 
NCC amino-terminus bevat drie aminozuren (Thr46, Thr55 en Thr60), die worden 
gefosforyleerd door de SPAK1, OSR1 en WNK1 kinases. Er is eerder aangetoond dat
158
- Chapter 8 -
mutatie van het Thr60 aminozuur de NCC activiteit vermindert, maar geen invloed heeft op 
de hoeveelheid NCC eiwit op het plasmamembraan. Dit bleek ook voor de NCC mutant 
Glu121Asp. Mutatie van het NCC Glu121 aminozuur zou de interactie tussen NCC en de 
SPAK1, OSR1 of WNK1 kinases kunnen verstoren, resulterend in verminderde fosforylatie 
en daardoor een verlaagd NaCl transport via het NCC eiwit. De laatste mutant is NCC 
Pro751Leu waarbij het aangedane aminozuur (Pro751) deel uit zou kunnen maken van een 
domein dat de functie van het NCC eiwit op het plasmamembraan reguleert. Samengevat 
biedt deze studie nieuwe inzichten in de rol van NCC aminozuren in stabiliteit, transport naar 
het plasmamembraan, regulatie en ion-gevoeligheid van de transporteur.
H oofdstuk 3: Kv1.1 fac ilitee rt het TRPM6 gedreven Mg2+ transport
Wij toonden aan dat een mutatie in het kaliumkanaal Kv1.1 de oorzaak is van 
hypomagnesiëmie in een Braziliaanse familie. Patiënten in deze familie hebben vanaf jonge 
leeftijd spierkrampen, tetanie, tremoren, spierzwakte, en myokymie. Magnetic resonance 
imaging (MRI), ofwel een magneetscan, liet bij een volwassen patiënt uit de familie ook een 
milde cerebellaire atrofie zien. Kv1.1 bleek naast TRPM6 voor te komen op het luminale 
membraan van de distaal convoluutcellen. Een onderzoek naar de functie toonde aan dat de 
Kv1.1 mutant Asn255Asp een niet-functioneel kanaal vormde dat tevens een dominant 
negatief effect had op het functioneren van gezonde kanalen. Dit laatste bleek in lijn met de 
dominante vorm van overerving in de bestudeerde Braziliaanse familie.
De vrije intracellulaire Mg2+ concentratie in de distaal convoluutcel wordt geschat op 0.5-1.0 
mmol/L. De Mg2+ concentratie in de voorurine is ongeveer 1.1 mmol/L. Er bestaat dus geen 
substantiële concentratiegradiënt voor Mg2+ ter hoogte van de distaal convoluutcellen. Om 
Mg2+ instroom toch toe te laten is de membraanpotentiaal aan de luminale zijde van de 
distaal convoluutcellen ongeveer -70 mV. Waarschijnlijk verzorgt Kv1.1 de 
membraanpotentiaal die nodig is voor Mg2+ resorptie via TRPM6. Als gevolg hiervan zal de 
mutatie in Kv1.1 de resorptie van Mg2+ verminderen en zodoende leiden tot een ernstig Mg2+ 
verlies via de nieren.
H oofdstuk 4: Functioneel bestudering van de Kv1.1 Asn255Asp m utatie
Zoals hierboven beschreven, is de Kv1.1 mutant Asn255Asp niet in staat om K+ te 
transporteren, terwijl de hoeveelheid kanalen op de plasmamembraan niet is verstoord.
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Daarom is er onderzoek gedaan naar het belang van het Asn255 aminozuur voor de werking 
van Kv1.1. Er werden 6 verschillende mutaties aangebracht op de Asn255 positie om het 
effect van verandering van lading, verlies van waterstofbrugvorming en sterische hindering 
op Kv1.1 activiteit te bestuderen. Het aanbrengen van de mutaties op de Asn255 positie had 
geen effect op het vervoeren van Kv1.1 kanalen naar het plasmamembraan aangezien de 
hoeveelheid kanalen op het plasmamembraan voor alle mutanten gelijk was. Het hydrofiele 
Asn255 aminozuur zou een rol kunnen hebben in de wijziging van de structuur van het Kv1.1 
kanaal in reactie op veranderingen in voltage. Dit proces wordt mogelijk verstoord door de 
mutatie in de Braziliaanse familie die leidde tot verandering in een negatief geladen 
aminozuur (Asn255Asp). Deze hypothese werd onderzocht door de invoering van een 
negatief geladen glutaminezuur (Asn255Glu) of een positief geladen histidine (Asn255His). 
In vergelijking met Asp, bevat het Glu aminozuur een extra CH2 groep. Als controle voor 
deze sterische hindering, werd het ongeladen glutamine (Asn255Gln), wat dezelfde grootte 
heeft als Glu, aangebracht. Een bestudering van de activiteit van Kv1.1 toonde aan dat beide 
Kv1.1 mutanten Asn255Glu en Asn255Gln geen K+ konden transporteren, terwijl de Kv1.1 
mutant Asn255His als een normaal kanaal werkzaam was. Dit betekent dat de werking van 
het Kv1.1 kanaal kan worden verstoord door de invoering van een negatieve lading en/of een 
extra CH2 groep op de 255 positie.
Mogelijk blokkeert het inbrengen van de Kv1.1 Asn255Asp mutatie de vorming van 
waterstofbruggen dat vervolgens de stabiliteit van het Kv1.1 kanaal zou kunnen verstoren. 
Om deze hypothese te testen werden de Kv1.1 alanine (Asn255Ala), valine (Asn255Val) en 
threonine (Asn255Thr) mutanten gemaakt. Alanine en valine bevatten beide een niet-polaire 
zijketen en kunnen hierdoor geen waterstofbruggen vormen. Threonine heeft echter een 
alcohol groep in de zijketen die waterstofbrugvorming mogelijk maakt. Een studie naar de 
functie van het kanaal wees uit dat invoering van deze aminozuurveranderingen geen effect 
had op Kv1.1 kanaalactiviteit. Vervolgens werden de voltageafhankelijkheid en de kinetiek 
van de werkzame Kv1.1 gemuteerde kanalen (Asn255Ala, Asn255Val, Asn255Thr, 
Asn255His) onderzocht. Er bleek echter geen duidelijke correlatie te zijn tussen enerzijds de 
grootte van het aminozuur, verlies van waterstofbrugvorming of introductie van lading en 
anderzijds de verandering in het halfmaximale voltage (V1/2) van activatie of inactivatie van 
het Kv1.1 kanaal. Het Asn255 aminozuur is dus essentieel voor een normale functie van het 
Kv1.1 kanaal, aangezien vervanging door andere aminozuren op de Asn255 positie tot 
significante verschillen in kanaalactiviteit, voltage-afhankelijkheid en kinetiek leidde. Er is 
echter meer gedetailleerde structurele informatie nodig om de betrokkenheid van dit 
aminozuur in Kv1.1 kanaalfunctie te ontrafelen.
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H oofdstuk 5: CisDDP geïnduceerde to x ic ite it van het d istaal convo luu t
Cisplatin (cisDDP) en gerelateerde geneesmiddelen worden regelmatig gebruikt bij de 
behandeling van tumoren. Helaas heeft het gebruik van cisDDP ook bijwerkingen op 
gezonde weefsels, met name op de nierfunctie. De hoge opname van cisDDP door de cellen 
in het nierbuisje veroorzaakt celdood. Een eerste indicatie voor nierproblemen (verhoogde 
uitscheiding van Mg2+, Ca2+ and Na+ via de urine, hypokalemia, metabole alkalose, 
verlaagde filtratiesnelheid van de glomerulus (GFR) and polyurie) is al vroeg na behandeling 
met cisDDP waarneembaar. De ernst van de nierproblemen is vermoedelijk afhankelijk van 
de cisDDP dosis en behandeltijd. Om die reden werden twee groepen muizen behandeld 
met één cisDDP dosis (acuut) of twee cisDDP doses (chronisch). Zowel de acute als 
chronische behandeling met cisDDP resulteerde in een verlaging van Mg2+ en K+ in het 
plasma. In tegenstelling tot de acute behandeling, die leidde tot een verlaagde Ca2+ 
uitscheiding in de urine, zorgde chronische behandeling voor een verhoogde Ca2+ 
uitscheiding.
Het ziektebeeld dat werd waargenomen na cisDDP-behandeling is vergelijkbaar met die van 
patiënten met GS. Dit suggereert dat de transportprocessen in de distaal convoluutcellen zijn 
verstoord als gevolg van cisDDP behandeling. In overeenstemming met deze hypothese, 
bleek de hoeveelheid mRNA (welke een maat is voor de hoeveelheid eiwit) van de distaal 
convoluuteiwitten NCC en TRPM6 verlaagd in beide cisDDP-behandelde groepen. 
Daarentegen was de mRNA hoeveelheid van eiwitten die een functie hebben in andere 
segmenten van het nierbuisje, zoals de Na+/H+ exchanger 3 (NHE3; proximale tubulus en het 
opstijgende dunne deel van de Lis van Henle), de Na+-K+-Cl- cotransporteur (NKCC2; het 
dikke opstijgende deel van de Lis van Henle) en het Na+ kanaal (ENaC; verzamelbuis), niet 
veranderd in één van de cisDDP-behandelde groepen. Deze resultaten doen vermoeden dat 
cisDDP-behandeling zorgt voor een specifieke verstoring van de transportprocessen in het 
distaal convoluut, met hypokalemie en hypomagnesemie tot gevolg.
H oofdstuk 6: D iscussie  en toekom stige  plannen
Gedurende de afgelopen 10 jaar hebben verscheidene studies, waaronder het werk 
beschreven in dit proefschrift, de kennis met betrekking tot het transport van elektrolyten in 
het distaal convoluut vergroot. Ondanks deze vorderingen zijn verschillende aspecten nog 
onbekend. Zo is het eiwit dat Mg2+ vanuit de distaal convoluutcellen over het basolaterale 
plasmamembraan naar het bloed transporteert nog niet ontdekt. Daarnaast is er
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onduidelijkheid over de werking van hormonen en geassocieerde eiwitten op de functie van 
TRPM6, NCC, Kir4.1, Kv1.1 and ClC-Kb. Deze processen kunnen worden opgehelderd door 
het gebruik van nieuwe technieken zoals: i) een apparaat dat specifieke distaal 
convoluutcellen kan isoleren. Na isolatie kunnen de eiwitten die een functie hebben in dit 
segment gemakkelijker worden bestudeerd; ii) de isolatie van plasmamembraan 
eiwitcomplexen met TRPM6, NCC, Kir4.1, Kv1.1 en/of ClC-Kb gevolgd door een 
massaspectrometrie studie om geassocieerde eiwitten te vinden; iii) ‘whole exome 
sequencing’ is een methode die kan worden gebruikt om nieuwe gendefecten in patiënten 
met hypomagnesiëmie te ontdekken.
Gedetailleerd onderzoek naar het ziektebeeld (elektrolytwaarden, leeftijd waarop eerste 
symptomen zichtbaar zijn, etc) in relatie tot het gendefect in patiënten met mutaties in NCC, 
TRPM6, Kv1.1 of ClC-Kb zal leiden tot aanknopingspunten voor de prognose van de 
verschillende ziektebeelden en zal op den duur ook ‘personalized medicine’ mogelijk maken. 
Het ultieme doel is om een beter inzicht te krijgen in alle processen die de NaCl en Mg2+ 
balans bepalen. Dit kan in de toekomst leiden tot een manier om GS te voorkomen, 
voorspellen en/of behandelen en zorgen voor betere perspectieven om de bloeddruk te 
reguleren in het geval van hyper- en/of hypotensie.
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List of abbreviations
ANOVA analysis of variance
ATP adenosine 5’-triphosphate
ATPase adenosine 5’-triphosphatase
bp base pair
BS Bartter syndrome
Ca2+ calcium ion
CaSR Ca2+, Mg2+-sensing receptor
cBS classic Bartter syndrome
CCD cortical collecting duct
CD collecting duct
cDNA copy DNA
Cl- chloride ion
CLC-Kb Cl- channel Kb
CLCNKB gene encoding the Cl- channel Kb
CLDN16 gene encoding claudin-16 (= paracellin-1)
CLDN19 gene encoding claudin-19
CNT connecting tubule
cM centi-Morgan
cRNA copy RNA
DCT distal convoluted tubule
DMEM dulbecco’s modified eagle medium
DMSO dimethylsulphoxide
EGF gene encoding pro-EGF
EGF epidermal growth factor
EGFR epidermal growth factor receptor
ELISA enzyme-linked immunosorbent assay
FHH familial hypocalciuric hypercalcemia
FHHNC familial hypomagnesemia with hypercalciuria and nephrocalcinosis
GS Gitelman syndrome
HCO3- bicarbonate
HEK293 cells human embryonic kidney cells
HPRT hypoxanthine-guanine phosphoribosyl transfers
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aBS antenatal Bartter syndrome
HSH hypomagnesemia with secondary hypocalcemia
IC50 concentration required to induce 50% of the maximum effect
IDH isolated dominant hypomagnesemia
IDHH isolated dominant hypomagnesemia associated with hypocalciuria
IOD integrated optical density
IRH isolated recessive renal hypomagnesemia
K+ potassium ion
KCNA1 gene encoding Kv1.1
KCNJ1 gene encoding ROMK
kDa kilo dalton
Kv1.1 voltage-gated K+ channel 1.1, shaker, member 1.1
MDCK cells madin darby canine kidney cells
Mg2+ magnesium ion
Mg2+-ATP Mg2+ bound to ATP
M-MLV-RT moloney-murine leukaemia virus-reverse transcriptase
mRNA messenger ribonucleic acid
mTAL medullary thick ascending limb of Henle’s loop
Na+ sodium ion
NaCl sodium chloride
NCC Na+,Cl--cotransporter
NKCC2 Na+, K+, Cl+ cotransporter 2
OMIM online mendelian inheritance in man
PAGE polyacrylamide gelelectrophoresis
PBS phosphate-buffered saline
PCLN-1 gene encoding claudin-16 or paracellin-1
PCR polymerase chain reaction
PCT proximal convoluted tubule
PLP periodate-lysine-paraformaldehyde
PMSF phenylmethylsulphonylfluoride
PST proximal straight tubule
PVDF polyvinylidine difluoride
PT proximal tubule
PTH parathyroid hormone
ROMK renal outer medullary K+ channel
RT-PCR reverse-transcriptase polymerase chain reaction
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SDS sodium dodecyl sulphate
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis
SEM standard error of the mean
SLC12A3 solute carrier family 12 (Cl- cotransporter family), member 3, encodes 
NCC
TAL thick ascending limb of Henle’s loop
TM transmembrane segment
TRP transient receptor potential channel
TRPM transient receptor potential channel subfamily melastatin
TRPM6 transient receptor potential channel subfamily M, member 6
TRPM7 transient receptor potential channel subfamily M, member 7
TRPV transient receptor potential channel subfamily vanilloid
TRPV5 transient receptor potential channel subfamily V, member 5
UTR untranslated region
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